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The regulation of gene expression resulting in the formation of the mammalian 
cerebral cortex is tightly regulated by a group of transcription factors. The deletion of 
any one of these transcription factors results in numerous defects whose nature and 
severity depends on the role of the transcription factor in the regulation of complex 
gene regulatory networks involved in development. There is currently relatively little 
knowledge about the gene networks that these transcription factors control and how 
they exert their regulatory effects.  
 
The paired-box transcription factor Pax6 has been identified as a master regulator of 
gene networks involved in cortical development and its deletion results in numerous 
cortical defects such as an abnormally thin cortical plate and a vastly expanded 
proliferative zone. Previous work in our lab identified a list of candidate genes that 
are likely to be regulated by Pax6 in the developing cortex. Members of the Notch 
signalling pathway were potential Pax6 targets of particular interest since Notch 
signalling plays a crucial role in the maintenance of neural progenitor cells during 
development and consequently plays a critical role during corticogenesis.  
 
Our work aims to identify the regulatory relationship between Pax6 and Notch 
ligands Dll1 and Jag1 during cortical development. Analysis by flow cytometry and 
double labelling analysis of both gene and protein expression has provided insight 
into the relationship between Pax6 and Dll1 in progenitor cell subpopulations during 
cortical development. In situ hybridisation and qPCR results confirmed that loss of 
Pax6 causes loss of Dll1 expressing cells and downregulation of Jag1, indicating that 
both ligands are regulated by Pax6. Bioinformatic screening and analysis by 
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1.0 Introduction  
 
 
1.1 The mammalian cerebral cortex 
 
The mammalian cerebral cortex is a complex; multi-layered structure comprised of a 
variety of different neuronal cell subtypes, as well as non-neural glial cells (Tabata, 
2015) and is predominantly accountable for both perceptual and cognitive functions, 
such as the process of conscious thought, emotions, memory and the ability to 
communicate (Martinez-Cerdeno, 2004). The study of cortical development during 
embryogenesis is of particular importance in our understanding of developmental 
(Manzini and Walsh, 2011) and neurodegenerative (Abdipranoto et al., 2008) 
diseases. Understanding how the cerebral cortex develops initially enables us to 
understand what happens when molecular mechanisms go wrong during 
development, such as occurs in autism (Hui et al., 2015), Fragile X syndrome (Fung 
et al., 2012) and cerebral palsy (MacLennan et al., 2015). Understanding how 
complex signalling pathways are disrupted in these diseases could potentially help to 
develop gene therapy approaches that could be implemented (Hui et al., 2015). 
Furthermore, the study of developmental processes such as neurogenesis can help 
develop gene therapy strategies for neurodegenerative diseases and brain injury, 
which could potentially regenerate cortical cells and effectively repair the cerebral 
cortex (Akhtar and Breunig, 2015; Lui and Deng, 2015). While there are some 
differences between species, mammalian cortical development is relatively well 
conserved and this thesis will focus on the development of the murine cerebral cortex 
unless otherwise stated.  
 
The cerebral cortex forms from the dorsal region of the telencephalon during the 
process of embryogenesis, and the prerequisites required for its prospective 
development occur following embryonic gastrulation, with molecular cues 
manipulating a simple epithelial sheet of cells to ultimately result in the formation of 
a complex network of cells that constitute a fully formed and functional brain 
(Wilson and Rubenstein, 2000; Wilson and Houart, 2004). General organisation of 
	 2
early forebrain patterning is well conserved in all vertebrates, and has been 
extensively studied in amphibian, avian and mammalian structures (Wilson and 
Houart, 2004). In terms of mammalian cortical development, the cellular and 
molecular processes are relatively similar with moderate differences between 
different species (Wilson and Rubenstein, 2000; Wilson and Houart, 2004). 
 
 
1.2 Induction of the forebrain 
 
The developmental onset of the mammalian telencephalon occurs early on during 
embryogenesis and is instigated by the process termed neurulation. Neurulation is 
initiated by the thickening of the ectoderm, the distal germinal layer formed during 
the primary stages of embryogenesis, and comprises three main stages (Morris-Kay, 
1993). This commences with the aforementioned thickening of the ectodermal cells, 
forming the neural plate and eventually causing its pseudo stratification and the 
expression of molecular markers, which instigate the second stage of neurulation. 
Following the formation and thickening of the neural plate, the neural plate 
undergoes rostrocaudal lengthening, mediolateral narrowing and further apico-basal 
thickening. This results in the morphological modification of the once flat neural 
plate, allowing subsequent bending of the structure (Morris-Kay 1993; 1994). This 
stage of neurulation involves the folding of the neural plate and culminates in the 
formation of the neural tube (Figure 1.1), a hollow nerve cord that acts as the 
precursor of the adult central nervous system (CNS) and a majority of the peripheral 
nervous system (PNS). The mammalian brain consequently arises when the anterior 
portion of the neural tube closes to form three vesicles: the prosencephalon, 
mesencephalon, rhombencephalon (Smith and Schoenwolf, 1997). The 
prosencephalon consists of the telencephalon and diencephalon, and comprises the 
forebrain of the developing embryo. The telencephalic vesicles make up the 
telencephalon and develop as two laterally enlarging bulges that delineate them from 





Figure 1.1  Early neurulation  
 
Taken from Gammil and Bronner-Fraser, 2003. The neural plate forms from the thickening of 
ectodermal cells to produce the neural plate. During neurulation, the borders of the neural 
plate (neural folds) elevate to instigate the folding of the neural plate to form the neural tube. 
The neural tube acts as the precursor of both the CNS and PNS, with the anterior portion of 




1.3  Early patterning of the telencephalon 
 
During embryogenesis, development of the forebrain is guided by signals originating 
from four patterning centres: the rostral patterning centre, the caudodorsal centre, the 
ventral centre and the lateral centre (Figure 1.2 (Hoch et al., 2009). These molecular 
signals act to transform the aforementioned anterior neural plate into distinct 
forebrain structures, including the telencephalon (Rubenstein and Beachy, 1998; 
Wilson and Rubenstein, 2000; Wilson and Houart, 2004; Hoch et al., 2009). The 
induction of the telencephalon results from the accumulation of specific and highly 
controlled signalling, transcriptional and regulatory events, which coordinate the 
regional development of distinct telencephalic areas along the rostrocaudal and 





Figure 1.2 The signalling centres that instruct telencephalic development. 
 
Taken from Hoch et al., 2009. The rostral signalling centre (S) (blue) is located in the anlage 
of the septum and secretes Fgfs. The caudodorsal signalling centre (green) is located at the 
cortical hem and secretes Wnts and BMPs. The ventral signalling centre (red) secretes Shh. 
There is also a lateral signalling centre located at the pallial-subpallial boundary PSPB (not 




The previously mentioned signalling centres responsible for the formation of the 
telencephalon act by contributing to the regionalisation of the forebrain and, 
consequently, the development of region-specific structures that comprise the 
forebrain (Figure 1.2) (Hoch et al., 2009). The rostral patterning centre is embedded 
in the anlage of the septum and secretes fibroblast growth factors (Fgfs). The 
caudodorsal centre, located at the cortical hem, secretes Wnts and bone morphogenic 
factors (BMPs), while the ventral signalling centre is located at the commissural pre 
optic area and secretes sonic hedgehog (Shh). Lastly, the lateral centre, which is 
located at the cortex/LGE interface, secretes an abundance of factors including: Fgf7, 
Fgf15, neuregulins, transforming growth factor α (Tgfα) and the Wnt antagonist, 
secreted frizzled-related protein 2 (Sfrp2) (Figure 1.2) (Hoch et al., 2009). 
 
Following neural induction, early regional specification of the telencephalon is 
mediated by the expression of Fgf8, BMP and Shh signalling, as well as the 
restriction of Wnt activity to dorsal domains by Wnt antagonists (Schneider et al., 
2001; Haliagic et al., 2003; Ribes et al., 2006; Halilagic et al., 2007; Molotkova et 
al., 2007). The formation of the dorsal and ventral regions of the telencephalon 
swiftly follows the closure of the neural tube during the process of neurulation and is 
tightly controlled by growth and morphogenic signals responsible for regional 
pattering of the forebrain. The dorsal and ventral regions of the developing 
telencephalon give rise to the pallium (comprised of structures such as the cerebral 
cortex and hippocampus) and subpallium (comprised of the medial and lateral 
ganglionic eminences) respectively and their development relies upon the expression 
of opposing morphogen signals in order to specify their positional identity 
(Rubenstein and Beachy, 1998; Wilson and Rubenstein, 2000; Wilson and Houart, 
2004; Hoch et al., 2009). 
 
Positional identity of telencephalic structures relies upon the interplay and 
crossregulation of multiple signalling factors in order to specify structural identity 
along the DV axis of the developing forebrain. The pallium and subpallium 
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principally arise from the activity of opposing morphogens; Shh from the ventral 
signalling centre and the secretion of Bmps and Wnts from the dorsal signalling 
centre respectively, allowing specification of positional identity along the DV axis 
(Hoch et al., 2009). The ventral secretion of Shh is present from early on during the 
process of shaping the forebrain, originating originally from the anterior mesoderm 
and then later from the ventral hypothalamus and rostroventral telencephalon as the 
telencephalon develops in its complexity (Wilson and Houart, 2004). On the other 
hand, morphogens responsible for specifying a dorsal structure are secreted from the 
paramedial neuroectoderm and the dorsal midline (Hoch et al., 2009). However, Shh 
and Bmps/Wnts are not solely responsible for the development of the pallium and 
subpallium, with multiple additional factors such as the Fgf family and transcription 
factors Gli3 and Pax6 to name but a few also playing a vital role during telencephalic 
patterning (Rubenstein and Beachy, 1998; Wilson and Rubenstein, 2000; Wilson and 







Figure 1.3 The structures of the developing telencephalon 
 
Taken from Cocas et al., 2001. A schematic representation of the structures that make up 
the developing telencephalon during embryogenesis. The telencephalon is divided into the 
pallium and subpallium and are separated by the pallial subpallial boundary (PSPB). The 
pallium includes the developing cortex (neocortex) and the subpallium includes the 




As mentioned, Fgfs are required during telencephalic development. Fgfs originate 
from the RPC and are a major contributor to the specification of the telencephalon 
into dorsal and ventral domains by their regulation of signalling factors residing at 
the pallial-subpallial boundary (PSPB) (Hoch et al., 2009). The PSPB resides 
between the pallium and subpallium and secretes a variety of signals, such as Fgf7, 
Fgf15, Sfrp2 and members of the Egf family, which act to define a molecular 
boundary between the pallium and subpallium as well as instructing development of 
forebrain structures (Assimacopoulos et al., 2003; Borello et al., 2008). Additionally, 
Fgfs are responsible for the activation of Shh and Nkx2.1 expression, which are both 
required for specification of the ventral region of the telencephalon. The activation of 
Shh by Fgf signalling induces the lateral ganglionic eminences (LGE) and medial 
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ganglionic eminences (MGE) that constitute the subpallium of the telencephalon. It 
is likely that Shh instigates this in part at least by its repression of the transcription 
factor Gli3, a factor that instigates a dorsal telencephalic fate over a ventral fate 
(Ishibashi and McMahon, 2002; Rallu et al., 2002; Rash and Grove, 2007; Ulloa and 
Briscoe, 2007). 
 
An abundance of experimental evidence suggests that the aforementioned 
morphogens secreted at the PSPB are of key importance during specification of 
telencephalic structures. It has been suggested that these signals potentially restrict 
Wnt activity to the dorsal telencephalon, consequently encouraging ventral 
specification (Assimacopoulos et al., 2003). Past studies using Pax6-/- mice observed 
that mutant embryos display a severe disruption of the PSPB and lack the anti-hem 
signals that are expressed there, resulting in telencephalic structures forming 
incorrectly (Yun et al., 2001). Furthermore, it has been suggested that the signals 
secreted at the PSPB either control the transcription factors Pax6 and Gsh2, or are 
controlled by them to compartmentalise the telencephalon into its specific regions 
(Yun et al., 2001; Hoch et al., 2009; Cocas et al., 2011). This notion is due to 
research by Yun et al., (2001) which showed that Pax6-/- mutant embryos see a 
dorsal expansion of ventral telencephalon gene expression and Gsh2-/- mutant 
embryos see a ventral expansion of dorsal telencephalon gene expression. In wild-
type (WT) embryos, Pax6 and Gsh2 are expressed in the pallium and subpallium 
respectively, and their expression patterns abut the PSPB, so the previously 
mentioned observations are particularly interesting in terms of how patterning of the 
telencephalon is achieved (Yun et al., 2001). Cocas et al., (2011) provided further 
evidence of the mutual relationship between Pax6 and Gsh2 to co-repress one 
another, where specific loss of Pax6 in Gsh2 expressing cells saw an expansion of 
the LGE of the subpallium, consequently distorting the formation of the 
telencephalon (Cocas et al., 2011). However, regardless of whether anti-hem signals 
regulate Pax6 and Gsh2 or vice versa, transcription factors Pax6 and Gsh2 and anti-
hem signals at the PSPB are critical during the specification of structures that 




1.4 Cortical development 
 
During embryogenesis, the cerebral cortex develops as a result of the process of 
neurogenesis and the migration of the resulting generated neurons from the 
ventricular zone (VZ), and at later stages in the subventricular zone (SVZ), of the 
telencephalon during embryonic development (Manuel et al., 2015). Neurogenesis is 
essentially the process that generates the neurons that come together to craft the 
structures that comprise the fully formed brain. During neurogenesis, neurons are 
produced from neural progenitor cells residing within the proliferative zone of the 
developing brain. The vast majority of neurogenesis occurs during embryonic 
development when a vast number of neurons are required to produce the developing 
brain, but neurogenesis continues postnatally while the brain continues to develop 
(Anderson and Vanderhaeghen, 2014). Furthermore, adult neurogenesis continues 
thereafter in a small number of structures such as the olfactory bulb and 
hippocampus (Eriksson et al., 1998; Temple and Alvarez-Buylla, 1999; Ma et al., 
2010). 
 
The generation of new neurons during embryonic neurogenesis implicates different 
types of cell division that are specific to different progenitor cell types and produce 
different cell types as a result (Laguesse et al., 2015). These cell divisions are: 
symmetrical progenitor cell divisions, asymmetrical progenitor cell divisions and 
terminal symmetrical progenitor divisions. Symmetrical cell divisions produce two 
new progenitor cells and replenish the proliferative cell pool as a result (Figure 1.4), 
while asymmetrical divisions generate a single neuron and one new progenitor cell, 
therefore still replenishing the progenitor cell population and allowing subsequent 
rounds of neurogenesis to take place (Figure 1.4). However, terminal symmetrical 
divisions produce two neurons, consequently diminishing the progenitor cell pool 
within the proliferative zone. Throughout development of the cerebral cortex, neural 
progenitor cells residing in both the VZ and SVZ, that constitute the proliferative 
zone of the cortex, carry out all three types of cell division depending on which 
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progenitor cell subtype they are (Chenn and McConnell, 1995; Farkas and Huttner, 




Figure 1.4 Cell divisions and progenitor cell subtypes during cortical neurogenesis  
 
Taken from Laguesse et al., 2015. Apical progenitors (APs) encompass neuroepithelial cells 
(NEs), short neural precursor cells (SNPs), radial glial cells (RGCs). NEs divide 
symmetrically to self- renew and expand the surface area of neural tube or to produce two 
RGCs. During neurogenesis, RGCs divide asymmetrically to produce one RGC and one 
neuron (direct neurogenesis), or one RGC and one intermediate progenitor cells (INP) 
(indirect neurogenesis). SNPs have no attachment to the basal lamina and tend to generate 
two neurons. INPs are basal progenitors (BPs) and reside in the SVZ. INPs are not attached 
to the apical membrane or the basal lamina. INPs retract their processes during M-phase 
and produce either two new INPs or two neurons by symmetric division.  
 
 
1.5 Progenitor cell sub populations  
 
Classically, three distinctive types of neural progenitor cells were proposed to be 
involved in cortical development and are distinguished by differing cellular 
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morphology, mitotic divisions, molecular expression, regional position, and daughter 
cell fate (Huttner et al., 2005; Pontious et al., 2007). These subpopulations are: 
neuroepithelial cells (NEs), radial glial cells (RGCs), and intermediate progenitor 
cells (INPs). In addition to the three classically defined progenitor cell populations, a 
further population has been identified; short neural precursor cells (SNPs). 
 
NEs are categorically the primary progenitor cell type and all subsequent progenitor 
cell subtypes are derived solely from them (Laguesse et al., 2015). In principle, NEs 
are neural stem cells, or stem cells of the CNS, in that they have acquired a neural 
fate although their eventual neuronal cell fate is yet to be determined. NEs have the 
ability to produce any type of neuronal cell and each subsequent differentiation into a 
different progenitor cell subtype further restricts neural cell fate (Götz and Huttner, 
2005). NEs derive from the ectoderm during neural induction and display similar 
features to epithelial cells, most notably an apical-basal polarity during the process of 
cellular mitosis (Huttner et al., 2005).  
 
The formation of cortical layers relies upon the production of RGCs by NEs. RGCs 
are formed when NEs undergo asymmetric cell division, producing one new NE and 
one RGC. Generally speaking, RGCs have similar properties to NEs but do differ 
from the latter by their expression of astroglial markers and their further restricted 
eventual cell fate (Laguesse et al., 2015). Due to the fact that RGCs are more fate 
restricted than their neural precursors and also essentially replace them in the 
progenitor zone, the vast majority of neurons that comprise the cerebral cortex are 
generated directly from them (Götz et al., 2005, Heins et al., 2008). As previously 
mentioned, progenitor cell subtypes are distinguished by unique characteristics, such 
as distinct molecular expression and how they undergo cellular mitosis and division. 
RGCs are widely recognised as expressing molecular markers such as Pax6, Sox2 
and Olig2 - providing a relatively quick and reliable way to identify the progenitor 
cell type by immunohistochemical analysis. RGCs have also been identified by 
previous studies as characteristically projecting from the apical surface of the VZ, 
and extending through the neural cell layers towards the basal lamina by basal 
processes. RGCs undergo mitosis towards the apical surface of the VZ, and divide 
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asymmetrically to produce one daughter cell that continues to reside within the VZ 
and either one neural precursor cell or one INP which migrate from the VZ to form 
the layers of the cortex or to reside within the SVZ respectively (Figure 1.4) (Noctor 
et al., 2001; Götz and Huttner, 2005; Huttner and Kosodo, 2005; Hevner, 2006; Tan 
and Shi, 2013). Alongside RGCs, the VZ also contain an additional subpopulation of 
progenitor cell, SNPs. SNPs undergo symmetric cell divisions only to produce pairs 
of neurons and are consequently unable to self-renew unlike other progenitor cell 
subtypes (Gal et al., 2006; Tan and Shi, 2013; Manuel et al., 2015).  
 
INPs are transient amplifying neural progenitor cells, in that they undergo a more 
restricted round of cell divisions before terminating and differentiating as neural 
precursor cells (Farkas and Huttner, 2008). INP cells differ from RGCs in that they 
undergo symmetric cell division, producing either two INP cells that continue to 
reside within the SVZ, or two neural precursor cells that migrate from the progenitor 
zone to create the neuronal layers of the cerebral cortex (Figure 1.5) (Haubensak et 
al., 2004; Miyata et al., 2004; Noctor et al., 2004). Furthermore, INPs undergo basal 
cell divisions within the proliferative zone of the developing cortex and differ from 
RGCs in terms of their expression of genes unique to their cell subtype, such as the 
transcription factor Tbr2 (Englund et al., 2005). These distinct differences between 
INPs and fellow progenitor cell subtypes were identified by previous studies 
conducted by groups investigating progenitor cells during embryogenesis, and 
incorporated time-lapse imaging analysis of slice cultures and by in-depth gene 
expression analysis (Hevner, 2006; Pontious, 2007; Pierfelice et al., 2011). 
 
Interestingly, although the majority of INPs are located within the SVZ and they are 
classically defined as residing within this region of the proliferative zone of the 
developing cerebral cortex, a fraction of INPs have been identified as being located 
within the VZ. INPs residing within the VZ (INPVZs) were initially identified by their 
expression of the transcription factor Tbr2, as RGCs do not express it. Additionally, 
INPs lack the apical end feet that are characteristic of RGCs and INPs residing 
within the VZ are no exception (Götz and Huttner, 2005). Why a small number of 
INPs are found within the VZ is still not entirely clear, however it has been 
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suggested that they are newly generated INPs in the process of migrating into the 
SVZ (Englund et al., 2005; Corbin et al., 2009), suggesting that INPVZ cells could be 
the link between RGCs and INPs, in that they have newly differentiated and could 




1.6  Laminar organisation of the cerebral cortex 
 
As previously discussed, the cerebral cortex is comprised of layers of neurons that 
are produced during embryogenesis by the process of corticogenesis; neurogenesis 
which is specific to cortical development. The formation of the layers of the cortex 
during cortical development is the product of the radial migration of newly generated 
neurons produced by cellular differentiation (Chenn and McConnell, 1995; Götz, 
2001). Neural cell division occurs as the nucleus of the cell moves from an apical to 
a basal position, towards the pial surface. S phase, when DNA replication 
commences, occurs at the pial surface and M phase, when mitosis occurs, takes place 
at the ventricular surface. As previously discussed, the cerebral cortex initially 
consists of the VZ only and its development occurs as progenitor cells divide to yield 
neurons. The newly generated neurons cease to have contact with the ventricular 
surface and settle underneath the pial surface to aid the formation of a layer of the 
cortex. As the process of neurogenesis continues, newly generated neurons proceed 
with forming additional cortical layers directly beneath the pial surface, guided by 
the processes of RGCs that retain a constant connection via a process with the pial 





Figure 1.5  The formation of cortical layers during development of the cerebral cortex 
 
Taken from Manuel et al., (2015). A coronal section through the developing cortex depicting 
progenitor cell subtypes residing in the VZ and SVZ and the migration of neurons to form the 
cortical plate (CP), subplate (SP) and intermediate zone (IZ). that will form the layers of the 




The developing cortex undergoes rounds of neurogenesis during embryonic 
development until it consists of three neuronal layers: the marginal zone (MZ), 
subplate (SP) and cortical plate (CP); and two proliferative layers, the VZ and SVZ, 
that together comprise the proliferative zone. Neurons produced initially after 
neurogenesis commences to form the preplate of the developing cortex (Götz and 
Sommer, 2005). During this early stage, the processes of RGCs that aid neuronal 
migration do not guide neurons to their destination. Later on, neurons migrating with 
the aid of RGC guidance settle in the preplate, dividing it into two layers, the 
marginal zone and the subplate, forming the cortical plate between them (Levitt et 
al., 1997). Following cortical plate formation, the SVZ develops directly above the 
VZ, producing an additional proliferative layer (Figure 1.4) (Götz, 2001). 
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In terms of the adult cerebral cortex, its layers are numbered according to their 
proximity to the pial surface, with the MZ of the developing cortex forming the first 
layer. Neurons which formed the cortical plate develop into layers 2-6 and the 
subplate forms layer 6b of the adult cortex (Götz, 2001). 
 
 
1.7 A comparison between mice and humans 
 
While mammalian embryonic cortical development is relatively conserved from 
species to species, there are some distinct differences amongst some. This is most 
notable when comparing murine cortical development to human cortical 
development during embryogenesis, where the obvious differences in cortical 
morphology reflect the different progenitor cell subpopulations and their 
characteristic cell divisions (Florio and Huttner et al., 2014). First and foremost, the 
human cerebral cortex is roughly around 1000 times larger than that of the mouse, 
with this stark difference in size largely being attributed to the increased level of 
neurogenesis that occurs during human – and more generally, primate - embryonic 
development (Azevedo et al., 2009). 
 
In comparison to mice, the SVZ of primates is much larger and contains both and 
inner (ISVZ) and outer (OSVZ) region. While the ISVZ predominately contains 
INPs akin to the INPs found in the murine SVZ, the OSVZ is comprised mainly of 
radial glial-like outer radial glial cells (ORGCs) (Florio and Huttner et al., 2014). 
ORGCs are similar to their RGC counterparts located in the VZ but differ 
morphologically as they do not have an apical process and instead only have a basal 
process extending towards the pial surface. Furthermore, ORGCs are incapable of 
directly generating neurons unlike their RGC counterparts, instead undergoing self-
renewing and proliferative asymmetric cell divisions in order to generate one ORGC 
and one INP, as well as neurogenic divisions (Fietz et al., 2010; Hansen et al., 2010; 
Reillo et al., 2011). While ORGCs are generally associated with primates, they have 
also been observed in the SVZ of mice but only contribute a small percentile of the 
total progenitor cell population of the SVZ in comparison (Manuel et al., 2015). To 
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put it simply, ORGCs in the OSVZ of the human/primate cortex undergo multiple 
rounds of self amplification in order to maintain the proliferative cell pool, and the 
majority of primate cortical neurons are generated by ORGC neurogenic divisions as 
a result (Florio and Huttner et al., 2014). 
 
An additional difference between the developing cortex of mice and humans is the 
difference between INPs of the SVZ and ISVZ in terms of their proliferative and 
differentiative abilities. While INPs located in the SVZ of the murine cortex undergo 
symmetrical divisions in order to produce a pair of INPs or a pair of neurons, INPs in 
the ISVZ of the primate cortex can yield any other INP subtype and undergo 
additional rounds of amplification unlike their murine counterparts (Haubensak et 
al., 2004; Miyata et al., 2004; Noctor et al., 2004).  
 
Lastly, in humans, PAX6 is expressed by progenitors in the VZ, ISVZ and OSVZ. 
This contrasts with the expression of Pax6 in mice where it is restricted to RGCs. 
Furthermore, while Pax6 and Tbr2 are expressed sequentially in mice and are 
associated as markers of RGCs and INPs respectively, many cells co-express Pax6 
and Tbr2 in the developing cortex of primates (Englund et al., 2005; Cappello et al., 
2006; Manuel et al., 2015).  
 
 
1.8 The role of notch signalling during cortical development  
 
Notch signalling occurs throughout the process of embryogenesis and also plays a 
key role in a variety of biological processes postnatally (Guruharsha et al., 2012; 
Mathieu et al., 2013). During embryogenesis, Notch signalling is involved in a 
variety of developmental processes including somatogenesis (Wahi et al., 2014), 
organogenesis (Fortini et al., 2012) and neurogenesis (Egger et al., 2011; Pierfelice 
et al., 2011). During the process of cortical neurogenesis in the mouse, Notch 
signalling plays a critical role in the regulation of the progenitor pool (Corbin et al., 
2009). The key importance of Notch signalling during neurogenesis was initially 
identified in Drosophila, where it was discovered that a disruption in the Notch 
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cascade resulted in the generation of too many neurons and a consequent radical 
depletion of the neural progenitor pool (Artavanis-Tsakonas et al., 1999). The 
classical view of Notch signalling is that a cell fated to differentiate into a neuron 
signals to a neighbouring cell, supressing cell fate and thus maintaining the 
proliferative cell pool. This mechanism, termed ‘lateral inhibition’ was discovered 
initially in Drosophila neuroblasts (Campos-Ortega, 1993) and has subsequently also 
become the universally accepted model for Notch signalling in the vertebrate CNS 
(Pierfelice et al., 2011). As a result, the role of Notch signalling during embryonic 
neurogenesis has been extensively researched in multiple animal models such as 
mammalian cell lines, Xenopus and chick embryos, as well as mouse embryos. 
Notable research included gain-of-function studies that observed that the activation 
of Notch signalling inhibits neuronal differentiation and promotes the maintenance of 
progenitor cells (Gaiano et al., 2000; Hitoshi et al., 2002; Yoon et al., 2005), and 
over-expression studies in Xenopus that revealed increased expression of the Notch 
ligand Delta inhibits neurogenesis and increases preservation of the progenitor cell 
pool (Chitnis et al., 1995). These studies determined that activation of Notch 
signalling influenced cell fate during neurogenesis, similar to the original Notch 
research conducted using Drosophila (Chitnis et al., 1995; Coffman et al., 1993; 
Henrique et al, 1995, 1997; Kopan et al., 1994; Nye et al., 1994; Pierfelice et al., 
2011; Wettstein et al., 1997).  
 
While Notch signalling is of key importance during embryonic neurogenesis, it is 
also crucial during development of the cerebral cortex specifically (corticogenesis), 
with the pathway playing a vital role in the regulation of cell proliferation and 
differentiation that allow the neuronal layers that make up the cortex to form 
correctly (Egger et al., 2012). In mammals, a simplified overview of the Notch 
signalling pathway is as follows: Proneural genes (e.g. Mash1 and Ngn2) induce the 
expression of Notch ligand genes, the Delta-like (Dll) and Jagged (Jag) families. 
Notch ligands move to the surface of a neighbouring progenitor cell, binding to one 
of the four Notch receptors (N1-N4). This results in the intramembranous cleavage of 
Notch receptors by the γ-secretase complex, which in effect releases the active form 
of Notch, referred to as the Notch intracellular domain (NICD). The NICD 
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translocates to the nucleus of the cell, where it forms a complex with the DNA 
binding protein (RBPj). The newly formed NICD/RBPj complex acts to induce the 
expression of target proneural inhibitor genes, such as the basic helix-loop-helix Hes 
and Hey families, which act to supress neurogenesis by antagonizing the function of 
the aforementioned proneural genes initially responsible for activating the Notch 
signalling cascade (Figure 1.6). Failure to fully activate Notch signalling results in all 
neural progenitor cells differentiating into early-born neurons and an extreme 
reduction in the progenitor cell pool (Pierfelice et al., 2011; Imayoshi et al., 2013). 
This would result in the proliferative zone of the cortex failing to produce the 
necessary spectrum or number of cells, resulting in the failure of the cerebral cortex 
to form correctly (Oshtsuka et al., 1999; Gaiano et al., 2000; Yoon and Gaiano 2005; 
Louvi et al., 2006; Basak and Taylor 2007; Kageyama et al., 2008a; Corbin et al., 







Figure 1.6 A simplified overview of Notch signalling 
 
A cell fated to differentiate into a neuronal cell expresses proneural genes (Ngn2, Mash1), 
which activate Notch ligands (Dll and Jag). Notch ligands then activate the Notch receptors 
on the surface of a neighbouring cell, cleaving the active form of Notch (NICD). The NICD 
translocates to the cell nucleus and activates the proneural inhibitor genes (Hes and Hey 




1.9  Mechanisms of Notch signalling  
 
In terms of mammalian cortical development, the aforementioned lateral inhibition 
hypothesis suggests that intracellular regulation between a neuronal fated cell and its 
neighbouring cell inhibits the latter from differentiating into a neuron also (Pierfelice 
et al., 2011). Lateral inhibition accounts for the maintenance of the neural progenitor 
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pool during the process of neurogenesis in order to give rise to the required number 
and full spectrum of cells necessary for the formation of complex brain structures 
during embryonic development (Kageyama et al., 2008b). In situ hybridisation 
analysis has shown that proneural genes and Notch ligand genes involved in the 
signalling pathway are expressed at varying levels in the proliferative zone, forming 
distinctive ‘salt and pepper’ expression patterns. The classic view of Notch signalling 
suggests that lateral inhibition is responsible for the formation of these salt and 
pepper patterns of gene expression and is based on neurogenesis studies in 
Drosophila melanogaster and Caenorhabditis elegans vulva development studies 
(Artavanis-Tsakonas et al., 1999). It is suggested that initially all neural progenitor 
cells express proneural genes and notch ligands at similar levels, but as neurogenesis 
continues during development some cells express higher levels of these genes due to 
stochastic variations and consequently possess the ability to activate Notch signalling 
in adjacent cells far more efficiently. This results in the latter cells expressing high 
levels of proneural inhibitor genes (such as Hes1), therefore inhibiting the expression 
of proneural genes and consequently, Notch ligand genes. As a consequence, the 
former cells are affected less by Notch signalling and subsequently up-regulate 
proneural and Notch ligand genes to a higher degree. Therefore, the classic view of 
Notch signalling suggests that lateral inhibition works to amplify stochastic 
variations between neighbouring cells, consequently resulting in the aforementioned 
characteristic salt and pepper expression patterns of proneural genes and Notch 
ligands (Kageyama et al., 2008b). This suggests that cells expressing proneural and 
Notch ligand genes are fated to differentiate into postmitotic neurons. However, it 
has been argued that the salt and pepper expression patterns of some Notch signalling 
genes are merely a snapshot of gene expression and therefore do not account for 
subsequent gene expression levels or the fate of the progenitor cells in question 
(Kageyama et al., 2008b).  
 
While this was the universally accepted view of Notch signalling for a lengthy period 
of time, more recent research has challenged the current view of lateral inhibition, 
showing that the expression of some Notch genes changes dynamically within single 
neural progenitor cells during embryogenesis (Shimojo et al., 2008; Kageyama et al., 
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2009). Real-time imaging carried out in the 2008 study by Shimojo et al., (2008) 
demonstrated that that the bHLH proneural inhibitor gene Hes1 oscillates in a 
cyclical fashion within neural progenitor cells in a period of 2-3 hours. Additionally, 
live imaging further showed that the proneural gene Ngn2 and the Notch ligand Dll1 
are also expressed in an oscillatory manner but with an inverse correlation to Hes1 
(Figure 1.7 B). In other words, when Hes1 expression is high, Ngn2 and Dll1 
expression is low, and vice versa, during oscillations (Shimojo et al., 2008). As a 
result of these observations coupled with the knowledge that Hes1 inhibits proneural 
gene expression, it has been suggested that Hes1 regulates the observed Ngn2 
oscillations and that Dll1 oscillations are regulated in turn by Ngn2 (Kageyama et al., 
2008b). As a result, it is likely that these oscillations are essential for the 
maintenance of the neural progenitor pool during embryonic development by 
keeping progenitor cells in a proliferative, undifferentiated state due to their mutual 
activation of Notch signalling. However, the exact mechanism that initiates and 







Figure 1.7 An overview of Notch oscillations during lateral inhibition 
 
Taken from Shimojo et al., 2008b. (A) Levels of Hes1 and Ngn2/Dll1 expression oscillate in 
proliferating neural progenitor cells with opposing levels of expression from one another. 
When Hes1 expression is high, Ngn2/Dll1 expression is low and vice versa. When a cell 
commits to differentiating, Hes1 expression remains low and Ngn2/Dll1 remains high. (B) 
The revised view of lateral inhibition suggests that when Hes1 expression is low in a cell, the 
neighbouring cell it signals to displays high Hes1 expression and vice versa. 
 
 
It was originally believed that only postmitotic neurons express Notch ligand genes 
such as Dll1 and that in turn only they could activate Notch signalling in neural 
progenitors to keep them in their undifferentiated state. However, it was later 
determined that Notch ligands are also expressed by neural progenitor cells early on 
in development (prior to embryonic stage E11.5) before they have started to give rise 
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to neurons (Guillemot and Joyner, 1993; Bettenhausen et al., 1995; Lindsell et al., 
1996; Sommer and Anderson, 1996; Nieto et al., 2001; Hatakeyama et al., 2004; 
Hatakeyama and Kageyama, 2006; Hämmerle and Tejedor, 2007; Nelson and Reh, 
2008). However, Hes1 is not expressed by postmitotic neurons and consequently, 
their oscillatory control of Notch signalling cannot apply to the maintenance of all 
neural progenitors. It has therefore been suggested that the cyclic expression of Ngn2 
and Dll1 is a mechanism required to initiate neuronal differentiation and following 
that, acts as a secondary source by which Notch signalling is activated in neural 
progenitor cells (Shimojo et al., 2009; Kageyama et al., 2008b). Consequently, a 
revised version of the classic model of lateral inhibition (Figure 1.6 B) has been 
suggested in order to account for the oscillatory expression of Notch genes in neural 
progenitor cells (Kageyama et al., 2008b). 
 
The revised lateral inhibition hypothesis accounts for the salt and pepper expression 
patterns of the Ngn2 and Dll1 by suggesting that their dynamic expression varies 
from cell to cell, resulting in the oscillations of cells occurring out of sync with one 
another. Consequently, the unsynchronised oscillations occurring in neural 
progenitor cells would cause differing gene expression levels from cell to cell, 
resulting in the distinct salt and pepper expression patterns for the above-mentioned 
Notch genes (Kageyama et al., 2008b; Imayoshi et al., 2013; Imayoshi et al., 2014; 
Shimojo et al., 2016; Shimojo and Kageyama, 2016). Numerous Notch genes have 
been observed to oscillate in neural progenitor cells during embryonic development, 
including the proneural genes Ngn2 and Mash1, the Notch ligand Dll1, and the 
proneural inhibitor genes Hes1, Hes5 and Hes7 (Kageyama et al., 2008b; Shimojo et 
al., 2008; Imayoshi et al., 2013; Imayoshi et al., 2014; Shimojo et al., 2016; Shimojo 
and Kageyama, 2016). Evidence that components of the Notch signalling pathway 
oscillate in neural progenitor cells during forebrain development was initially 
discovered by Shimojo et al., (2009), who observed dynamic oscillations of Hes1, 
Ngn2 and Dll1 by live image analysis of their expression in single cells. In order to 
achieve this, ubiquitinated firefly luciferase reporters under the control of the Hes1, 
Ngn2 or Dll1 promoter were used and biolumiensance levels were monitored in both 
dissociated and slice cultures taken from the telencephalon of embryos that had been 
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electroporated with the luciferase construct of choice (Shimojo et al., 2009). Hes1 
levels were found to be high when Ngn2/Dll1 levels were low and vice versa, while 
the sustained up-regulation of Ngn2/Dll1 in a cell resulted in the sustained down-
regulation of Hes1 and the expression of the neuronal marker Tuj1. This suggests 
that components of the Notch signalling pathway oscillate dynamically in order to 
keep neuronal progenitors in an undifferentiated state until they are selected by a yet 
to be identified mechanism that causes them to differentiate into a neuron (Shimojo 
et al., 2009). Further work by Imayoshi et al., (2013; 2014) identified that Hes1 is 
not only responsible for periodically repressing the proneural gene Ngn2, but also 
Mash1. Furthermore, it was observed that oscillatory expression of Mash1 promotes 
neural progenitor cell proliferation, while its sustained expression induces neuronal 
differentiation, suggesting that Mash1 is capable of promoting opposing functions 
that are dependant on its expression dynamics (Imayoshi et al., 2013; Imayoshi et al., 
2014; Shimojo and Kageyama, 2016). In light of these findings, it can be assumed 
that oscillatory vs. sustained expression of proneural factors is crucial in cell 
proliferation and differentiation during brain development (Shimojo and Kageyama, 
2016).  
 
Further investigations of the dynamic expression of Notch pathway components was 
recently undertaken by Shimojo and colleagues, who found that Dll1 protein 
expression also oscillates dynamically in neural progenitor cells (Shimojo et al., 
2016). Quantification of time-lapse imaging found that the average period of Dll1 
oscillation was ~2.3 hours, a similar length to that of Hes1 oscillations (Shimojo et 
al., 2008; Shimojo et al., 2016). Furthermore, it was found that in a number of 
dividing neural progenitor cells, Dll1 was distributed between both daughter cells but 
that Dll1 expression had begun to oscillate in an anti-phase manner between them, 
suggesting that these cells remained as progenitor cells following cell division 
(Shimojo et al., 2016). In order to further analyse the effects of Dll1 oscillations on 
cell proliferation and differentiation, two type of transgenic mice were generated: 
Type1, where introns were removed causing Dll1 expression to be accelerated by ~6 
minutes in comparison to WT controls, and Type2, where Dll1 expression was 
delayed by ~6 minutes compared to the WT control. In both types of Dll1 mutant, 
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Dll1 expression patterns appeared similar to that of WT mice, however, Dll1 
oscillations were quenched, as were Hes1 oscillations. Furthermore, both Dll1 
mutant types were found to have an increase in the expression of the INP marker 
Tbr2 and the neuronal marker Tuj1 when compared to WT control embryos, as well 
as a reduction in the size of the VZ and a reduction in mitotic cells within the VZ, 
suggesting that a premature cell cycle exit for neural progenitors when Dll1 
expression is steady as opposed to dynamic. Additionally, it was found that there was 
an overall reduction in brain size in Dll1 Type1 and Type2 mutant embryos, but an 
increase in thickness of post-mitotic neuronal layers when compared to WT controls, 
suggesting that the dampening of Dll1 oscillations subsequently disrupts Hes1 
oscillatory expression, resulting in accelerated neuronal differentiation at the expense 
of the progenitor cell population. Overall, this suggests that dynamic expression of 
Dll1 favours the maintenance of progenitor cells in their proliferative state, while 
sustained Dll1 expression favours neuronal differentiation during embryogenesis 
(Shimojo et al., 2016). Furthermore, due to the fact that continuous, sustained Dll1 
expression results in the quenching of Hes1 and Hes7 oscillations and consequently 
neural defects, it can be suggested that the correct dynamic expression of Dll1 is of 
great importance for normal Notch pathway signallingand as a result, correct 
embryonic brain development (Shimojo et al., 2016). 
 
Following the initial study of Notch oscillations in neural stem cells by Shimojo et 
al., (2008), it was suggested that Notch signalling is only required for maintenance of 
the neural progenitor cell pool and unlikely to be required for neuronal selection. 
This assumption was based on the fact that dynamic expression of Ngn2 and Dll1 
was only observed in progenitor cells (Shimojo et al., 2008). The classic model of 
lateral inhibition stated that the expression of Ngn2 and Dll1 by a cell meant that it 
was selected for a neuronal fate, but the oscillatory expression of these genes indicate 
that their fate remains unrestricted and that the expression of these genes does not 
automatically determine their fate (Kageyama et al., 2008b). As a result, it has been 
concluded that the salt and pepper patterns of expression that were previously 
thought to indicate neuronal selection, are in fact merely the evidence of oscillatory 
expression (Kageyema et al., 2008b). However, while evidence suggests that Notch 
	 26
signalling does not directly control neuronal fate, it cannot be completed excluded as 
a likely candidate for exerting control upon the process. While it has been suggested 
that neuronal selection is likely to actually be regulated by Numb, a gene that has 
been implicated in regulating elements of Notch signalling, it is perhaps a rash 
assumption that the aforementioned Notch gene oscillations do not have an effect on 
neuronal selection. It has been suggested that cyclic expression can lead to the 
gradual accumulation of downstream factors that induce neuronal differentiation, 
such as the cell cycle exit gene BM88 that is known to induce neuronal 
differentiation (Politis et al., 2007). If this was to be the case, the number of 
oscillatory cycles of Notch genes could potentially be acting as a molecular clock, 
therefore determining when postmitotic neurons are generated (Kageyama et al., 
2008b). 
 
Recent analysis of Notch oscillations have identified that the Notch ligand Dll1 of 
the effects of Dll1 oscillatory expression vs sustained expression suggested that the 
precise timing of Dll1 expression is of the utmost importance to correct neural 
development. The fact that the acceleration of delay of Dll1 expression by just ~6 
minutes results in severe dampening of the oscillatory expression of Dll1 and 
proneural inhibitors Hes1 and Hes7 and a subsequent decrease in embryonic brain 
size attests to this, along with the fact that the quenching of Hes1 by Dll1 was highly 
unexpected due to the fact that Hes1 oscillates autonomously in the presence of 
steady NICD levels in neural progenitor cells (Shimojo and Kageyama, 2016). 
Furthermore, while oscillations in neural progenitor cells have been found to be out-
of-phase between neighbouring cells, Notch oscillations in the PSM have been found 
to occur in-phase of one another. This negates the original hypothesis that the salt 
and pepper expression pattern of Dll1 is characteristic of oscillatory expression, but 
rather a trademark of out-of-phase oscillations that occur specifically in neural 
progenitor cells. It has been suggested that the out-of-phase oscillations of Dll1 
observed in neural progenitor cells may be of importance to producing a diverse 
range of neural cell types and that it would be of interest to observe what happens to 
neural development if out-of-phase oscillations were switched to in-phase 
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oscillations and in order to better understand the significance of phase control of 
oscillations (Shimojo et al., 2016; Shimojo and Kageyama, 2016). 
 
While the traditional view of Notch signalling has been adapted to account for the 
oscillatory expression of Notch genes in neural progenitor cells, how these 
oscillations are controlled and induced is unknown. It is possible that that a further 
cellular mechanism of Notch signalling could initiate these oscillations. During the 
process of Notch signalling, Notch ligands act upon Notch receptors in two distinctly 
different ways. While the generalised view of Notch signalling sates that Notch 
ligands bind to the Notch receptors of neighbouring cells, Notch ligands are capable 
of binding to the receptors on the surface of the cell that secreted them (del Álamo et 
al., 2011). This phenomenon is referred to as ‘Cis-inhibition’, while the more 
traditional act of Notch ligands binding to Notch receptors on the surface of 
neighbouring cells is termed ‘Trans-activation’. While trans-activation results in the 
activation of proneural repressor genes, cis-inhibition blocks the cleavage of the 
NICD, in turn preventing the expression of proneural inhibitor genes and resulting in 
the up-regulation of proneural genes and Notch ligand genes (del Álamo et al., 
2011). Cis-inhibition was first discovered in Drosophila melanogaster where 
evidence of the repression of Notch by its ligands in a cell-autonomous manner was 
revealed by overexpression studies (Couso et al., 1995; Doherty et al., 1996; Klein et 
al., 1996; de Celis et al., 1997; Glittenberg et al., 2006). Evidence of cis-inhibition 
has also been shown in vertebrates with overexpression studies conducted in chick, 
Xenopus laevis and mouse (Franklin et al., 1999; Sakamoto et al., 2002; Itoh et al., 
2003), suggesting that cis-inhibition is a conserved mechanism of Notch signalling. It 
has been proposed that Notch signalling utilises both cis-inhibition and trans-
activation in order to promote both cell maintenance and differentiation (Lowell et 
al., 2000; Estrach et al., 2008). However, exact mechanisms underlying cis-
inhibition and the consequences of cis-interactions still remain poorly understood 
(del Álamo et al., 2011).  
 
It is plausible that cis-inhibition and trans-activation could be involved in controlling 
Notch oscillations that have been observed in neural progenitor cells. This would 
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account for the cyclical expression of Ngn2 and Dll1, as there are multiple Notch 
receptors on the surface of a cell. This would suggest that an onslaught of cis-
inhibition and trans-activation could occur upon a progenitor cell, potentially 
activating and repressing the expression of downstream genes involved in neuronal 
differentiation until their levels peak to the point that they win out the majority and a 
cell differentiates, as suggested by Kageyama et al., (2008b). However, while this 
hypothesis may provide an explanation for why oscillations of Notch genes occur, it 
does not fully account for what actually drives Notch expression and controls its 
regulation of the progenitor pool. What drives Notch signalling and its oscillations 
remains elusive. It could be postulated that Notch could be driven by Numb 
(Kageyama et al., 2008b), a collection of factors working together, or by an as yet 
unidentified master regulator. 
 
 
1.10 Pax6 and cortical development  
 
The paired-box transcription factor Pax6 is expressed from E8.5 during murine 
embryogenesis in an abundance of developing structures, including the forebrain 
(Walther and Gruss, 1991; Stoykova and Gruss 1994; Geotgala et al., 2011). Pax6 
belongs to the class IV Pax transcription factors, which characteristically have two 
DNA binding domains, a paired domain (PD) and a paired-type homeodomain (HD), 
as well as a C-terminal transactivation domain (Mansouri et al., 1996; Chi and 
Epstein, 2002). The PD and HD recognise different Pax6 consensus binding sites and 
it is likely that they regulate distinct developmental processes during embryogenesis 
by regulating specific gene targets both cooperatively and independently of one 
another (Jun and Desplan, 1996; Singh et al., 2000; Mikkola et al., 2001; Chi and 
Epstein, 2002; Xie and Cvekl, 2011). Pax6 expression is important for successful 
development of multiple regions of the mammalian CNS, acting at a molecular level 
upon its formation. Pax6 expression is vital for cell proliferation and differentiation 
during embryonic neurogenesis in the mammalian telencephalon, including the 
developing cerebral cortex (Sansom et al., 2009). In the developing cerebral cortex 
of WT embryos, Pax6 displays a very distinct high rostrolateral to low caudomedial 
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gradient expression pattern (Figure 1.8 B-D) (Manuel et al., 2014). Pax6 expression 
is mainly restricted to the mitotically active VZ of the pallium and in a small region 
of the ventral pallium at the level of the pallial-subpallial boundary (PSPB) (Walther 




Figure 1.8 The effects of loss of Pax6 expression during development and Pax6 
expression in the developing cerebral cortex 
 
Taken from Manuel et al., 2015 (B-D). (A) A coronal section of the brain of a Pax6+/+ and a 
Pax6-/- embryo stained for Jag1. The structures of the forebrain appear malformed in the 
Pax6-/- embryo. (B) A diagram of Pax6 expression illustrating that Pax6 is normally in a high 
rostrolateral to low caudomedial gradient in the developing cortex of WT embryos. (C) Pax6 
expression in a sagittal section (D) Pax6 expression in a coronal section. 
 
 
The importance of Pax6 for development of the CNS is demonstrated by the 
multiplicity of CNS defects observed in Pax6 mutants. A spontaneous mutation in 
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Pax6 known as the small eye (Sey) mutation is caused by a point mutation in the 
Pax6 gene, resulting in the production of a non-functional form of the protein. Sey is 
predominantly characterised by a radical reduction in eye size and can affect either 
one copy (heterozygous) or both copies (homozygous) of the Pax6 gene (Hill et al., 
1991). Heterozygous mutations in human PAX6 result in the congenital eye 
malformation termed aniridia (Hanson et al., 1993), while homozygous PAX6 
mutations result in multiple CNS defects, specifically in the eye, forebrain, 
cerebellum and spinal cord; as well as individuals who are homozygous for PAX6 
characteristically dying at birth. Furthermore, heterozygous (Pax6+/-) mutant mouse 
embryos are phenotypically characterised as having a reduced eye size in comparison 
to their wild type (WT) counterparts while the eyes in homozygous (Pax6-/-) mutant 
embryos fail to form at all (Hill et al., 1991; Stoykova et al., 2000). Previously 
mentioned forebrain defects in Pax6-/- mutants include an abnormally thin CP and an 
enlarged proliferative zone in the developing cerebral cortex (Schmahl et al., 1993; 
Caric et al., 1997). 
 
As Pax6 is expressed in RGCs located in the VZ of the cortex, it is generally 
accepted that Pax6 is of key importance during cortical development and that Pax6 is 
a key regulator of cell proliferation and differentiation during corticogenesis 
(Stoykova et al., 2000; Englund et al., 2005; Georgala et al, 2011a; 2011b); Mi et al., 
2013a; 2013b). Previous research focused on the role of Pax6 during cortical 
development has indicated that specific levels of Pax6 are required for normal 
development to occur during embryogenesis. The 2007 study by Quinn et al., 
utilising Pax6-/- ↔ Pax6+/+ chimeras, detected an under-representation of Pax6-/- 
progenitor cells in the developing cerebral cortex and that loss of Pax6 increases 
neural differentiation suggesting that Pax6 helps to maintain the progenitor cell pool 
during corticogenesis (Quinn et al., 2007). Furthermore, research into the effects of 
overexpression of Pax6 undertaken using Pax6 overexpressing (PAX77) transgenic 
mice, utilised BrdU labelling to show a reduction in the number of proliferating 
progenitors in the rostral and medial regions of the cortex, where Pax6 levels are 
highest (Manuel et al., 2007).  
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Furthermore, studies involving Pax6-/- mutants detected severe developmental brain 
defects, including an inability to form proper thalamocortical connections (Pratt et 
al., 2000; Pratt et al., 2002; Piñon et al., 2008; Simpson et al., 2009).  
 
	
1.11 Pax6 as a master regulator of corticogenesis  
 
As previously described, during formation of the mammalian brain, it is crucial that 
cell proliferation and differentiation are tightly controlled and coordinated as 
regulation of the number of generated neurons and progenitor cell subtypes has a 
profound influence upon the functional properties of the CNS (Walcher et al., 2013). 
The molecular mechanisms governing embryonic neurogenesis are relatively 
unknown. However, it is widely accepted that early patterning of the brain and 
progenitor cell fate are greatly influenced by transcriptional regulators (Zaret and 
Carrol, 2011). It has been suggested that certain transcription factors act as master 
regulators to coordinate developmental processes, such as neurogenesis, at a 
molecular level, by exerting their regulatory effects upon complex downstream gene 
networks (Davidson, 2010; Peter and Davidson, 2011; Xie et al., 2013; Sun et al., 
2015). However, the molecular mechanisms by which these regulatory proteins exert 
their effects remain poorly understood (Walcher et al., 2013). 
 
Pax6 acts as one of the aforementioned master regulators in various structures 
comprising the CNS (Hanson and Van Heyingen, 1995; Dohrmann et al., 2000; 
Kozmik et al., 2008; Osumi et al., 2008) and, as previously discussed, has been 
identified as having a crucial role in correct CNS development due to its key 
regulatory role over patterning, cell fate and proliferation (Hanson and Van 
Heyningen, 1995; Stoykova et al., 1996; Stoykova et al., 1997; Götz et al., 1998; 
Chapouton et al., 1999; Stoykova et al., 2000; Toresson et al., 2000; Yun et al., 
2001; Estivill-Torrus et al., 2002; Heins et al., 2002; Haubst et al., 2004; Quinn et 
al., 2007; Sansom et al., 2009; Tuoc et al., 2009).  
 
At the onset of neurogenesis, Pax6 is expressed predominantly to influence 
arealisation of the cortex and regulation of neural progenitor cell proliferation 
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(Bishop et al., 2000, 2002; Muzio et al., 2003; Muzio and Mallamac, 2003; Hevner 
et al., 2006; Manuel et al., 2015). Previous research into the role of Pax6 during 
embryonic development of the forebrain has highlighted the regulatory role of the 
transcription factor in both temporal and spatial control of cell cycle duration cell 
cycle exit, cell cycle length and proliferation; as well as its implication in the 
temporal and spatial control of cell cycle duration in cortical progenitor cells 
(Manuel et al., 2015). For example, it has been documented that a loss of Pax6 leads 
to a reduction in the cell cycle duration of cortical progenitor cells and an increase in 
the proportion of asymmetrical cell divisions, resulting in a surge in the production 
of post-mitotic neurons and as a result, a reduction of progenitor cells within the 
proliferative zone of the cortex (Warren et al., 1999; Estivill-Torrus et al., 2002; 
Walcher et al., 2013). Additionally, cultured Pax6-/- cortical cells displayed 
inhibited progenitor cell proliferation (Estivill-Torrus et al., 2002). 
 
For example, gain-of-function studies have demonstrated that forced expression of 
Pax6 diminishes progenitor cell proliferation in vitro (Heins et al., 2002; Hack et al., 
2004; Cartier et al., 2006); while the 2007 study by Manuel et al., (2007) that utilised 
PAX77 (Pax6 overexpressing) embryos, found a reduction in proliferating neural 
progenitor cells in the areas of the developing cortex where Pax6 expression levels 
are highest (Manuel et al., 2007). Furthermore, INPs located the rostral and caudal 
areas of the developing cortex in PAX77 mice proliferate at a much slower rate in 
comparison to WTs.  
 
As previously mentioned, it has been determined that Pax6 regulates both cell cycle 
length and cell cycle exit, with past studies indicating that Pax6 primarily exerts a 
repressive effect upon cell cycle progression of progenitor cells within the cerebral 
cortex; and Pax6 expression levels confirming its region and age specific role in the 
regulation of neural progenitor proliferation (Manuel et al., 2015). Early on during 
the process of corticogenesis, expression levels of Pax6 vary between different 
cortical regions but its expression levels become increasingly uniform as the embryo 
develops (Mansouri et al., 1994; Stoykova and Gruss, 1994; Manuel et al., 2007). 
When the Pax6 expression gradient is at its steepest during early cortical 
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development (E12.5), areas found to have the highest levels of Pax6 expression 
correlate with regions where cell cycle duration is longest (Manuel et al., 2015). 
Furthermore, a loss of Pax6 results exclusively in a shortening of the cell cycle in 
areas where there would have been high Pax6 expression normally (Manuel et al., 
2015). These findings indicate that the effects that Pax6 exerts upon the cell cycle of 
cortical progenitor cells are associated with its expression levels. This was further 
supported by the 2013 study by Mi et al., where cell cycle parameters were examined 
in different cortical regions during different stages of embryonic development using 
mouse models with a conditional inactivation of Pax6 or a constitutive inactivation 
of Pax6 (Mi et al., 2013a); Manuel et al., 2015). Consequently, the fact that Pax6 is 
expressed in a gradient during early cortical development, the dosage-dependent 
effects of Pax6 on cell proliferation are of great importance in terms of 
understanding how the cerebral cortex is organized into regions of specific 
cryoarchitectures and functions (Manuel et al., 2015). 
 
 While it is widely accepted that Pax6 regulates developmental processes, such as 
corticogenesis, and advances have been made in identifying Pax6-regulated genes 
implicated in the process of neurogenesis (Xie and Cvekl, 2007; Wolf et al., 2009; 
Sansom et al., 2009; Carr, 2009; Xie et al., 2013; Sun et al., 2015), many of the gene 
networks regulated by Pax6 and how Pax6 is specifically exerting its regulatory 
effects upon these genes remain unidentified and unexplained. Some advances into 
understanding how Pax6 regulates progenitor cell proliferation during corticogenesis 
have been made by identifying targets of Pax6. These include the cyclin-dependent 
kinases and their activating cyclins (Cdk4, Cdk6, Cdca2, Cdca7) which are 
responsible for cell cycle progression (Sansom et al., 2009; mi et al., 2013 a, b). 
 
As previously stated, Pax6 possesses two DNA binding domains, the PD and the 
HD, with both recognizing different Pax6 consensus binding sites. This suggests that 
the PD and HD are likely to regulate distinct functions by controlling specific gene 
targets (Chi and Epstein, 2002), both separately or cooperatively of one another (Jun 
and Desplan, 1996; Singh et al., 2000; Mikkola et al., 2001; Mishra et al., 2002; Xie 
and Cvekl, 2001). Previous studies have identified that the HD is involved in lens 
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formation during embryogenesis and has little involvement in development of the 
forebrain (Haubst et al., 2004; Ninkovic et al., 2010). This suggests that the PD 
facilitates the effects Pax6 exerts upon development of the mammalian forebrain 
(Walcher et al., 2013). The Pax6 PD possesses two subdomains, an N-terminal PAI 
subdomain and a C-terminal RED subdomain, which can bind cooperatively or 
independently of one another to their cognate sites (Epstein et al., 1994a; Yamaguchi 
et al., 1997). Moreover, recent investigations into how Pax6 utilizes particular 
subdomains of the PD, to coordinate patterning and neurogenesis in the developing 
forebrain, using mutations of the RED and PAI subdomains, showed that only the 
PAI subdomain affects neurogenesis as embryos with PAI mutations had similar 
neurogenic defects to Pax6-/- mutants (Walcher et al., 2013). In short, Pax6 exerts its 
regulatory effects upon its target genes by binding to target DNA sequences through 
one or both of the aforementioned DNA-binding domains (Bertuccioli et al., 1996; 
Jun and Desplan, 1996; Sheng et al., 1997; Singh et al., 2000; Walcher et al., 2013), 
and transcriptional regulation of Pax6 target genes is mediated by a carboxy terminal 
proline/serine/threonine (PST) rich transactivation domain (Singh et al., 1998, 2001; 
Tang et al., 1998; Manuel et al., 2015). 
 
 
1.12 Pax6 controls progenitor cell proliferation via regulation of Notch 
signalling 
 
Amongst the numerous gene candidates for regulation by Pax6 during cortical 
development, members of the Notch signalling pathway are consistent and of 
particular interest due to their role during the process of embryonic neurogenesis. 
Research centred around identifying transcriptional targets has predominately 
utilised sequencing strategies such as DNA microarray analysis, chromatin 
immunoprecipitation (ChIP) and the newer approach of ChIP-sequencing (ChIP-
seq), allowing the study of protein-DNA interactions and gene expression levels. 
Furthermore, research following on from sequencing analysis has yielded evidence 
of direct binding between Pax6 and its target genes (Scardigli et al., 2001; 2003; Carr 
et al., 2009 Sansom et al., 2009; Mi et al., 2013a; Xie et al., 2013; Sun et al., 2015) 
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(Table 1.1). Although steps are being taken to determine which genes Pax6 regulates 
and how its regulatory control over complex gene networks controls forebrain 
development, relatively little is currently known about the scope of Pax6’s regulatory 
effects and, as a result, it is an area of embryonic development which continues to be 
of importance to investigate. 
 
Table 1.1 Examples of identified Pax6 targets 
 
Paper Key Identified Targets Method Used 
Scardigli et al., 2002; 
2003 
Ngn2 EMSA, Transgenic Mice  
Carr, 2009  Ngn2, Mash1, Jag1, N1 Microarray 
Sansom et al., 2009 Cdk4, Mcm3, Cdca2, 
Cdca7 
ChIP-chip, Microarray 
Mi et al., 2009 Cdk6 ChiP, EMSA, Luciferase 
Assay 
Xie et al., 2013 Isl1 ChIP-chip, Microarray 
Sun et al., 2015   
 
 
Previous work in our lab has also concentrated on identifying targets of Pax6 and 
undertaking the challenge of identifying which genes are directly regulated by the 
transcription factor, as well as highlighting how these regulatory relationships allow 
Pax6 to orchestrate its considerable control over forebrain development (Carr 2009; 
Mi et al., 2013a). Previous microarray analysis carried out on the PSPB of Pax6-/- 
mice identified a list of candidate genes that were likely to be regulated by Pax6. The 
list included a number of genes implicated in the Notch signalling pathway such as 
the proneural genes Ngn2 and Mash1, the Notch ligand Jag1, and the Notch receptor 
N1. Research into previously published literature identified the Notch ligand Dll1 
and the bHLH proneural inhibitor Hes5 as targets of Pax6 (Sansom et al., 2009). As 
previously discussed, the Notch signalling pathway is crucial during the process of 
corticogenesis due to its role in maintaining the pool of proliferative cells required to 
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ensure that the cortex develops correctly. Additionally, Pax6 is involved in the 
process of cell proliferation during cortical development (Stoykova et al., 2000; 
Estivill-Torrus et al., 2002; Englund et al., 2005; Manuel et al., 2007; Quinn et al., 
2007; Georgala et al., 2011b; Mi et al., 2013a; 2013b). One of the interests of our lab 
has been to explore the role of Pax6 during cortical development and, consequently, 
investigating the relationship between Pax6 and the Notch signalling pathway was of 
particular interest. Initial investigations determined that a number of Notch pathway 
genes were down-regulated in the cortex of Pax6-/- mutant embryos (Carr, 2009), 
although not all of the Notch genes displayed altered expression when tested by in 
situ hybridisation analysis previously carried out during an Msc project (Dorà, 2011). 
Out of the Notch pathway genes initially investigated by in situ hybridisation, the 
Notch ligands Dll1 and Jag1 were determined to be the targets of Pax6 that were of 
greatest interest to pursue further. Microarray analysis provided Jag1 as a likely 
target of Pax6 (Carr, 2009). Dll1 on the other hand, appears more likely to be 
indirectly regulated by Pax6 rather than directly regulated, as ChiP-Seq analysis 
carried out by Sansom et al. (2009) did not identify Dll1 as a Pax6 target but 
hypothesised that Dll1 was a likely indirect target of Pax6 (Sansom et al., 2009). 
However, past determining direct or indirect regulation of target genes by master 
regulators, an important relationship between Pax6 and Notch could exist in terms of 
the process of neurogenesis. Due to the role of Notch ligand genes and the known 
functions of Pax6, a potential relationship between the two on a cellular level would 
be particularly interesting and could provide insight into mechanisms involved in the 
regulation of cell proliferation, such as how Pax6 exerts its regulatory effects upon 
proliferation via its interactions with key genes implicated in Notch signalling. 
 
In order to explain how the Notch ligands and Pax6 could be interacting with one 
another, a model was designed by interpreting findings documented in the literature 
(Figure 1.9). The model suggests that Pax6 drives the proliferation of progenitor 
cells by regulating the Notch ligands Jag1 and Dll1. However, the relationship 
between Pax6 and these two ligands is likely to differ. In the model depicted in 
Figure 1.8, Jag1 is expressed in RGCs within the VZ of the developing cortex 
(Nelson et al., 2013; Chapter 4). It has been shown that Pax6 is expressed within 
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RGCs also (Götz et al., 1998). As a result, we have predicted that the suggested 
direct regulatory relationship between Pax6 and Jag1 occurs exclusively within 
RGCs residing in the VZ (Figure 1.8 depicted by a solid green arrow). As for Dll1, 
our hypothesis suggests that the regulatory relationship between Pax6 and the ligand 
is likely to be indirect and far more complex. Study of previously published literature 
on Dll1 expression in the developing cerebral cortex revealed startling contradictions 
over which progenitor cell population Dll1 is expressed in, with studies stating that 
the gene is expressed in the VZ (Campos et al., 2001), in INPs in the SVZ (Mizutani 
et al., 2007; Kawaguchi et al., 2008; Yoon et al., 2008) and within both ventricular 
and subventricular zones (Nelson et al., 2013). The latter study, which concentrated 
on the expression of Dll1 protein in the developing telencephalon, showed that Dll1 
was expressed in INP cells within the SVZ and also expressed by a subpopulation of 
INP that reside basally within the VZ (INPvz). As previously discussed, it has been 
suggested that INPVZs are the link between RGCs and INPs, in that INPVZs are 
actually INPs newly generated from RGCs in the VZ and are simply migrating to 
their correct position in the SVZ where they will undergo proliferation and/or 
differentiation (Englund et al., 2005; Corbin et al., 2009). If this is indeed the case, 
INPVZ could be considered as a cell type making the transition from a RGC to an INP 
and could very well express markers for both cell types at varying levels. This would 
account for Dll1 expression in the VZ as INPVZs would start to express INP markers 
as they migrate to the SVZ. Furthermore, the proneural gene Ngn2 is expressed in 
both the VZ and the SVZ. This is likely due to the fact that both RGCs and INPs are 
capable of making the shift to differentiate into neuronal cells, coupled with what we 
know about the oscillatory expression of Ngn2 in proliferating cells. However, due to 
the cyclical expression of Ngn2, it is highly likely that Ngn2 is also expressed in 
INPVZs and could therefore act as the regulatory link between Pax6 and Ngn2 if they 
were both expressed in INPVZs simultaneously. Therefore, we hypothesise that there 






Figure 1.9  Model of project hypothesis  
 
Pax6 directly regulates the expression of Jag1 in RGCs residing in the VZ (green cell). 
Newly generated INPs by RGCs (INPvz) migrate from the VZ to the SVZ where they settle as 
mature INPs. INPvz s (blue cell) begin to express Ngn2, Dll1 and Tbr2 and in turn begin to 
lose Pax6 expression. Cis-inhibition by Dll1 in INPVZs prevents repression of Ngn2, resulting 
in the repression of Pax6 by Tbr2. Consequently, Dll1 and Pax6 indirectly regulate each 
other in INPVZ cells. Mature INP cells in the SVZ (purple cell) express Dll1, Ngn2 and Tbr2 
but no longer express Pax6. Cis-inhibition of a cell promotes neural differentiation, while 
trans-activation between cells promotes remaining in a proliferative state. Arrows = 
activation. Repression symbol = repression. Dotted lines depict differentiation and migration 
of a cell.  
 
 
Our interpretation of the literature further expanded our model to explore the notion 
that while INPVZ cells are migrating to the SVZ, where they would become mature 
INP cells, Pax6 and Dll1 could mutually co-regulate one another. It is plausible that 
transitioning INPVZs could express RGC markers and INP markers simultaneously at 
varying levels, providing a tangible link between RGCs and INPs. As a result, we 
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hypothesise that newly generated INPVZ cells still retain Pax6 expression, resulting 
in the activation of both Ngn2 and Dll1 expression (Figure 1.9 depicted by solid blue 
arrows). Activation of Ngn2 by Pax6 would also results in the activation of the INP 
marker Tbr2. Tbr2 has been shown to repress Pax6 (Englund et al., 2005; Sessa et 
al., 2008; Ochai et al., 2009; Kovach et al., 2012) and thus, as the INPVZ migrates 
towards the SVZ, Tbr2 levels would increase and consequently diminish Pax6 
expression until the transcription factor is no longer expressed. This phenomenon 
would most likely occur at a reduced rate due to the cyclical expression of Ngn2 and 
Dll1 in proliferative cells, meaning that expression of Tbr2 would slowly increase 
and Pax6 expression would gradually decrease. We further hypothesise that the 
aforementioned Notch signalling mechanisms of cis-inhibition and trans-activation 
would aid this event. As previously discussed, cis-inhibition promotes neural 
differentiation and trans-activation encourages the cell to remain in a proliferative 
state (del Álamo et al., 2011). However, due to Notch oscillations in proliferating 
cells, a cell targeted by cis-inhibition does not guarantee that the cell will 
automatically differentiate as the cyclical nature of Notch indicates that the effect 
may be more gradual. Subsequently, we believe that the act of cis-inhibition in 
INPVZs prevents the repression of the proneural gene Ngn2, resulting in the 
repression of Pax6 by Tbr2. If this is the case, while INPVZs are making the 






Chapter 3: The aim was to investigate the effects of Pax6 levels on Dll1 expression 
in the cerebral cortex, thereby testing the possibility of regulation of Dll1 by Pax6 
(Figure 1.9). 
 
Chapter 4: The aim was to investigate the effects of Pax6 levels on Jag1 expression 




Chapter 5: The aim was to determine which progenitor cell subpopulation Dll1 is 
expressed in in the cerebral cortex and to further characterise how Pax6 and Dll1 
interact with one another during neurogenesis (Figure 1.9).  
 
Chapter 6: The aim was to determine whether Jag1 is directly regulated by Pax6 by 
identifying potential binding sites for Pax6 surrounding the Jag1 gene and testing 
them.  
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2.0 Methods and materials 
 
 
2.1 Solutions and suppliers 
 
All chemicals were supplied by Sigma Aldrich or Thermo Fisher Scientific, unless 





All procedures were performed under licence in accordance with the Animals 
(Scientific Procedures) Act 1986.  
 
2.2.1 Pax6-/- mice 
 
Pax6-/- mouse embryos were derived from Pax6SeyEd heterozygote (Pax6+/-) crosses 
maintained on an inbred Swiss background, and wild-type siblings were used as 
controls. The Pax6SeyEd allele has a premature stop codon caused by a point mutation. 
This point mutation prevents the production of functional Pax6 (Hill et al., 1991). 
Pregnant females were sacrificed by anaesthesia followed by cervical dislocation. 
Embryos were dissected from the uterus at gestational age E11.5, E12.5, E13.5 and 
E14.5.  
 
2.2.2 PAX77 transgenics 
 
PAX77 hemizygous mice (Schedl et al., 1996) (PAX77) carry 5 to 7 copies of a 
420Kb human PAX6 YAC (Y593) with all copies incorporated at the same locus. 
The integrated copies are referred to as the PAX77 transgene. The PAX77 line was 
maintained on a CD1 background (Manuel et al., 2007). 
 
2.2.3 Emx1CreErT2;Pax6loxP/loxP transgenics 
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For conditional inactivation of Pax6 in the developing cortex, a transgenic line 
carrying Pax6loxp (Simpson et al., 2009), Emx1-CreERT2 (Kessaris et al., 2006) ND 
Rosa26-YFP (Srinivas et al., 2001) alleles were generated. Cre expression was 
induced with 10mg single dose of tamoxifen by gavage (Sigma UK) at E9.5 
(50mg/ml-1 in corn oil, Sigma UK). Pregnant females were sacrificed by anaesthesia 
followed by cervical dislocation. Embryos were dissected from the uterus at 
gestational age E12.5 and E13.5. 
 
2.2.4 Ngn2-Cre transgenics 
 
Homologous recombination in embryonic stem cells was used to replace the Ngn2 
coding sequence with Cre (Danielian et al., 1998) using the same strategy that 
generated Ngn2 knockouts (Fode et al., 1998). Ngn2-Cre mice bred onto a C57Bl6/J 
background were crossed to Rosa26-loxp reporter mice (Soriano, 1999) to generate 
an Ngn2-Cre mouse line that produces Ngn2-/- embryos (Zirlinger et al., 2002).  
 
2.2.5 Tissue collection 
 
Embryos were dissected out in ice-cold RNAse free phosphate buffered saline (PBS) 
and heads were removed and kept.  
 
 
2.3 Tissue preparation 
 
2.3.1 Tissue fixation 
 
Following dissection, tissue fixed in 4% PFA/ 1X PBS overnight. Fixed tissue was 
then washed three times in PBS. Tissue was cryoprotected in 30% sucrose/1X PBS at 
4°C overnight or until the tissue sunk. Tissue was then equilibrated in a 50:50 
mixture of 30% sucrose:OCT (Thermo Scientific) for one hour on a rocking 
platform. Tissue was embedded in the same 50:50 30% sucrose:OCT mixture and 
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frozen on dry ice. Tissue was embedded at an orientation suitable for coronal 
sectioning. Frozen tissue was stored at -80°C until required.  
 
2.3.2 Cryostat sectioning 
 
Frozen tissue for cryosectioning was transported on ice from -80°C storage freezers 
to the cryostat. Blocks were allowed to come up to temperature for 30 minutes prior 
to sectioning. OCT embedding medium was used to attach the tissue to the chuck at -
20°C. Cryostat sections were cut at 10µm or 12µm (for fluorescent staining) and 
mounted on superfrost positively charged slides. Sections were then stored at -20°C 
until required. All sections cut were coronal and 8 sections were mounted per slide as 
standard. Slides displaying Rostral, medial and caudal sections (from the front, 
middle and towards the back of the cortex, respectively) were selected for all 







Figure 2.1 Selection of cortical sections for staining 
 
A brief summary of how coronal forebrain sections were selected for expression analysis. (A) 
A schematic depicting roughly where the rostral, medial and caudal areas of the cortex 
reside within a mouse embryo head. (B) An example of a rostral, medial and caudal section 




2.4 PCR genotyping 
 
2.4.1 Preparation of genomic DNA 
 
Genomic DNA was extracted from embryonic limb tissue. Tissue was lysed in 75µl 
of hotshot lysis buffer (25mM NaOH; 0.2mM EDTA) at 96°C for 30 minutes and 
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then cooled to 4°C. 75µl of neutralising buffer (40mM Tris-HCl) was then added to 
stop the reaction. 1µl of this solution was added to 24µl of PCR reaction mix. 
 
2.4.2 Genotyping of PAX77 mice and Emx1CreErT2;Pax6loxP/loxP mice 
 
PCR reaction mix: 
2.5mM dNTPs - 2.5µl 
TPSX loading dye - 5µl  
25µM Fp6 primer mix (F and R primers) – 0.5µl 
Taq polymerase – 0.2µl 
ddH2O – 15.8µl 
 
 
Table 2.1  Primers for genotyping by PCR 
 






Forward 5’ GAGGGTTTCCTGGATCTGG 
Reverse 5’ CGCAAATACACCTTTGCTCA 
Fp6 Forward 5’ AAATGGGGGTGAAGTGTGAG 
Reverse 5’ TGCATGTTGCCTGAAAGAAG 










For PAX77, Fp6 and Ngn2 primers, cycle conditions were as follows: 
94°C for 1 minute  
(96°C for 30 seconds, 59°C for 30 seconds, 72°C for 30 seconds) for 35 cycles 
 
2.4.3 Agarose gel electrophoresis  
 
PCR samples were run on a 2% agarose gel (1.5g agarose, 75ml TBE 
(Tris/Borate/EDTA)) at 115V for 1 hour. 
 
2.5 Histological analysis 
 
2.5.1 Haematoxylin and eosin staining 
 
H&E staining was carried out on adjacent sections to in situ hybridisation sections 
and repeats were stained simultaneously for each developmental stage. Frozen 
sections stored at -20°C were brought to RT for 30 minutes prior to staining. Slides 
were then rinsed under running water for 2 minutes before being dipped in 
Haematoxylin for 2 minutes. Slides were then rinsed under running water for 2 
minutes and then placed in Scott’s Tap Water Substitute (STWS) (Leica) for 2 
minutes. Slides were then rinsed under running water for 2 minutes before being 
dipped in alcoholic Eosin. Slides were then dipped in running water, before being 
placed in Potassium Aluminium for 2 minutes. Slides were then rinsed under running 
water for 2 minutes before being dehydrated through a series of alcohol dips at 
increasing concentrations: 70%, 90%, 95% and two absolute alcohol dips. Slides 
were then dipped in Xylene and slides were mounted with coverslips using DPX 






The following DNA plasmids were used: Dll1, Jag1 and Ngn2. Dll1 was kindly 
gifted by the lab of Dr Thomas Theil from the Centre for Integrative Physiology at 
the University of Edinburgh. Jag1 was kindly gifted by the lab of Dr Kim Dale from 
the School of Life Sciences at the University of Dundee. Ngn2 was readily available 
from our own lab.  
 
2.6.1 Plasmid transformation 
 
Transformations were set up in 14ml PP tubes and plasmids were heat shocked into 
JM109 competent cells (Promega) according to Promega protocol instructions, in 
order to amplify the gene of interest. Plasmid heat shock reactions are shown in the 
tables below (Jin and Lloyd, 1997). 
 
 










Plasmid 2µl 2µl 0µl 
Competent Cells 100µl 100µl 100µl 




250µl of ampicillin was added to 250ml of agar before pouring into petri dishes to 
ensure that only cells which had taken up the plasmid grew. Dishes were then left to 
set and stored upside down until required to prevent contamination from 
condensation droplets. JM109 competent cells (Promega) and DNA plasmids were 
thawed on ice. In order to insert the DNA into the cells, tubes were placed on ice for 
30 minutes. Tubes were then placed in the water bath at 42°C for 90 seconds before 
being placed back on ice. 450µl of SOC medium was added to each test tube. Tubes 
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were then incubated at 37°C in a shaking oven for 60 minutes. Three separate 
dilutions, a 1:10 positive control (using N1 plasmid which has been previously 
validated) and an undiluted no plasmid control (competent cells only and no in situ 
plasmid), were set up in tubes as shown in the table below. 
 
 
Table 2.3 Transformation Dilutions  
 
Component Undiluted 1:10 1:100 Control 
Plasmid 100µl 10µl 1µl 0µl 
SOC Medium 0µl 90µl 100µl 100µl 
 
 
100µl of each dilution was streaked onto individual agar plates using sterilised glass 
rods. Plates were then incubated overnight at 37°C. 500µl of ampicillin (AMP) was 
then added to 500ml of Lennox broth (LB broth) and 2ml of LB + Amp was added to 
four separate test tubes. Colonies were then selected from 1:100 dishes and one 
colony was put into each individual tube. Tubes were placed in a shaking oven and 
incubated at 37°C for 2 hours. 200ml of LB + Amp was then poured into a conical 
flask with 1ml of one of the four 3ml starter cultures and was incubated overnight at 
37°C in a shaking oven. 
 
2.6.2 Plasmid Midi Prep  
 
Plasmid midi prep was performed using a Qiagen HiSpeed plasmid maxi kit. Cells 
were harvested from 200ml of culture at 6000xg for 15 minutes at 4°C. Centrifuge 
tubes were then inverted to remove all traces of supernatant. The bacteria pellet 
formed during centrifugation was then resuspended in 10ml of chilled Buffer P1by 
gently vortexing the mix until dissolved. 10ml of buffer P2 was then added and the 
tube inverted 6 times before being incubated at RT for 5 minutes. The lysate was 
then poured into the barrel of a QIA filter cartridge and incubated at RT for 10 
minutes. A HiSpeed Maxi Tip was then equilibrated by applying 10ml of buffer QBT 
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and allowing the column to empty by gravity flow. A plunger was then fitted to the 
QIAfilter Maxi Cartridge and the cell lysate filtered into the equilibrated HiSpeed 
Tip. The HiSpeed Maxi Tip was then washed with 20ml of Buffer QC by gravity 
flow. Collected DNA was then eluted with 15ml of Buffer QF. 10.5ml of isopropanol 
was added to precipitate the eluted DNA and the mix was incubated at RT for 5 
minutes. The eluate/isoproanol mix was then passed through a QIA precipitator 
before being washed with 2ml of 70% ethanol. The membrane of the QIA 
precipitator was then dried by passing air through by force twice. The QIA 
precipitator was then attached to a 5ml syringe and held over a 1.5ml collection tube. 
1ml of Tris buffer (10mM Tris pH 8.0 + 1mM EDTA) was added to the 5ml syringe 
and DNA was eluted into the 1.5ml collection tube. Eluate was then transferred to a 
new 5ml tube with the QIA precipitator attached and DNA was eluted for a second 
time into a 1.5ml collection tube. DNA was then measured using a Nanodrop and 
stored at -20°C until required. 
 
2.6.3 DNA Digest 
 
DNA digest reactions for each plasmid is shown in the tables below. Restriction 
enzymes and buffers were supplied by New England Biolabs. Digests were incubated 
at 37°C for 2 hours. 
 
An example of the digest mix follows: 
(DNA concentration was required to be 10ug and the following was adjusted 
accordingly). 
ddH2O – 164.5µl 
DNA – 10.5µl 
10X Buffer - 20µl 
Enzyme (100,000 units/ml) - 5µl 
 
 
Table 2.4 Plasmid digest information 
 
	 50






2.6.4 DNA Clean-up 
 
600µl of Isopropanol and 200µl of buffer QG (Qiagen) were added to the digest mix. 
The mix was then applied to a QIA quick spin column (Qiagen) in a 2ml collection 
tube and centrifuged for 1 minute in order to bind the DNA to the column membrane. 
Flow-through was discarded and 0.5ml of buffer QG was added to the QIA quick 
spin column. The QIA spin column was then centrifuged for 1 minute and flow 
through was discarded. 0.75ml of buffer PE (Qiagen) was then added to the QIA spin 
column which was then centrifuged for 1 minute. Flow through was discarded. 
Centrifugation for 1 minute was repeated to dry the QIA quick spin column. The 
QIA quick spin column was then placed in a clean 1.5ml tube and DNA was eluted 
by adding 30µl of buffer EB (Qiagen). Following application of buffer EB, the 
column and collecting tube was left to sit for 1 minute and then centrifuged for 1 
minute. Flow through was retained in the 1.5ml collecting tube and stored at -20°C.  
 
2.6.5 Plasmid Analysis 
 
Uncut, cut and cleaned plasmids, and Dig-labelled probes were visualised using 
agarose gel electrophoresis. A 1% agarose gel was used to visualise products used 
for in situ hybridisation. All agarose gels contained Sybrsafe in order for DNA bands 
to be seen under ultraviolet light. All agarose gels were run at 100 V for 45 minutes. 
 
 
2.7 DIG-labelled Antisense RNA Probes 
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Labelling mixes (Roche) were made up for each probe in 1.5ml test tubes and were 
incubated at 37°C for 2 hours. Labelling mix was as follows: 
 
ddH2O - 12µl 
Plasmid digest - 10µl 
10X transcription buffer - 2µl 
Dig label mix (10x solution with: 10 mM ATP, CTP, GTP (each), 6.5 mM UTP, 3.5 
mM DIG-11-UTP) - 2µl 
RNA polymerase (≥20 U/μl) - 2µl 
 
 
Table 2.5 Plasmid polymerase information  
 






2µl of DNase (2,000 U/mg) (Roche) was then added to the tubes and the mix was 
incubated for an additional 15 minutes at 37°C. The following was then added to the 
reaction mix: 
 
0.2M EDTA (pH8) - 2µl 
4M LiCl - 2.5µl 
100% ETOH - 75µl 
 
Tubes were then stored at -20°C overnight. Tubes were then removed from -20°C 
storage and centrifuged for 15 minutes to remove supernatant. The remaining pellet 
was then washed twice in 70% EOH. The pellet was left to dry (until clear) and was 








Sections were selected in a rostral-caudal series; an additional slide was included to 
act as a no probe control. All slides were mounted with 8 sections as standard. 
Preliminary in-situ runs using a new probe included a positive control in order to 
validate the tissue and reagents (N1 probe which has been previously validated by 
our lab). A no probe control was used as a negative control. Sense probes were not 
utilised as a negative control. Slides were defrosted at room temperature (RT) for 30 
minutes prior to hybridisation.  Slides were defrosted in their storage box to prevent 
RNA degradation by condensation.  A sealable plastic box was then lined with two 
sheets of Tork roll soaked in 100ml of 50% formamide/ 1X salt (1ml of 10X salt).  
The box was incubated at 65°C until required. 
 
10X Salt: 
NaCl – 22.8g 
Tris HCl (pH 7.5) – 2.8g 
Tris Base – 0.27g 
NaH2PO4.2H2O – 1.56g 
Na2HPO4 – 1.42g  
0.5M EDTA – 20ml 
ddH2O – up to 200ml  
 
Probes were thawed quickly and diluted in hybridisation solution in 1.5ml screw cap 
tubes.  Probe dilution was optimised for each individual probe. A range of 
concentrations were used (1:250, 1:500, 1:1000, 1:10000, 1:15000, 1:25000) and the 
dilution that produced the clearest stain was selected. This process was repeated for 
each batch of labelled probe. Hybridisation/probe mixes were then vortexed 
vigorously in order to allow the probe to mix thoroughly. Diluted probes were then 
denatured on a hot block at 85-90°C for 10 minutes.  Denatured probes were then 
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centrifuged briefly. Sections were outlined with a hydrophobic pen and 20µl of 
diluted probe was pipetted directly onto each section.  Slides were then placed in the 





Slides were transferred from the sealed box to a glass Coplin jar. Sections were then 
washed in wash buffer (pre-warmed to 70°C) for 15 minutes at 70°C. This was 
repeated for 2X 30 minutes using fresh wash buffer each time. Slides were 
transferred to a new Coplin jar and incubated in 1X MABT at RT on a rocker for 30 
minutes. This step was then repeated.  
 
Wash Buffer: 
1X SSC – 15ml  
50% formamide – 150ml 
0.1% Tween-20 - 300µl 
ddH2O – 135ml  
5X MABT 
 
0.5M Maleic Acid – 29.1g 
NaOH – 16g 
0.75M NaCl – 21.9g  
0.5% Tween 20 – 2.5ml 
ddH2O – up to 500ml 
 
2.8.3 Blocking and antibody staining 
 
A box was lined with 2 sheets of Tork roll soaked with PBS in order to prepare a 
humidified environment. Slides were removed from 1X MABT (5X MABT diluted 
in PBS) and then edges were dried. Sections were then outlined using a hydrophobic 
pen. Reactions were blocked by adding 200µl of blocking solution (20% heat-
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inactivated sheep serum/ 2% blocking reagent in 1X MABT) onto each slide. Slides 
were then incubated in the pre-prepared humidified box at RT for 1 hour. 
Blocking solution was removed and 100µl of anti-DIG antibody diluted in 1:1500 
blocking solution was then added to the slides in order to detect RNA expression. 
Slides were placed back in the humidified box and incubated at 4°C overnight.  
 
2.8.4 Post-antibody washes 
 
Slides were transferred to a glass Coplin jar and sections were washed 5 times for 20 
minutes each in fresh 1X MABT at RT on a rocker. Sections were equilibrated in 




5M NaCl – 6ml  
1M MgCl2 – 15ml  
1M Tris-pH 9.5 – 30ml  
Tween 20 - 300µl  
ddH2O – 250ml  
 
2.8.5 Colour reaction 
 
In order to visualise RNA expression, 1.4ml of nitro-blue tetrazolium and 5-bromo-
4-chloro-3'-indolyphosphate (NBT/BCIP) complex was added to staining buffer 
before being directly added to a foil wrapped Coplin jar. The staining reaction was 
then incubated in the dark at RT for ~24-48 hours until developed. The staining 
reaction was then stopped by transferring slides to a new Coplin jar and washing in 
1X PBS several times. Slides were then left in 1X PBS for 2 days at 4°C. 
 
Stain Buffer: 
5M NaCl – 2ml 
1M Tris pH 9.5 – 10ml  
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ddH2O – 83ml 
 
Slides were then removed from 1X PBS and mounted with coverslips using Aquatex 








Refer to 2.6.1 for Hybridisation protocol. Both Digoxygenin (DIG) labelled and 





Slides were transferred from the sealed box to a glass Coplin jar.  Sections were then 
washed in wash buffer (pre-warmed to 70°C) for 15 minutes at 70°C.  This was 
repeated for 2X 30 minutes using fresh wash buffer each time.  Slides were 
transferred to a new Coplin jar and incubated in TNT buffer (0.1 M TrisHCl, 0.15 M 
NaCl, 0.05% Tween-20) at RT on a rocker for 30 minutes.  This step was then 
repeated.  
 
2.9.3 Blocking and DIG antibody staining 
 
An immunohistochemistry box was lined with 2 sheets of Tork roll soaked with PBS 
in order to prepare a humidified environment.  Slides were removed from TNT 
buffer and slide edges were dried using a square of tissue paper.  Sections were then 
outlined using a hydrophobic pen.  Reactions were blocked by adding 150µl of TNB 
blocking solution (0.1M TrisHcl pH7.5, 0.15M NaCl, 0.5% Perkin Elmer blocking 
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reagent in ddH20) onto each slide.  Slides were then incubated in the pre-prepared 
humidified box at RT for 1 hour. 
Blocking solution was removed and 100µl of anti-DIG POD antibody diluted in 
1:500 TNB blocking solution was then added to the slides in order to detect RNA 
expression.  Slides were placed back in the humidified box and incubated at 4°C 
overnight.   
 
2.9.4 Post-antibody washes and detection of DIG probe  
 
Slides were transferred to a glass Coplin jar covered in foil and sections were washed 
3 times for 5 minutes each in fresh TNT at RT on a rocker. 100µl of Cyanine3 
tyramide diluted 1:500 in amplification diluted and 100µl was added to each slide. 
Slides were then incubated at RT for 10 minutes. Slides were then transferred to a 
glass Coplin jar and covered in foil and sections were washed 5 times for 5 minutes 
each with fresh TNT buffer.  
 
2.9.5 Peroxidase inactivation and detection of DNP probe 
 
100µl of 10mM HCl was then added to each slide and slides were then incubated for 
30 minutes at RT, in order to inactivate deposited peroxidase. Slides were then 
placed in a glass Coplin jar covered in foil and sections were washed 3 times for 5 
minutes each in TNT. 100µl of anti-DNP POD antibody diluted in 1:500 TNB 
blocking solution was then added to the slides in order to detect RNA expression.  
Slides were placed back in the humidified box and incubated at 4°C overnight.   
 
2.9.6 Post-antibody washes and detection of DNP probe 
 
Slides were transferred to a glass Coplin jar covered in foil and sections were washed 
3 times for 5 minutes each in fresh TNT at RT on a rocker. 100µl of fluorescein 
tyramide diluted 1:50 in amplification diluent was added to each slide. Slides were 
then incubated at RT for 10 minutes. Slides were then transferred to a glass Coplin 
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jar and covered in foil and sections were washed 5 times for 5 minutes each with 
fresh TNT buffer.  
 
2.9.7 Counterstain with DAPI  
 
Slides were transferred back into the humidified box and 100µl of DAPI diluted 
1:1000 in 1X PBS was added to each slide. Slides were incubated at RT for 5 
minutes. Slides were then transferred to a glass Coplin jar and covered in foil and 
sections were washed 3 times for 5 minutes each with fresh 1X PBS. Slides were 
then removed from 1X PBS and mounted with 22mm X 50mm coverslips using 
Vectashield (Vectorlabs) hard set mounting medium. Slides were left to dry in the 
dark and were then stored at 4°C until required for imaging.  
 
2.10 Double immunofluorescence/fluorescent in situ hybridisation staining 
 
2.10.1 Antigen retrieval  
 
Sections were selected in a rostral-caudal series; an additional slide was included to 
act as a no probe control. Slides were defrosted at RT for 30 minutes prior to 
hybridisation.  Slides were defrosted in their storage box to prevent RNA 
degradation by condensation. Slides were washed for 10mins in 10mM sodium 
citrate. Slides were placed in a plastic Coplin jar and placed in a 95°C water bath for 
90°C. Slides were then removed and left to cool down for 20mins. Slides were then 








Refer to 2.7.2 for post-hybridisation protocol. 
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2.10.4 Blocking and DIG antibody staining 
 
An immunohistochemistry box was lined with 2 sheets of Tork roll soaked with 1X 
PBS in order to prepare a humidified environment.  Slides were removed from TNT 
buffer and slide edges were dried using a square of tissue paper.  Sections were then 
outlined using a hydrophobic pen.  Reactions were blocked by adding 150µl of TNB 
blocking solution (0.1M TrisHCl pH7.5, 0.15M NaCl, 0.5% Perkin Elmer blocking 
reagent in ddH20) onto each slide.  Slides were then incubated in the pre-prepared 
humidified box at RT for 1 hour. 
 
Blocking solution was removed and 100µl of anti-DIG POD antibody diluted in 
1:500 TNB blocking solution was then added to the slides in order to detect RNA 
expression.  Slides were placed back in the humidified box and incubated at 4°C 
overnight. 
 
2.10.5 Post-antibody washes and detection of DIG probe  
 
Slides were transferred to a glass Coplin jar covered in foil and sections were washed 
3 times for 5 minutes each in fresh TNT at RT on a rocker. 100µl of Cyanine3 
tyramide diluted 1:500 in amplification diluted and 100µl was added to each slide. 
Slides were then incubated at RT for 10 minutes. Slides were then transferred to a 
glass Coplin jar and covered in foil and sections were washed 5 times for 5 minutes 
each with fresh TNT buffer. 
 
2.10.6 Blocking and antibody staining  
 
Slides were blocked for 30 minutes in 10% goat serum in PBT in the dark. Slides 
were then incubated O/N at 4°C in rabbit anti-Tbr2 (ab23345) (Abcam) 1:100 in 
block in the dark. 
 
2.10.7 Post antibody washes and secondary antibody staining 
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Slides were washed 4 x 15mins in PBT in the dark and then incubated O/N at 4°C in 
goat anti-rabbit IgG alexa fluor® 488 (ab150077) (Abcam) 1:400 in block in the 
dark. 
 
2.10.8 Post antibody washes and counterstain with DAPI 
 
Slides were washed 4x15mins in PBT in the dark. Slides were then counterstained 
with DAPI (Thermo Fisher Scientific) 1:1000 in 1X PBS for 5mins in the dark. 
Slides were then washed 2x 5mins in PBT in the dark. Slides were then mounted 
with Vectashield (Vectorlabs) hard set mounting medium. Slides were left to dry in 
the dark and were then stored at 4°C until required for imaging. 
 
 
2.11 Quantitative polymerase chain reaction  
 
2.11.1 Dissection of cortical tissue  
 
The uterus of Sey females at gestational stage E12.5, E13.5 and E14.5 were dissected 
out and placed into ice-cold RNAse free 1X PBS in a petri dish. Embryos were then 
dissected out genotyped by eye with WT and Pax6-/- kept and Pax6+/- discarded. 
Embryos were then decapitated and the brain was removed using forceps and a 
beaver blade. Telencephalic vesicles were removed from the brain and cortices 
dissected and placed in 1.5ml eppendorf and placed immediately on dry ice. Whole 
WT brains were taken to act as a control. 
 
2.11.2 Preparation of RNA 
 
RNA was extracted from dissected cortical tissue using Qiagen RNeasy kit. A 
QIAshredder spin column was used to disrupt membranes and homogenise the 
lysate. 70% RNase free ethanol was added to assist the binding of RNA to the 
membrane of the RNeasy spin column. Traces of genomic DNA were eradicated by 
	 60
on-column DNase digestion (Qiagen RNeasy kit). Contaminants were removed by 
washing with buffer RPE (Qiagen) and the RNA was then eluted in RNAse free 
ddH2O. RNA was then stored at -80°C. 
 
2.11.3 Reverse transcription 
 
Cortical RNA was reverse transcribed to cDNA using Invitrogen Superscript III 
First-Strand Synthesis Supermix kit as follows: 
RNA - 8 µl 
Random hexamers (50ng/ µl) - 1µl 
Annealing buffer - 1µl 
The mix was incubated at 65°C for 5mins and then chilled on ice for 5mins. 
The following was added to the mix: 
2X First-Strand reaction mix - 10µl 
Superscript III/RNase out enzyme mix - 2µl 
The mix was then vortexed briefly and incubated for 10mins at 25°C followed by 
50mins at 50°C and then 5mins at 85°C. Samples were then chilled on ice and stored 
at -20°C. 
 
2.11.4 qPCR protocol 
 
Standards for qPCR were prepared as follows: 
 
 
Table 2.6 qPCR Standards 
 
1000 250 62.5 15.62 1000 250 62.5 15.625 
WT 1 Sey 1 WT 2 Sey 2 WT 3 Sey 3 -rt H2O 
 
Tube 1000  4.5µl + H2O  4µl + 12ul H2O  3µl + 9ul H2O 
 
The qPCR reaction mix was prepared as follows: 
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H2O – 7µl 
Primer Mix – 0.5µl 
SYBR green – 12.5µl 
cDNA – 5µl 
 
 
Table 2.7  PCR primers for qPCR 
 
Gene Primer Sequence 
GAPDH Forward 5’GGGTGTGAACCACGAGAAAT 
Reverse 5’CCTTCCACAATGCCAAAGTT 
Jag1 Forward 5’GGAAGACAAGCCAAGGACCA 
Reverse 5’GTGCTTGCACTGGGTTTCTG 




2.11.5 qPCR programme 
 
Cycle conditions for qPCR for all primers were as follows: 
95°C for 15 minutes 
(94°C for 15 seconds, 55°C for 30 seconds and 72°C for 30 seconds, plate read) 35 
cycles 
Perform melting curve from 60°C to 90°C; read every 1°C; hold for 001 seconds 
between reads 
 
2.11.6 qPCR analysis 
 
qPCR results were produced using OpticonMonitorTM analysis software version 1.08. 
Results were then exported and statistical analysis was carried out using Excel. 





2.12.1 Selection of Jag1UE predicted enhancer element 
	
Identification of the Jag1 enhancer element was made by bioinformatic screening 
using a customised track on the UCSC Genome Browser. The customised Jag1 track 
was developed by Dr Ian Simpson (Institute for Adaptive and Neural Computation, 
School of Informatics, University of Edinburgh). The customised track implemented 
the Mouse Dec. 2011 (GRCm38/mm10) assembly and compared the Jag1 gene to 
various Pax6 binding motifs  
 
2.12.2 Amplification of Jag1UE from genomic DNA 
 
Primers (Figure 6.4) were designed to clone our region of interest (Jag1UE) from 
genomic DNA. The following programme was used: 
94°C for 1min 
(94°C for 30secs, 55°C for 30secs and 68°C for 3mins and 30secs) 20 cycles 
 
Jag1UE was then run on a 2% agarose gel at 80V for 60mins and the approximately 
3.5Kb band was cut from the gel on a UV box and a gel extraction was carried out 
using a Qiagen QIAquick Gel Extraction Kit according to kit instructions.  
 
Jag1UE was sequenced by Eurofins Genomics DNA sequencing service in order to 
validate the fragment.  
 
2.12.3 In fusion PCR 
 
Cloning was carried out using a Clontech® In-Fusion® HD Cloning Kit according to 
kit instructions. Jag1UE  and a pGL4.23 construct (Promega) with a mimimal 
promoter were used. Bacterial transformations were carried out according to kit 
instructions. Colonies were selected and minipreps were carried out using a Qiagen 
QIAprep Spin Miniprep Kit according to kit instructions. Mini preps were sequenced 
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2.13 Routine cell culture techniques  
 
2.13.1 Cell culture conditions 
 
Cell lines were maintained at 37°C in 5% CO2. Media suitable for the selected cell 
line was used at 37°C and stored at 4°C. Media was routinely changed every 24-48 
hours and the cells passaged at regular intervals to ensure the maintenance of a 
constant, healthy stock of cultured cells.  
 
2.13.2 HEK 293 cell line 
 
The human embryonic kidney (HEK 293) cell line was used (Graham and Smiley 
1977). The cell line was maintained in standard culture conditions in Dulbecco’s 
Modified Eagle Serum (D-MEM) (Invitrogen) containing 10% Foetal Bovine Serum 
(FBS) and routinely passaged.  
 
2.13.3 Cell culture conditions 
 
1ml of HEK 293 cells, stored in liquid nitrogen, were thawed rapidly and suspended 
in 9ml of Dulbecco’s Modified Eagle Serum (D-MEM) (Invitrogen) containing 10% 
Foetal Bovine Serum (FBS) (check FBS source) in a universal tube. Cells were then 
pelleted by centrifugation at 5000rpm for 5 minutes and supernatant was discarded. 
Cells were then re-suspended in 4mls of D-MEM + 10% FBS and transferred to a 
T25 flask. Cells were incubated overnight at 37°C. Cells were fed with D-MEM + 
FBS the subsequent day and then transferred to a T75 flask, with 5mls of media. 
 
2.13.4 Cell passage 
 
	 64
Cell passage was carried out at regular intervals to ensure the maintenance of a 
constant stock of cultured cells maintained in the optimum conditions for growth. 
Cells were grown to confluence in 75cm2 flask before being passaged. 
Cells were dissociated in 3ml of 1X Trypsin/EDTA (0.25% Trypsin/0.02% EDTA) 
at 37°C, 7ml of culture media was added to the flask to inactivate the trypsin. The 
cell mixture was centrifuged at 1000 revolutions per minute (rpm) for 5 minutes. 
Supernatant was discarded and the cell pellet was re-suspended in 10ml of fresh 
media. Cells were maintained in standard conditions as stock cells. 
 
2.13.5 Freezing and defrosting cell lines 
 
Cells were grown to confluence in 75cm2 culture flasks and dissociated in trypsin, 
7ml of culture media was added to inactivate the trypsin. The cells were pelleted by 
centrifugation at 1000rpm for 5 minutes. Cell pellets were re-suspended in 1ml of 
freezing buffer and transferred to pre-chilled cryovials. Freezing was carried out 
slowly to minimise cell damage, first on dry ice, before being transferred to a -80°C 
freezer for 24-48 hours, and then long term storage in liquid nitrogen.  
Cells frozen in cryovials were defrosted rapidly at 37°C and placed in a volume of 
fresh media. Cells were then pelleted by centrifugation at 1000rpm for 5 minutes and 
supernatant was discarded. The cell pellet was re-suspended in fresh media to 
prevent DMSO toxicity and transferred to a 25cm2 culture flask. Cells were left to 
adhere overnight at 37°C and the media was then removed and replaced with fresh 







2.13.6 Transient transfections 
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Transient transfections were carried out in the HEK 293 cell line, in cells which had 
reached 70-90% confluence.  
 
2.13.7 Lipofectamine 2000 
 
Cells were plated in a 24 well plate at 1 x 105 cells per well in 1ml of fresh media and 
incubated at 37°C overnight. Transfections were carried out using 5µl of 
Lipofectamine 2000 (Invitrogen) mixed in 50µl of OptiMEM (Thermo Fisher) per 
well. The lipofectamine/OptiMEM mix was incubated at RT for 5 minutes. A DNA 
cocktail of the required constructs was prepared to give a final working concentration 
of 815ng per well, with each well containing an increasing concentration of the CMV 
Pax6 construct (pCMV-Pax6 construct was generated by inserting full-length Pax6 
cDNA into a pCMV-Script plasmid (Stratagene) ) (Da Mi et al., 2013 a) ). The 
empty CMV construct was used to make up the total concentration of DNA. A 
replicate of three was carried out for each Pax6 concentration. Each experiment 
included experimental transfections using the developed Jag1UE luciferase construct 
(Chapter 6, Figure 6.5) and a control experiment using an empty pGL4.23 luciferase 
vector (Chapter 6, Figure 6.4) (Promega). Luciferase constructs were used at a 
concentration of 30ng per well and the control SV40 Renilla vector (Promega) 
(Figure 2.1) was used at a concentration of 15ng (Table 2.8 and Table 2.9). 
 
 
Table 2.8 Jag1UE experimental transfection DNA mix  
 
1 2 3 4 5 6 








































Table 2.9 Pgl4.23 control transfection DNA mix 
 
1 2 3 4 5 6 












































Figure 2.2 SV40 renilla vector 
 
A plasmid map detailing the Promega SV40 Renilla Vector used as a control during 
luciferase assay analysis. 
 
The DNA cocktail was mixed with OPTIMEM and incubated at RT for 5 minutes. 
The lipofectamine solution and DNA solutions were then mixed and incubated for 20 
minutes at RT. 50µl of the final mix was then added to each well and incubated for 
48 hours at 37°C until cells displayed a transfection efficiency of 70-80%. Media 
was changed 6 hours after transfection and 24 hours following transfection. 
Transfection efficiency was checked using a GFP microscope.  
 
 
2.14 Luciferase assay 
 
48 hours post transfection, media was removed and cells were washed in 1X PBS. 
100µl of passive lysis buffer (Promega) was then added to each well and cells were 
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incubated for 15 minutes on a shaker at RT. A cell scraper was then used to help lift 
any remaining cells from the surface of the well. The cell lystate solution was then 
aliquoted into 2ml Eppendorf tubes and spun down at 4°C by centrifugation at 
13000rpm for 5 minutes. Following centrifugation, 20µl of the supernatant was 
added per well to a 96 well assay plate (bio-rad). The remaining sample volume was 
stored at -20°C and used for western blot analysis.   
Lysates were then analysed using a Promega Dual Luciferase Reporter Assay System 
(DLR) kit (Promega) according to kit instructions (see appendix1). Assays were 
carried out using a GloMax 96 Microplate Luminometer with dual injectors 




Results were then compiled in Microsoft Excel and quantified using Microsoft Excel 
and Prism software.  
 
2.15 Western blot analysis 
 
2.15.1 Preparation of cell lysate for western blot 
 
Transfected HEK 293 cells previously lysed for luciferase assay analysis were 
defrosted and placed on ice. The samples were transferred into 1.5µl eppendorf tubes 
and 1µl of β-Mercaptethanol (Sigma Aldrich) was added to each tube in a fumehood. 
A volume of 4X protein running buffer (Li-COR) containing 1:10 β-Mercaptethanol 
was added and the samples were then boiled for 10 minutes on a hot block in order to 
denature the proteins. 
 
2.15.2 One-dimensional electrophoresis 
 
One-dimensional electrophoresis was used to separate proteins according to their 
molecular weight for further analysis. An adaptation of the discontinuous 
polyacrylamide system described by Laemmli (1970) using precast gels was 
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implemented. 4-12% Bis Tris pre-cast 1mm 12 well polyacrylamide gels (NuPAGE) 
were rinsed in ddH2O and set up in a western blot gel tank. Gels were fully 
immersed in fresh MOPS 1X running buffer (50ml NuPAGE MOPS SDS running 
buffer + 950ml ddH2O).   
Samples were loaded into the gels along with a pre-stained protein ladder 
(PageRuler). Samples were then run at a constant voltage of 200V for 50 minutes.  
 
2.15.3 Protein transfer 
 
Following sample separation, samples were transferred to a nitrocellulose membrane. 
Standard methods were used (Appendix 3). The transfer was carried out at 100V 
with a current limit of 0.4A at 4°C for 1 hour. Care was taken to ensure that the 
cassette was completely immersed in transfer buffer and that all air bubbles were 
removed from the cassette.  
 
2.15.4 Western blotting 
 
Following the transfer, nitrocellulose membranes were stained for 5 minutes in 0.1% 
Ponceau S solution (Sigma) in 5% acetic acid (Fisher Scientific) in order to visualise 
the separated protein bands and assess sample quality. The nitrocellulose membrane 
was then rinsed in ddH2O and blocked in blocking buffer (5% dry milk powder + 
0.25% PBT). Western blots were carried out using optimum concentrations of both 
primary and secondary antibodies (Table 2.10).  
 
 
Table 2:10 Primary and secondary antibody concentrations 
 
Antibody Source Concentration 
GAPDH Abcam.  




















2.15.5 Incubation with primary antibodies 
 
Blots were incubated with primary antibodies diluted in blocking buffer overnight at 
4°C. Primary antibodies used were: mouse anti-GAPDH (Abcam) and rabbit anti-
Pax6 (Millipore). The nitrocellulose membrane was equally covered by the solutions 
and rocked gently. Following incubation the blot was washed 3 x 10 min in 0.25% 
PBT. 
 
2.15.6 Incubation with the secondary antibodies 
 
Blots were incubated with secondary antibody diluted in blocking buffer for 45 
minutes at room temperate. Secondary antibodies used were: AF680 goat anti-mouse 
IgG (H+L) (ThermoFisher) and AF790 goat anti-rabbit IgG (H+L) (ThermoFisher). 
The nitrocellulose membrane was equally covered by the solutions and rocked gently. 
Following incubation the blot was washed 3 x 10 min in 0.25% PBT and then 
washed 2 x 5min in 1X PBS.  
 
2.15.7 Imaging  
 
The Nitrocellulose membrane was removed from PBS and covered in a thin layer of 
cling film. Bubbles were carefully removed to ensure that the samples were imaged 
correctly. The Nitrocellulose membrane was then imaged using a Li-COR Odyssey 
(Li-COR Biosciences) and Odyssey software. Samples were scanned at varying 





Samples scanned at optimum exposure levels were then quantified using imageJ. 
Pax6 intensity levels were normalised to GAPDH intensity levels for each sample.  
 
 
2.16 Cell dissociation  
 
Dissociation of cortical cells was carried out using a Papain Dissociation Kit 
(Worthington Biochemical Corporation). 
 
2.16.1 Preparation of papain dissociation kit reagents 
 
100ml of Earle’s Balanced Salt Solution (EBSS) was oxygenated for 3-5 minutes and 
aliquoted into 20ml universal tubes. Ovomucoid inhibitor was prepared by adding 
32mls of oxygenated EBSS to vial 4, containing ovomucoid powder and shaken well 
to suspend. The ovomucoid inhibitor was then placed in a 37°C incubator for to 
dissolve the powder fully. DNAse was dissolved in 500µl of oxygenated EBSS and 
stored in a Bijou for later use. Papain solution was prepared by dissolving Papain 
powder in 5mls of oxygenated EBBS and 250µl of DNAse solution was added prior 
to placing the Papain solution into a 37°C incubator.  
 
2.16.2 Dissection of embryonic cortices 
 
The uterus of Pax6-/- females at gestational stage E12.5 and E14.5 were dissected out 
and placed into EBSS in a petri dish. Embryos were then dissected and placed into a 
fresh dish of EBSS and genotyped by eye and sorted into control and mutants. 
Embryos were then decapitated and the brain was removed using forceps and a 
beaver blade. Telencephalic vesicles were removed from the brain and cortices 
dissected and placed in a bijou containing EBSS on ice. Control cortices were 
grouped together and Sey cortices were also grouped together.  
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2.16.3 Dissociation of embryonic cortical cells 
 
EBSS and cortical tissue sections were then transferred to a conical centrifuge tube 
and EBSS was removed with a sterile pipette. 2mls of prepared Papain solution was 
then added in its placed and the tube was placed in a 37°C incubator for 45 minutes 
to allow the cortical tissue to be digested.  Cells were then suspended in solution by 
gentle pipetting with a round-ended sterile pipette. Cells were then centrifuged at 
300g (1500rpm) for 5 minutes and supernatant was removed and discarded. A low-
ovo solution was then prepared by mixing 1.35mls of EBSS, 300µl of ovomucoid 
inhibitor and 75µl DNAse, and cells were suspended in the mix. 5mls of ovomucoid 
inhibitor was then added to a new centrifuge tube and cell suspension was added 
very slowly to the top of the ovomucoid solution. The tube containing the ovomucoid 
inhibitor/cell mix was then centrifuged at 70g (~500rpm) for 5 minutes. Supernatant 
was then removed and the dissociated cells re-suspended in 5mls of culture medium. 
 
2.16.4 Estimation of cell concentration 
 
20µl of the final cell suspension was pipetted onto a haemocytometer and counts 
were carried out using a light microscope (Leica). Counts were carried out for four 
different areas and the average was calculated for the number of cells in x104 in 1ml 
in order to calculate how many were in the prepared 5ml solution.   
 
2.16.5 Fixation of dissociated cells  
 
Following the estimation of cell concentration, cells were pelleted by centrifugation 
and supernatant was discarded. For 20,000 cells, 250µl of 1X PBS was added to the 
pelleted cells in order to re-suspend them, and 750µl of ice-cold 100% ethanol was 





2.17 Flow cytometry  
 
2.17.1 Staining cells  
 
1x106 cells (5ml of 200, 000 cell/ml suspension) were pelleted by centrifugation at 
5000rpm and supernatant was discarded.  Cell pellets were then re-suspended in 50µl 
of FACS buffer (1X PBS and 0.5% bovine serum albumins (BSA)).  
Primary antibody mix was prepared in a total volume of 50µl per cell sample. 
Primary antibodies were titrated by flow cytometry analysis and used at an optimised 
ratio of 1:100 for Sox-2 af488 and Tbr2 pe-ef610 (eBioscience), and a ratio of 1:50 
for Dll1 APC (BioLegend). Optimisation was carried out for the reported 
experiments in this thesis. Primary antibodies were diluted in FACS buffer to a total 
volume of 50µl and added to the cell sample. Cell samples were then incubated for 1 
hour in the dark at RT.  
Cells were then washed with 1ml of FACS buffer and pelleted by centrifugation at 
5000rpm. Supernatant was then discarded and cell pellets were re-suspended in 
110µl of DNA dye solution (0.11µl of 10mg/ml Hoechst 33342 stock solution and 
109.89µl FACS buffer). Samples were then incubated for 1 hour in the dark at RT. 
 
Cell samples were then washed with 1ml of FACS buffer and pelleted by 
centrifugation at 5000rpm, supernatant was discarded and cells were re-suspended in 
300µl of FACS buffer and stored at 4°C until required. 
 
2.17.2 Flow cytometry analysis 
 
Cell samples were run on an LSRII and analysed using FlowJo V10.  
 
 
2.18 Cell counts 
 
Cell density for Dll1 expressing cells and total cell density were quantified using 
images produced from in situ hybridisation and H&E staining experiments.  Sample 
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areas were defined at caudal, medial and rostral regions of the cortex.  Within these 
regions, a sub region was defined by dividing analysis of the cortex into the dorsal 
cortex and the ventral cortex.  A replicate of 3 sections per region, per embryo were 
analysed for each mutant and their control littermate.  An N of three was used for 
each genotype and developmental stage, other than analysis of Dll1 density in 
PAX77 embryos at E12.5 where an N of 5 was used and the left telencephalic lobe 
was defined as the sample area for each individual embryo.  For each section, a high 
powered image (X40) of both the dorsal and ventral areas of the developing cortex 
were taken. 
 
The width of the cortex of each replicate was measured and a square was drawn on 
the cortex with each side equating to the width recorded.  The boxed area was treated 
as the sample area.  Total number of cells within the cortex was recorded and the 
sample area was calculated (cortex width mm2).  Cell density was then calculated 
(no. cells x 0.01 ÷ area, chosen in order to reduce size of graph axis).  The average 
cell density for each region was calculated and statistical analysis by Two-way 
ANOVA and Tukey’s multiple comparison test was conducted. 
 
Cell count analysis was carried out using ImageJ software and statistical analysis was 
carried out using Prism 6 software. 
 
 
2.19 Identification of the VZ and the SVZ in the embryonic cortex 
 
Identification of the SVZ was achieved by immunohistochemistry. The SVZ marker 
Tbr2 was used in order to visualise the SVZ and separate it from the VZ in the 






Figure 2.3 Identification of the VZ and the SVZ in the telencephalon  
 
Panels showing an E14.5 WT telencephalon double stained by in situ 
hybridisation/immunohistochemistry with Dll1 (red) and Tbr2 (green). (A and D) Caudal 
section (B and E) Medial section (C and F) Rostral section. Tbr2 is a well established marker 
of INPs residing in the SVZ, allowing separation of the SVZ (Green) from the VZ (red) in the 
cortex telencephalic vesicles. (A-C) Scale bars = 80µm (D-F) Scale bars = 60µm 
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3.1 Introduction  
 
Dll1, the mouse homolog of the Drosophila gene Delta1 (Dll1), is one of four genes 
in the Dll family (Dll1-4). The Dll1 family, along with the Jagged family (comprised 
of Jagged 1-2) form the group of Notch ligands responsible for the cleavage and 
activation of the NICD in a neighbouring cell, inhibiting its differentiation into a 
neural cell and consequently, preserving the progenitor cell pool required for the 
cortex to form correctly (Chapter 1.7). As a result, Dll1 is a crucial element of the 
Notch signalling pathway and therefore of great importance in maintaining the 
balance between cell proliferation and differentiation during the process of cortical 
neurogenesis (Campos et al., 2001; Kageyama et al., 2008a; 2008b; Pierfelice et al., 
2011; Nelson et al., 2013).  
 
A disruption in the levels of Dll1 expression has been documented to have adverse 
effects during embryonic development and postnatally. An increase in Dll1 has been 
linked to brain tumor development (Ignatova et al., 2002; Purow et al., 2005; de 
Antonellis et al., 2011; Zhang et al., 2011), while a decrease in Dll1 expression 
prevents correct arteriogenesis (Limbourg et al., 2007; Van den Akker et al., 2007). 
However, despite the clear role of Dll1 in forebrain development (Pierfelice et al., 
2011; Shimojo et al., 2008; Nelson et al., 2013), few studies have addressed how an 
alteration in Dll1 expression levels would affect corticogenesis.  
 
Past studies, which have observed the expression of Dll1 during neurogenesis, have 
observed a punctate expression pattern throughout the developing telencephalon. 
This expression pattern has a striking resemblance to the proneural gene Ngn2, 
which directly regulates Dll1 expression (Shimojo et al., 2008). In terms of the 
cortex specifically, there has been some controversy over the precise location of Dll1 
expression within the proliferative zones of the developing cortex. Campos et al. 
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(2001) originally reported Dll1 to be expressed in the VZ between E12.5-E14.5 of 
embryonic development (Campos et al., 2001), while subsequent research has 
suggested that Dll1 is expressed solely within the SVZ and is a cell marker for INPs 
(Mizutani et al., 2007; Kawaguchi et al., 2008; Yoon et al., 2008). Furthermore, 
recent studies by Nelson et al. (2013) have suggested that Dll1 is predominately 
expressed within the SVZ but is also expressed at lower levels in the VZ, in a sub 
population of INPs that reside there (Nelson et al., 2013). 
 
As previously discussed (Chapter 1), microarray analysis of potential Pax6 targets 
has suggested Dll1 as a likely candidate. A study by Sansom et al. (2013) proposed 
Dll1 to be regulated by Pax6 from their chromatin immunopreciptiation (ChIP) 
analysis of the Pax6-/- mutant and PAX77 mutant. However, Dll1 has yet to be 
confirmed as a Pax6 target and no Dll1 expression pattern analysis has been 
conducted in Pax6 mutants. 
 
Due to published research directly suggesting Dll1 to be regulated by Pax6, and 
other genes implicated in the Notch signalling pathway also being classified as 
potential targets (Carr, 2009; Sansom et al., 2009), it stands to reason that Dll1 could 
be a Pax6 target. In order to ascertain whether Dll1 could be regulated by Pax6 
expression, analysing Dll1 gene expression in the Pax6-/- mutant, which is null for 
Pax6 expression, provides a clear insight.  
 
 If Dll1 expression is affected by a loss of Pax6, it is plausible that its expression will 
also be affected by varying levels of Pax6. As a result, analysis of Dll1 expression in 
the PAX77 overexpressing mutant and the floxed Pax6 conditional knockout (Fp6 
cKO) mutant would provide insight into how differing Pax6 levels affect Dll1 
expression in the developing cortex. Previous work on the PAX77 mutant has shown 
that an increase in Pax6 expression results in a depletion of the progenitor pool due 
to a decrease in progenitor cell proliferation vs. differentiation (Manuel et al., 2007; 
Georgala et al., 2011). Additionally, analysis using a floxed Pax6 transgenic line 
expressing a tamoxifen inducible Cre recombinase targeted to the Emx1 locus 
(Emx1CreErT2;Pax6loxP/loxP) (Kessaris et al., 2006; Simpson et al., 2009), allowing 
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the knockdown of Pax6 at specific stages of development and exclusively in the 
cortex from E9.5, will give further insight into the role of Pax6 during telencephalic 
development and how it affects the complex gene networks that it controls (Simpson 
et al., 2009).  
 
 
3.2 Analysis of Dll1 gene expression in Pax6-/- mutants  
 
In order to better understand the effects of Pax6 on Dll1, in situ hybridisation 
analysis of Dll1 gene expression in Pax6-/- mutants was carried out in a 
developmental series of embryonic stages E11.5-E13.5, spanning the peak of 
neurogenesis. WT littermates acted as controls. Due to the fact that Dll1 was 
suggested as a potential indirect target of Pax6 by Sansom et al., 2009, it was 
anticipated that Dll1 gene expression would be altered in Pax6-/- embryos. 
 
At E11.5, Dll1 was observed to have a punctate expression pattern throughout the 
telencephalic vesicles (Figure 3.1 A-C) and the diencephalon (Figure 3.1 B-C) of 
WT embryos. A punctate expression pattern was also observed in telencephalic 
vesicles (Figure 3.1 D-F) and diencephalon of Pax6-/- mutant embryos (Figure 3.1 E-
F). Dll1 expression remained uniform throughout the cortex and no obvious gradient 
was observed from a rostral to caudal position. No striking difference in Dll1 
expression was observed between WT controls and Pax6-/- mutants at a low powered 
magnification (Figure 3.1 A-F). A comparison of Dll1 expression between WT 
controls and Pax6-/- mutants at a higher power of magnification suggested that the 
number of cells expressing Dll1 may be reduced throughout the developing cortex. 
The cerebral cortex of Pax6-/- mutant embryos also appeared notably thinner, 
particularly in rostral cortical regions, in comparison to the cortex of WT controls 





Figure 3.1 Dll1 gene expression in the developing forebrain of Pax6-/- embryos at 
E11.5. 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a Sey mutant 
embryo. (D) Dll1 expression in the rostral region of the Sey forebrain. (E) Dll1 expression in 
the medial region of the Sey forebrain. (F) Dll1 expression in the caudal region of the Sey 
forebrain. (G-I) Dll1s punctate expression pattern in the developing cerebral cortex of WT 
control embryos at E11.5. (J-L) The number of Dll1 expressing cells appears reduced in the 
cortex of Sey mutant embryos at E11.5. (A-F) Scale bars = 200µm. (G-L) Scale bars = 
20µm. Sey = Pax6-/-. WT = Pax6+/+. * indicates the cortex and is the area of cortex that is 
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shown at higher magnification in G-L. GE = ganglionic eminence. Di = diencephalon. Ctx = 
cortex. (N=3 embryos).  
 
 
At E12.5, Dll1 was observed to have a similarly punctate expression pattern 
throughout the telencephalic vesicles (Figure 3.2 A-C) and the diencephalon (Figure 
3.2 B-C) of WT embryos and Pax6-/- embryos (Figure 3.2 D-F and E-F). The number 
of cells expressing Dll1 appears to be higher at E12.5 (Figure 3.2) when compared to 
E11.5 (Figure 3.2). Dll1 expression remains uniform throughout the cortex at E12.5 
and no obvious difference was observed at a low magnification between WT control 
embryos and Pax6-/- mutants (Figure 3.2 A-F). Examination of the cortex at a higher 
power magnification also observed a potential decrease in the number of Dll1 
expressing cells in Pax6-/- mutants (Figure 3.2 J-L) when compared to WT controls 





Figure 3.2 Dll1 gene expression in the developing forebrain of Pax6-/- embryos at E12.5  
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a Sey mutant 
embryo. (D) Dll1 expression in the rostral region of the Sey forebrain. (E) Dll1 expression in 
the medial region of the Sey forebrain. (F) Dll1 expression in the caudal region of the Sey 
forebrain. (G-I) Dll1s punctate expression pattern in the developing cerebral cortex of WT 
control embryos at E12.5. (J-L) The number of Dll1 expressing cells appears reduced in the 
cortex of Sey mutant embryos at E12.5. (A-F) Scale bars = 200µm. (G-L) Scale bars = 
20µm. Sey = Pax6-/-. WT = Pax6+/+. * indicates the cortex and is the area of cortex that is 
shown at higher magnification in G-L. GE = ganglionic eminence. Di = diencephalon. Ctx = 




At E13.5, the punctate expression pattern of Dll1 remains consistent with the 
expression observed at E11.5 and E12.5. Dll1 expression remains consistent 
throughout the telencephalic vesicles (Figure 3.3 A-C) and diencephalon (Figure 3.3 
B-C) in WT controls and in Pax6-/- mutants (Figure 3.3 D-F and E-F). In WT 
embryos, Dll1 expression appears to be denser in the VZ of the developing cortex 
when compared to the SVZ. This difference is evident in the rostral and medial 
regions of the cortex (Figure 3.3 A-B) but does not appear to be the case in the 
caudal region of the cortex (Figure 3.3 C). In contrast, Pax6-/- embryos do not display 
denser expression of Dll1 in the VZ (Figure 3.3 D-F). Analysis of the cortex at a 
higher magnification also presented a likely reduction in the number of cells 
expressing Dll1 in Pax6-/- mutants (Figure 3.3 G-I) when compared to WT controls 





Figure 3.3 Dll1 gene expression in the developing forebrain of Pax6-/- embryos at E13.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a Sey mutant 
embryo. (D) Dll1 expression in the rostral region of the Sey forebrain. (E) Dll1 expression in 
the medial region of the Sey forebrain. (F) Dll1 expression in the caudal region of the Sey 
forebrain. (G-I) Dll1s punctate expression pattern in the developing cerebral cortex of WT 
control embryos at E13.5 Expression appears to be denser in the VZ. (J-L) The number of 
Dll1 expressing cells appears reduced in the cortex of Sey mutant embryos at E13.5. (A-F) 
Scale bars = 200µm. (G-L) Scale bars = 20µm. Sey = Pax6-/-. WT = Pax6+/+. * indicates the 
cortex and is the area of cortex that is shown at higher magnification in G-L. GE = ganglionic 
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eminence. Di = diencephalon. Ctx = cortex. (N=3 embryos). Analysis carried out by project 
student Gabrielle Clark.  
 
 
Analysis of Dll1 gene expression in Pax6-/- embryos identified that there appeared to 
be less Dll1 expressing cells when compared to WT control littermates. However, the 
difference in expression is very subtle and could only be seen at a high power of 
magnification. It was concluded that the images would need to be quantified by cell 
count in order to confirm that there was a reduction in the mutant embryos. It was 
also concluded that it would of interest to observe the effects of different levels of 




3.3 Analysis of Dll1 gene expression in PAX77 mutants 
 
Due to the fact that Dll1 expression appeared reduced in some areas of cortex at 
E11.5-E13.5 in Pax6-/- embryos, in situ hybridisation analysis of Dll1 gene 
expression in PAX77 mutants was carried out in a developmental series of embryonic 
stages E11.5-E13.5, spanning the peak of neurogenesis. WT littermates acted as 
controls. As Dll1 expression appeared reduced in Pax6-/- embryos, it was anticipated 
that Dll1 expression would increase in the PAX77 embryos as they overexpress 
Pax6. 
 
At E11.5, both WT control embryos and PAX77 mutant embryos have a punctate 
expression pattern, identical to the pattern observed in the Pax6-/- mutant embryos 
and their WT littermates. Dll1 expression remains uniform throughout the 
telencephalic vesicles and the diencephalon of both WT (Figure 3.4 A-C and B-C) 
and PAX77 embryos (Figure 3.4 D-F and E-F). No difference in expression pattern 
was detected in PAX77 embryos when compared to their WT littermates at a low 
magnification (Figure 3.4 A-C and D-F). No difference in expression pattern was 
detected in the cortex of PAX77 mutants (Figure 3.4 G-I) compared to WT controls 




Figure 3.4 Dll1 gene expression in the developing forebrain of PAX77 embryos at 
E11.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a PAX77 
mutant embryo. (D) Dll1 expression in the rostral region of the PAX77 forebrain. (E) Dll1 
expression in the medial region of the PAX77 forebrain. (F) Dll1 expression in the caudal 
region of the PAX77 forebrain. (G-I) Dll1s punctate expression pattern in the developing 
cerebral cortex of WT control embryos at E11.5. (J-L) No obvious difference is evident in the 
cortex PAX77 mutant embryos when compared to WT controls at E11.5. (A-F) Scale bars = 
200µm. (G-L) Scale bars = 20µm. * indicates the cortex and is the area of cortex that is 
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shown at higher magnification in G-L. GE = ganglionic eminence. Di = diencephalon. Ctx = 
cortex. (N=3 embryos).  
 
 
At E12.5, PAX77 mutant embryos exhibit the punctate expression pattern as their 
WT control littermates (Figure 3.5 A-C and D-F). Uniform Dll1 expression is 
observed throughout the telencephalic vesicles (Figure 3.5 A-C) and the 
diencephalon (Figure 3.5 B-C) in WT controls and in PAX77 mutants (Figure 3.5 D-
F and E-F). No difference in expression between WT and PAX77 embryos was 
detected at a low magnification (Figure 3.5 A-C and D-F) or at a higher 





Figure 3.5 Dll1 gene expression in the developing forebrain of PAX77 embryos at 
E12.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a PAX77 
mutant embryo. (D) Dll1 expression in the rostral region of the PAX77 forebrain. (E) Dll1 
expression in the medial region of the PAX77 forebrain. (F) Dll1 expression in the caudal 
region of the PAX77 forebrain. (G-I) Dll1s punctate expression pattern in the developing 
cerebral cortex of WT control embryos at E12.5. (J-L) No obvious difference is evident in the 
cortex PAX77 mutant embryos when compared to WT controls at E12.5. (A-F) Scale bars = 
200µm. (G-L) Scale bars = 20µm. * indicates the cortex and is the area of cortex that is 
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shown at higher magnification in G-L. GE = ganglionic eminence. Di = diencephalon. Ctx = 
cortex. (N=3 embryos). Analysis carried out by project student Milena Blaga.  
 
 
At E13.5, both WT and PAX77 embryos continue to display a uniformly punctate 
expression pattern for Dll1 throughout the telencephalic vesicles (Figure 3.6 A-C) 
and diencephalon (B-C). At a higher magnification, WT embryos display an increase 
in Dll1 expressing cells in the VZ (Figure 3.6 G-I) when compared to the SVZ. This 
increase in Dll1 expression does not appear to be present in the VZ of PAX77 





Figure 3.6 Dll1 gene expression in the developing forebrain of PAX77 embryos at 
E13.5 
 
(A) Dll1 expression in the rostral region of the WT forebrain. (B) Dll1 expression in the 
medial region of the WT forebrain. (C) Dll1 expression in the caudal region of the WT 
forebrain. (D-F) Dll1 expression in a PAX77 mutant embryo. (D) Dll1 expression in the rostral 
region of the PAX77 forebrain. (E) Dll1 expression in the medial region of the PAX77 
forebrain. (F) Dll1 expression in the caudal region of the PAX77 forebrain. (G-I) Dll1 appears 
to be most densely expressed in the VZ of the developing cortex. (J-L) The denser 
expression of Dll1 in the VZ appears to be lost in PAX77 mutants when compared to WT 
controls. (A-F) Scale bars = 200µm. (G-L) Scale bars = 20µm. * indicates the cortex and is 
the area of cortex that is shown at higher magnification in G-L. GE = ganglionic eminence. Di 
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Analysis of Dll1 gene expression in PAX77 embryos identified no discernable 
difference when compared to WT control embryos. However, quantification of Dll1 




3.4 Analysis of Dll1 gene expression in cKO Fp6 mutants 
 
While Pax6-/- embryos provide an excellent model to study the effects of a loss of 
Pax6 on cortical development, the fact that Pax6 is never present allows for 
compensation from other genes that could reduce the detrimental effect of a loss of 
Pax6 expression. In order to combat this potential compensatory effect, a conditional 
knockout for Pax6 exclusively in the cortex was also used. In situ hybridisation 
analysis of Dll1 gene expression in Emx1CreErT2;Pax6loxP/loxP (herein referred to as 
‘cKO’) was carried out in a developmental series of embryonic stages E12.5-E13.5. 
Heterozygous littermates for Emx1CreErT2;Pax6loxP/loxP embryos (herein referred to 
as ‘controls’) were used at controls. Embryonic stage E11.5 was excluded from the 
series due to the fact that previous analysis of the cKO mutants carried out in our lab 
has indicated that tamoxifen injections at E9.5 do not sufficiently knock down Pax6 






Figure 3.7 Dll1 gene expression in the developing forebrain of cKO embryos at E12.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a cKO mutant 
embryo. (D) Dll1 expression in the rostral region of the cKO forebrain. (E) Dll1 expression in 
the medial region of the cKO forebrain. (F) Dll1 expression in the caudal region of the cKO 
forebrain. (G-I) Dll1s punctate expression pattern in the developing cerebral cortex of WT 
control embryos at E12.5. (J-L) The number of Dll1 expressing cells appears reduced in the 
cortex of cKO mutant embryos at E12.5. (A-F) Scale bars = 200µm. (G-L) Scale bars = 
20µm. * indicates the cortex and is the area of cortex that is shown at higher magnification in 




At E12.5, Dll1 expression remained punctate and uniform throughout the 
telencephalic vesicles and the diencephalon of control (Figure 3.7 A-C and B-C) and 
cKO mutant (Figure 3.7 D-F and E-F) embryos. No difference in expression was 
observed at a lower magnification when comparing cKO mutants (Figure 3.7 B-C) to 
their control littermates (Figure 3.7 A-C). A potential reduction in the staining 
intensity of Dll1 was observed in the cKO cortex at a higher power magnification 
(Figure 3.7 J-L) when compared to the cortex of control embryos (Figure 3.7 G-I). 
At E13.5, Dll1 expression was also observed to be punctate throughout the 
telencephalic vesicles and the diencephalon of control embryos (Figure 3.8 A-C and 
B-C) and cKO littermates (Figure 3.8 D-F and E-F). No difference in the expression 
of Dll1 was observed between control embryos and cKO embryos when observed at 
a low power of magnification. Images taken at a high power magnification suggested 
that staining could potentially be reduced in cKO embryos (Figure 3.8 G-L). As was 
the case with Pax6-/- analysis at E13.5, Dll1 expression appears to be denser in the 







Figure 3.8 Dll1 gene expression in the developing forebrain of cKO embryos at E13.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in a cKO mutant 
embryo. (D) Dll1 expression in the rostral region of the cKO forebrain. (E) Dll1 expression in 
the medial region of the cKO forebrain. (F) Dll1 expression in the caudal region of the cKO 
forebrain. (G-I) Dll1s punctate expression pattern in the developing cerebral cortex of WT 
control embryos at E13.5. Dll1 expression appears denser in the VZ. (J-L) The number of 
Dll1 expressing cells appears reduced in the cortex of cKO mutant embryos at E13.5. (A-F) 
Scale bars = 200µm. (G-L) Scale bars = 20µm. * indicates the cortex and is the area of 
cortex that is shown at higher magnification in G-L. GE = ganglionic eminence. Di = 
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As was the case with the Pax6-/- embryos, analysis of Dll1 expression in cKO 
mutants suggested a decrease in the number of Dll1 expressing cells in the 
developing cortex when compared to WT control littermates. However, due to the 
subtlety of the difference observed, it was concluded that quantification of the 
images by cell count analysis would be required for confirmation. 
 
 
3.5 Cell count analysis of Dll1 gene expression in Pax6-/- mutants  
 
In order to confirm the observations made by in situ hybridisation analysis, cell 
counts of the images were performed as described in chapter 2 (Chapter 2.18) 
(Figure 3.9). Cell counts were performed on Dll1 in situ slides and H&E slides. H&E 
cell counts allowed us to assess whether total cell density was affected in the cortex 
of mutant embryos when compared to their control littermates. This allowed us to 






Figure 3.9  Example of cell count sample selection 
 
(A) Three replicate sections were selected for each cortical region. (B) An example of the 
dorsal and ventral regions of the cortex selected for cell counts. (C) An example of a cell 





Two-way ANOVA results for the dorsal region of the developing cortex (Figure 3.10 
A) determined that there were no interaction, region or genotype effects found when 
comparing the WT control and Pax6-/- mutant data sets, with all P values found to be 
non-significant (NS). All Tukey multiple comparison tests were also not significant. 
The ventral region of the cortex (Figure 3.9 B) was found to have no interaction or 
region effect, but did have a genotype effect (P=0.0331) when analysis by two-way 
ANOVA was carried out at E11.5. However, Tukey’s multiple comparison tests were 
all non-significant.  
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Two-way ANOVA analysis of the total density of cells in the dorsal region of WT 
and Pax6-/- cortices (Figure 3.9 C) reported that there were no interaction, region or 
genotype effects, and that all Tukey’s multiple comparison tests were non-
significant. However, in the ventral region of the cortex (Figure 3.9 D), analysis by 
two-way ANOVA reported a region effect (P=0.0195) and Tukey’s multiple 





Figure 3.10 Cell density in the cortex of Pax6-/- embryos at E11.5 
 
 (A) Dll1 density in the dorsal region of the cortex. (B) Dll1 density in the ventral region of the 
cortex. (C) Total cell density in the dorsal region of the cortex. (D) Total cell density in the 
ventral region of the cortex. (A-B) No significant decrease in Dll1 density was detected when 
comparing Sey mutants to WT controls. (C-D) No significant decrease in cell density was 





Statistical analysis of Dll1 expression in the dorsal region of the developing cortex at 
E12.5 (Figure 3.11 A) demonstrated a genotype effect (P=0.0004) between Wt and 
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Pax6-/- embryos. The implementation of Tukey’s multiple comparison tests reported 
a significant difference between caudal Wt: caudal Pax6-/- (P=0.0056). The ventral 
region of the developing cortex (Figure 3.10 B) showed a genotype effect (P= 
<0.0001) by two-way ANOVA, while Tukey’s multiple comparison tests yielded a 
significant difference between rostral Wt: rostral Pax6-/- (P=0.0008), medial Wt: 
medial Pax6-/- (P=0.0003), caudal Wt: caudal Pax6-/- (P=0.0168). 
 
Analysis of the total density of cells in the dorsal region of the developing cortex 
(Figure 3.10 C) by two-way ANOVA reported no interaction, region or genotype 
effect, and all Tukey’s multiple comparison tests were not significant. However, 
analysis of the ventral region of the cortex (Figure 3.11 D) reported a region effect 
(P=0.0205) by two-way ANOVA and a significant difference between rostral Pax6-/-: 






Figure 3.11 Cell density in the cortex of Pax6-/- embryos at E12.5 
 
 (A) Dll1 density in the dorsal region of the cortex. A significant decrease in Dll1 density is 
observed in the dorsal-caudal region of the cortex when comparing Sey to WT. 
(**P=0.0329). (B) Dll1 density in the ventral region of the cortex. Dll1 expression in the 
ventral region of the cortex in WT controls and Sey mutants. A significant decrease in Dl11 
density was observed in all regions of the ventral cortex when comparing Sey mutants to WT 
controls. (Rostral ***P=0.0008, Medial ***P=0.0003, *P=0.0168). (C) Total cell density in the 
dorsal region of the cortex. (D) Total cell density in the ventral region of the cortex. (C-D) No 
significant decrease in cell density was detected when comparing Sey mutants to WT 





Two-way ANOVA testing carried out on Dll1 expression of samples from the dorsal 
region of the cortex at E13.5 (Figure 3.11 A) observed interaction (P=0.0292), region 
(P=0.0133) and genotype (P=<0.0001) effects. Further analysis by Tukey’s multiple 
comparison testing found significant differences between rostral Wt: caudal Wt 
(P=0.0167); medial Wt: medial Pax6-/- (P=0.0141); caudal Wt: caudal Pax6-/- 
(P=0.0028). Evaluation of the ventral region of the cortex at E13.5 (Figure 3.12 B) 
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displayed a genotype effect (P=0.0118) but no significant differences were detected 
by Tukey’s multiple comparison test.  
 
Two-way ANOVA analysis of the total density of cells in the dorsal region of Wt 
and Pax6-/- cortices (Figure 3.11 C) reported that there was no interaction effect. 
However, a region effect (P=0.0325) and genotype effect (P=0.0475) were reported. 
All Tukey’s multiple comparison tests were non-significant. However, in the ventral 
region of the cortex (Figure 3.11 D), analysis by two-way ANOVA reported a region 
effect (P=0.0006) but no interaction or genotype effect. Tukey’s multiple comparison 
tests yielded a significant difference between rostral:Sey vs. caudal:Sey (P=0.0228) 





Figure 3.12 Cell density in the cortex of Pax6-/- embryos at E13.5 
 
 (A) Dll1 density in the dorsal region of the cortex. A significant decrease in Dll1 density is 
observed in the dorsal-medial and dorsal-caudal regions of the cortex when comparing Sey 
to WT. (* P=0.0118, ** P=0.0275). (B) Dll1 density in the ventral region of the cortex. No 
significant decrease in Dll1 density was observed in any ventral region of the cortex. Dll1 
expression in the ventral region of the cortex in WT controls and Sey mutants. (C) Total cell 
density in the dorsal region of the cortex. (D) Total cell density in the ventral region of the 
cortex. (C-D) No significant decrease in cell density was detected when comparing Sey 
mutants to WT controls. Sey = Pax6-/-. WT = Pax6+/+. N=3. Analysis carried out by project 
student Gabrielle Clark. 
 
 




Analysis by two-way ANOVA of both the dorsal (Figure 3.12 A) and ventral (Figure 
3.12 B) region of the cortex at E11.5 found no interaction, region or genotype 




Two-way ANOVA analysis of the total density of cells in the dorsal (Figure 3.12 C) 
and ventral (Figure 3.12 D) regions of Wt and PAX77 cortices reported that there 
were no interaction, region or genotype effects, and that all Tukey’s multiple 





Figure 3.13 Cell density in the cortex of PAX77 embryos at E11.5 
 
(A) Dll1 density in the dorsal region of the cortex. (B) Dll1 density in the ventral region of the 
cortex. (C) Total cell density in the dorsal region of the cortex. (D) Total cell density in the 
ventral region of the cortex. (A-B) No significant difference in Dll1 density was detected in 
the dorsal or ventral regions of the cortex when directly comparing cortical regions of WT 
controls and PAX77 mutants. (C-D) No significant difference in total cell density was 
detected in the dorsal and ventral regions of the cortex when directly comparing cortical 





The dorsal region of the cortex (Figure 3.13 A) was found to have a region effect 
(P=0.0256) and a genotype effect (0.0022), while multiple comparison testing found 
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a significant difference between rostral Wt: Caudal PAX77 (P=0.0147) and Medial 
Wt: Caudal PAX77 (P=0.0248). However, the ventral region of the cortex (Figure 
3.13 B) yielded no interaction, region or genotype effects, and all comparison tests 
were not significant. 
 
Analysis of the total number of cells in both the dorsal (Figure 3.13 C) and ventral 
(Figure 3.13 D) regions of the cortex yielded no interaction, region or genotype 
effects by two-way ANOVA. All Tukey’s multiple comparison tests for both regions 





Figure 3.14 Cell density in the cortex of PAX77 embryos at E12.5 
 
(A) Dll1 density in the dorsal region of the cortex. (B) Dll1 density in the ventral region of the 
cortex. (C) Total cell density in the dorsal region of the cortex. (D) Total cell density in the 
ventral region of the cortex. (A-B) No significant difference in Dll1 density was detected in 
the dorsal or ventral regions of the cortex when directly comparing cortical regions of WT 
controls and PAX77 mutants. (C-D) No significant difference in total cell density was 
detected in the dorsal and ventral regions of the cortex when directly comparing cortical 







Analysis of the dorsal region of the cortex (Figure 3.14 A) and ventral region of the 
cortex (Figure 3.14 B) found no interaction, region or genotype effects at E13.5. All 
multiple comparison tests were reported as non-significant.  
 
Two-way ANOVA analysis of the total density of cells in the dorsal (Figure 3.14 C) 
and ventral (Figure 3.14 D) regions of Wt and PAX77 cortices reported that there 
were no interaction, region or genotype effects, and that all Tukey’s multiple 




Figure 3.15 Cell density in the cortex of PAX77 embryos at E13.5 
 
(A) Dll1 density in the dorsal region of the cortex. (B) Dll1 density in the ventral region of the 
cortex. (C) Total cell density in the dorsal region of the cortex. (D) Total cell density in the 
ventral region of the cortex. (A-B) No significant difference in Dll1 density was detected in 
the dorsal or ventral regions of the cortex when directly comparing cortical regions of WT 
controls and PAX77 mutants. (C-D) No significant difference in total cell density was 
detected in the dorsal and ventral regions of the cortex when directly comparing cortical 









Analysis of Dll1 expression in the dorsal region of the cortex at E12.5 (Figure 3.15 
A) identified a genotype effect (P=<0.0001) when analysis by two-way ANOVA was 
carried out, but there were no reported interaction or region effects. A variety of 
significant differences between both region and genotype were reported by Tukey’s 
multiple comparison tests: rostral C: rostral cKO (P=0.0046), medial C: medial cKO 
(P=0 Analysis of the ventral region of the cortex (Figure 3.15 B) detected an effect 
for both region (P=0.0043) and genotype (P=0.0003), while multiple comparison 
testing detected numerous significant differences between combinations of regions 
and genotype (Table 3.1)  
 
 




P Value P Value Summary 
Rostral:C vs. Rostral:cKO 0.0046 ** 
Rostral:C vs. Medial:cKO 0.0022 ** 
Rostral:C vs. Caudal:cKO 0.0040 ** 
Rostral:cKO vs. Medial:C 0.0076 ** 
Rostral:cKO vs. Caudal:C 0.0075 ** 
Medial:C vs. Medial:cKO 0.0036 ** 
Medial:C vs. Caudal:cKO 0.0066 ** 
Medial:cKO vs. Caudal:C 0.0036 ** 
Caudal:C vs. Caudal:cKO 0.0065 ** 
 
 
Two-way ANOVA analysis of the total density of cells in the dorsal (Figure 3.15 C) 
region of control and cKO cortices reported that there were no interaction, region or 
genotype effects, and that all Tukey’s multiple comparison tests were non-
significant. However, two-way ANOVA analysis of the ventral region reported a 
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region (P=0.0014) and genotype (0.0395) effect, while analysis by Tukey’s multiple 






Figure 3.16 Cell density in the cortex of cKO embryos at E12.5 
 
(A) Dll1 density in the dorsal region of the cortex. A significant decrease was detected 
between all dorsal regions of the cortex when comparing cKO mutants to WT controls. (** 
Rostral P=0.0046, **Medial P=0.0036, ** Caudal P=0.0065). (B) Dll1 density in the ventral 
region of the cortex. A significant decrease was detected between the rostral regions and the 
medial regions of the ventral cortex when cKO mutants were compared to WT controls. (* 
Rostral P=0.0102, * Medial P=0.0487). (C) Total cell density in the dorsal region of the 
cortex. (D) Total cell density in the ventral region of the cortex. (C-D) No significant 
difference in total cell density was detected in the dorsal and ventral regions of the cortex 





Two-way ANOVA results for the dorsal region of the cortex at E13.5 (Figure 3.16 
A) detected both region (P=0.0043) and genotype (P=0.0003) effects, while Tukey’s 
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multiple comparison tests reported multiple significant differences between both 
genotype and regions. In contrast, while a genotype effect (P=0.0005) was detected 
in the ventral region of the cortex (Figure 3.16 B), all multiple comparison tests were 
found to be non-significant. 
 
Total cell density. Dorsal (Figure 3.16 C). Ventral (Figure 3.17 D). 
Two-way ANOVA analysis of the total density of cells in the dorsal (Figure 3.16 C) 
region of Wt and cKO cortices reported that there were no interaction, region or 
genotype effects, and that all Tukey’s multiple comparison tests were non-
significant. However, two-way ANOVA analysis of the ventral (Figure 3.16 D) 
region observed a region effect (P=0.0012) and analysis by Tukey’s multiple 






Figure 3.17 Cell density in the cortex of cKO embryos at E13.5 
 
(A) Dll1 density in the dorsal region of the cortex. A significant decrease was detected 
between the rostral regions and the medial regions of the ventral cortex when cKO mutants 
were compared to WT controls. (* Rostral P=0.0102, * Medial P=0.0487). (B) Dll1 density in 
the ventral region of the cortex. No significant difference in Dll1 density was detected in the 
ventral cortex when comparing WT controls and Pax6-/- mutants. (C) Total cell density in the 
dorsal region of the cortex. (D) Total cell density in the ventral region of the cortex. (C-D) No 
significant difference in total cell density was detected in the dorsal and ventral regions of the 
cortex when directly comparing cortical regions of WT controls and PAX77 mutants. N=3. 
Analysis carried out by project student Gabrielle Clark.  
 
 
Cell count analysis of Dll1 density in Pax6-/- and cKO embryonic cortices observed a 
reduction in Dll1 density in some cortical regions at specific embryonic stages when 
compared to WT controls; while analysis of PAX77 embryos identified no significant 
change in Dll1 density when compared to their WT littermates. Further 
quantification of Dll1 in the cortex by qPCR would also be beneficial in order to 
support these findings.  
 
3.8 qPCR analysis of Dll1 gene expression in Pax6-/- mutants 
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Further analysis of Dll1 in the developing cortex from E12.5-E14.5 was carried out 
by qPCR (Figure 3.18). No significant difference in Dll1 expression was detected at 
E12.5 or E13.5 when Pax6-/- mutants were compared to WT controls. A significant 
decrease (P=0.0575) in Dll1 expression in the cortices of Pax6-/- mutants when 




Figure 3.18 Dll1 gene expression in the developing cortex of Pax6-/- embryos 
 
Detection of Dll1 gene expression in the developing cortex by qPCR. qPCR was carried out 
on three developmental stages (E12.5-E14.5) on Pax6-/- mutants and WT control littermates. 
Results were normalised to GAPDH. A significant decrease in Dll1 expression was detected 
in Pax6-/- mutants at E14.5. * P=0.05. N=3.  
 
Analysis by qPCR did not reflect the findings of the previously described cell count 
analysis, with no significant decrease in Dll1 expression observed at E12.5 and 
E13.5, despite there being a decrease in Dll1 density in specific cortical regions at 





Although the expression pattern of Dll1 in the developing forebrain has previously 
been documented, Dll1 gene expression in the forebrain of embryos with differing 
levels of Pax6 has not been investigated. Initial investigation into the effects of Pax6 
levels on Dll1 by in situ hybridisation observed a similar, punctate expression pattern 
throughout the telencephalon of Pax6-/-, PAX77 and cKO cortices. Dll1s punctate 
expression pattern bears a striking resemblance to the expression pattern of the 
proneural gene Ngn2. As previously discussed, Ngn2 has been reported as a direct 
regulator of several Notch ligands, including Dll1. Furthermore, previous studies by 
Shimoji et al., (2008) have highlighted the complementary oscillatory expression 
levels that Ngn2 and Dll1 exhibit, most likely to be a result of the direct activation of 
Dll1 by Ngn2 (Shimojo et al., 2009). As a result, it is unsurprising that Ngn2 and 
Dll1 share a near identical type of expression pattern to one another. The fact that 
Ngn2 directly regulates Dll1 provides a tangible connection to Pax6 and the Notch 
ligand. Work by Scardigli et al., (2003) provided evidence that Ngn2 is a direct 
target of Pax6, with multiple enhancer sites for Pax6 being located upstream of Ngn2 
(Scardigli et al., 2003). The evidence that Pax6 directly regulates the gene that is 
responsible for the activation of Dll1 automatically typecasts Dll1 as a candidate for 
indirect regulation by Pax6. Initial examination of the mutant cortices in comparison 
to their control littermates found there to be no obvious difference in expression 
patterns. However, in situ images produced at a higher power of magnification 
suggested that there may potentially be fewer Dll1 expressing cells in the developing 
cortex of Pax6-/- mutants and cKO mutants when compared directly with control 
littermates. Examination of PAX77 samples did not display a discernible difference 
from Wt controls. While analysis of gene expression by in situ hybridisation 
provides insight into expression patterns and provides insight into differences in gene 
expression in mutants compared to WT controls, they are not directly quantitative. 
 
In order to quantify the suspected change in Dll1 expression that was observed by in 
situ hybridisation in the cortex of embryos mutant for Pax6, cell count analysis was 
carried out on the in situs for each mutant of interest and their Wt controls. In order 
to verify that any significant difference detected was the result of a loss of Pax6 and 
not just an increase or decrease in cell density within the cortex of mutant embryos, 
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cell counts on the total number of cells within the cortex of mutant samples and their 
control counterparts were also undertaken. Previous work by Sansom et al., 
suggested Dll1 to be a potential Pax6 target, and Dll1 was listed as a gene target of 
Pax6 in their microarray data. However, there has previously been no expression 
analysis undertaken to confirm this (Sansom et al., 2009). 
 
Cell count analysis of the Pax6-/- mutant from E11.5-E13.5 showed no significant 
decrease in density of cells expressing Dll1 density at E11.5, but a significant 
decrease in Dll1 density begins to be detected from E12.5, with a decrease in Dll1 
expression being observed in the dorsal-caudal region of the cortex when Wt and 
Pax6-/- are compared, contributing to the genotype effect that was identified by two-
way ANOVA. The fact that the ventral region was found to have a genotype effect of 
greater significance, and a high number of significantly different multiple 
comparison tests which included a significant decrease in Dll1 cell density in each 
specified region of the Pax6-/- cortex when compared to its control, was of particular 
interest. The ventral region of the developing cortex is where Pax6 expression is at 
its highest, suggesting that at E12.5, Dll1 cell density is potentially tightly controlled 
by the level of Pax6 expression. However, this trend is lost by E13.5, with the dorsal 
region of the cortex being affected by Pax6 to a greater extent than the ventral region 
of the cortex. 
 
A reduced cell density of Dll1 expressing cells in the cortex of Pax6-/- mutants when 
compared to WT controls was observed in a variety of cortical regions from E12.5. 
However, no obvious pattern emerged for the significant differences between cortical 
regions, genotype or developmental stage. Although the lack of pattern could be 
entirely random, it could be that Dll1 is required at higher levels in specific cortical 
areas at specific stages of development. Furthermore, oscillations in Dll1 expression 
could be contributing to the random pattern in regional and genotypic significant 
differences. This would be due to the fact that the cell counts have been performed 
on a snapshot of what oscillating Dll1 expression levels were like at the specific time 
that each embryo was sacrificed. As a result, Dll1 expression levels may be vastly 
diverse in embryos taken from different litters and may even differ to a degree from 
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their littermates. Furthermore, embryos from a different litter are even more likely to 
be prone to differing levels of Dll1 expression, due to the fact that the specific stages 
that the embryo was taken at are not going to be identical as a result of estimated 
times of fertilisation and varying times for sample collection. Consequently, some 
samples may be older than others and as a result, there would be an even larger 
variation in oscillatory cycles. While this minute variance in developmental stage by 
a matter of hours would normally make little difference to the analysis of gene 
expression, caution should be applied when analysing genes proven to oscillate 
within a period of 2-3 hours (Shimojo et al., 2008). In order to rule out any 
discrepancy in results due to Dll1 oscillations, any future cell counts for Dll1 need to 
be carried out with each N taken from the same litter, allowing Dll1 levels to be as 
close as possible to one another for each sample. 
 
Dll1 cell density increases in Wt cortices from E11.5-E12.5, but reduces at E13.5. 
This is likely to be due to a reduction in the size of the VZ as the SVZ forms. As 
previously discussed, Dll1 expression appears to become denser in the VZ at E13.5. 
This decrease could be the result of the sample area being produced from the width 
of the cortex, as the proportion of Dll1 positive cells within the sample area will have 
reduced dramatically. In order to remedy this, analysis of Dll1 expression in the 
future may need to implement a sample area restricted to the width of the VZ only, 
where Dll1 expression is at its highest, or apply two sample areas in later 
developmental stages to account for the VZ and the SVZ. 
 
Cell count analysis observed little significant difference in Dll1 expression in PAX77 
mutants, with the only significant differences being found at E12.5 in the dorsal 
region of the cortex between different dorsal cortical regions of the cortex when 
genotypes were compared. The fact that the PAX77 over expressing mutant routinely 
used by our lab is heterozygous, carrying 5-7 copies of a 420 kb human Pax6 YAC, 
may account for no significant change in Dll1 expression from E11.5-E13.5. It could 
be the case that co-effectors could be responsible for maintaining Dll1 levels by 
compensating for an increase in Pax6. Therefore it may be probable that a higher 
level of Pax6 might be required to alter Dll1 levels, suggesting that the use of the 
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homozygous PAX77 mutant that contains 10-14 copies of Pax6 would be beneficial 
for this study and an effect may be observed (Manuel et al., 2007). 
 
Cell count analysis for the cKO mutant observed a greater effect when compared to 
the Pax6-/- mutant. This is likely to be due to the fact that in the naturally occurring 
Pax6-/- mutation, co-effectors compensate for a loss of Pax6. However, a sudden 
knockout of Pax6 at E9.5 followed by a collection of the embryos within 72-96 
hours, would most likely prevent these compensatory mechanisms. It can therefore 
be suggested that losing Pax6 at a specific time point is more detrimental to Dll1 
expression than if Pax6 was never expressed to begin with (Lewandoski et al., 2001; 
Simpson et al., 2009). 
 
Analysis of Dll1 gene expression was also carried out by qRT-PCR. A significant 
decrease in Dll1 expression was detected at E14.5 (P=0.0575) but no significant 
decrease was observed at E12.5 or E13.5. This data conflicts with the previously 
discussed cell count analysis data, where specific regions of the cortex were found to 
be significantly different at both E12.5 and E13.5. This could be the a result of using 
the entire cortex for qPCR, as any subtle regional decreases could potentially be lost 
when detecting Dll1 levels as a whole in the cortex. Future qPCR analysis using 
specific cortical regions could remedy this issue and give a more accurate account of 
Dll1 expression. Furthermore, technical error when dissecting the cortex could also 
affect the result, as accidentally including tissue from the ventral area of the 
telencephalon where Pax6 is not expressed and Dll1 levels would not be affected, 
would undoubtedly mask the reduction of Dll1 levels in the cortex where Pax6 is 
expressed. 
 
Despite the discrepancies between experimental techniques used to analyse Dll1 
expression in the developing cortex of mutant embryos exhibiting different levels of 
Pax6, it can be implied that Pax6 regulates Dll1 expression on some level. The subtle 
decreases in Dll1 expression in specific cortical regions at specific stages of 
embryonic development suggest that Dll1 is more likely to be indirectly regulated by 
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Pax6 rather than a direct target. However, the notion that Dll1 could be a direct 
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Table 3.1 Chapter 3 results summary 
 
A summary of the cell count analysis detailed in chapter 3. Summary of the statistical 
analysis by ANOVA and Tukey’s multiple comparison testing of the density of Dll1 
expressing cells and total cell density in WT/Sey embryos at E11.5-E13.5; WT/PAX77 
embryos at E11.5-E13.5; and C/cKO embryos at E12.5-E13.5. Region specific significant 
differences and any genotype effects are reported. 
 
	 116






The mammalian Jag1 gene, a ligand and member of the Notch signalling family, is 
one of two genes which comprises the Jagged family, the mammalian homolog of 
the Drosophila Serrate family. Jag1 was initially discovered in the rat, when 
isolation of a cDNA clone observed that the newly identified gene was able to 
activate Notch receptors in a similar manner to its Drosophila counterpart (Lindsell 
et al., 1995). 
 
As previously discussed, Jag1 is a key component of the Notch signalling pathway 
and is consequently involved in the proliferation and differentiation of neural 
progenitor cells during murine embryonic neurogenesis (Basak and Taylor 2007; 
Corbin et al., 2009; Gaiano et al., 2000; Götz and Sommer 2005; Kageyama et al., 
2008b; Pierfelice et al., 2011). As well as the well-documented involvement of Jag1 
in murine neurogenesis, Jag1 has been implicated in maintaining neural progenitors 
during human embryonic development, with its down-regulation resulting in 
abnormal differentiation of progenitor cells, and an increase in the expression of 
Jag1 observed in neuroectodermal spheres (Woo et al., 2009; Li et al., 2015). 
 
A link between Jag1 and brain tumors has recently been established, with an over-
expression of the ligand observed in childhood medulloblastoma (Fiaschetti et al., 
2014). Additionally, an increase in Jag1 expression has also been identified in 
human glioblastomas (Jubb et al., 2012; Liu et al., 2014). This is of particular 
interest due to the fact that Pax6 has been identified as a suppressor of tumor 
formation in in vivo murine models for gliomagenesis, and provides a link between 
the genes of interest in our hypothesis for their interaction with one another during 
corticogenesis (Appolloni et al., 2012). 
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In the murine developing telencephalon, it has been reported Jag1 protein is 
expressed in the developing cortex, with highest expression at the pallial subpallial 
boundary (PSPB) and particularly strong staining also observed in the ganglionic 
eminences of the telencephalon at E14.5 (Nelson et al., 2013). Previous research has 
found Jag1 to be enriched in the RGC population, suggesting that Jag1 is involved in  
Notch signalling in a specific progenitor cell subpopulation during the process of 
neurogenesis (Nelson et al., 2013). Despite recent advances in our knowledge of the 
expression pattern of Jag1 protein and research implementing FACS to identify the 
cell population that Jag1 is expressed in during cortical development, there is little 
documentation of the expression pattern of the Jag1 gene during murine forebrain 
development. 
 
While information concerning the role of Jag1 during embryonic forebrain 
development is scarce, the role of Jag1 during postnatal and adult forebrain 
development has been documented. Research into postnatal and adult neurogenesis 
in the dentate gyrus has identified that Jag1 is expressed specifically in transient 
amplifying cells residing in the subgranular zone (SGZ) of the dentate gyrus 
(Breunig et al., 2007; Lavado et al., 2010; Imayoshi and Kageyama, 2011) and that 
conditional inactivation of the gene Prox1 results in the loss of Jag1 expressing 
transient amplifying cells, resulting in a reduction in Notch signalling in neural stem 
cells (NSCs) in the SGZ (Lavado et al., 2010). Furthermore, a recent study by 
Lavado and Oliver demonstrated that Jag1 is necessary for neurogenesis in the adult 
dentate gyrus by demonstrating that the inactivation of Jag1 reduces neural stem cell 
maintenance and proliferation in the SGZ (Lavado and Oliver, 2014). 
 
Previous microarray research by our group has identified Jag1 as a potential target of 
Pax6. Jag1 was found to be down-regulated at the PSPB of E12.5 Pax6-/- mutants, 
with a fold change of -1.625 (Carr, 2009). As previously discussed in the case of 
Dll1, no analysis of the expression pattern of Jag1 in the developing cortex has been 
conducted in Pax6 mutant embryos. Due to the fact that Jag1 has been identified as a 
gene down-regulated in the cortex of Pax6-/- mutant embryos, it has been 
hypothesised that a reduction in the expression of Jag1 in the developing cortex will 
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be observed when analyzed by in situ hybridisation. Furthermore, as previously 
discussed in the case of the Notch ligand Dll1, it would stand to reason that an effect 
observed in the cortex of embryos homozygous for Pax6 might suggest that a 
variance in Jag1 expression could also be observed in embryos which express 
increased levels of Pax6, and that embryos with a timed knock down of Pax6 
exclusively within the developing cerebral cortex could provide insight into how 
Pax6 exerts its regulatory effects without compensation from other genes involved in 
neurogenesis (Chapter 3.1). 
 
 
4.2 Analysis of Jag1 expression in Pax6-/- mutants 
 
In order to confirm the microarray data carried out by our lab (Carr, 2009) and 
confirm that Jag1 expression is reduced in Pax6-/- embryos when compared to WT 
embryos, in situ hybridisation analysis of Jag1 expression was carried out in Pax6-/- 
mutant embryos and their WT littermate counterparts at E11.5 and E12.5 of 
embryonic development. Analysis was also carried out at the later developmental 
stage of E14.5, when the SVZ has formed and progenitor cell subpopulations have 
been established. 
 
Analysis of Jag1 expression in WT embryos at E11.5 showed strong staining in the 
ganglionic eminences of the developing telencephalon (red arrows, Figure 4.1 A-C). 
Staining was also observed at the PSPB (black arrows, Figure 4.1 A-C), and lighter 
staining observed in the developing cortex (asterisk, Figure 4.1, A-C). In Pax6-/- 
mutant embryos, Jag1 expression in the ganglionic eminences (red arrows, Figure 
4.1 D-F) remains consistent with staining observed in WT littermates. Staining at the 
PSPB of Pax6-/- mutant embryos appears reduced (black arrows, Figure 4.1 D-F), 






Figure 4.1 Jag1 gene expression in the developing forebrain of Pax6-/- embryos at 
E11.5 
 
(A-C) Jag1 expression in the forebrain of a WT control embryo. (A) Expression in the rostral 
region of a WT forebrain. (B) Jag1 expression in the medial region of a WT forebrain. (C) 
Jag1 expression in the caudal region of a WT forebrain. (A-C) Black arrows indicate the 
PSPB where there is strong Jag1 expression and red arrows indicate the ganglionic 
eminences where there is also strong Jag1 expression. (D-E) Jag1 expression in the 
forebrain of a Sey mutant embryo. (D) Jag1 expression in the rostral region of a Sey 
forebrain. (E) Jag1 expression in the medial region of a Sey mutant forebrain. (F) Jag1 
expression in the caudal region of a Sey mutant forebrain. (D-F) Black arrows indicate the 
PSPB. A loss of Jag1 expression at the PSPB in Sey mutant embryos is shown. Red arrows 
indicate the presence of strong Jag1 expression in the ganglionic eminences at E11.5. (A-D) 
* indicates the cortex. Wt = Pax6+/+ and Sey = Pax6-/-. Scale bars = 200µm. (N=3 embryos). 
 
 
At E12.5, Jag1 exhibited weak staining within the dorsal region developing cortex, 
with staining appearing strongest in the medial section in WT embryos (Figure 4.2 
B). Strong staining was exhibited at the PSPB (black arrows, Figure 4.2 A-C) and 
within the ganglionic eminences in WT controls (red arrows, Figure 4.2 A-C). This 
expression pattern corresponds well with previously reported protein expression 
pattern studies for Jag1 (Nelson et al., 2013). However, in the cortices of Pax6-/- 
mutant embryos, Jag1 expression appeared reduced in the cortex (asterisk, Figure 4.2 
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D-F) when compared to the cortices of WT littermates (asterisk, Figure 4.2 A-C), 
and was entirely gone at the PSPB (black arrows, Figure 4.2 D-F). Staining remained 





Figure 4.2 Jag1 gene expression in the developing forebrain of Pax6-/- embryos at 
E12.5 
 
(A-C) Jag1 expression in the forebrain of a WT control embryo. (A) Jag1 expression in the 
rostral region of a WT forebrain. (B) Jag1 expression in the medial region of a WT forebrain. 
(C) Jag1 expression in the caudal region of a WT forebrain. (A-C) Black arrows indicate the 
PSPB where there is strong Jag1 expression, and red arrows indicate the ganglionic 
eminences where there is strong Jag1 expression. Jag1 expression is also observed in the 
developing cortex. (D-E) Jag1 expression in the forebrain of a Sey mutant embryo. (D) Jag1 
expression in the rostral region of a Sey forebrain. (E) Jag1 expression in the medial region 
of a Sey mutant forebrain. (F) Jag1 expression in the caudal region of a Sey mutant 
forebrain. (D-F) Black arrows indicate the loss of Jag1 expression at the PSPB in Sey 
mutant embryos and red arrows indicate strong Jag1 expression in the ganglionic 
eminences at E12.5. Jag1 expression in the developing cortex appears reduced in Sey 





In situ analysis at E14.5 showed staining in the ganglionic eminences (red arrows, 
Figure 4.3 A-C) and at the PSPB (black arrows, Figure 4.3 A-C) of WT embryos, 
while staining that was observed in the cortex (asterisk, Figure 4.3 A-C) at earlier 
gestational stages was found to no longer be present. In contrast, mutant littermates 
retained the staining observed in the ganglionic eminences of WT controls but Jag1 
expression was lost at the PSPB (black arrows, Figure 4.3 D-F). As was the case with 
their WT counterparts, no Jag1 expression was observed in the cortex of Pax6-/- 






Figure 4.3 Jag1 gene expression in the developing forebrain of Pax6-/- embryos at 
E14.5 
 
(A-C) Jag1 expression in the forebrain of a WT control embryo. (A) Jag1 expression in the 
rostral region of a WT forebrain. (B) Jag1 expression in the medial region of a WT forebrain. 
(C) Jag1 expression in the caudal region of a WT forebrain. (A-C) Black arrows indicate the 
PSPB where Jag1 expression is present and red arrows indicate the ganglionic eminences 
where Jag1 expression is present. (D-E) Jag1 expression in the forebrain of a Sey mutant 
embryo. (D) Jag1 expression in the rostral region of a Sey forebrain. (E) Jag1 expression in 
the medial region of a Sey mutant forebrain. (F) Jag1 expression in the caudal region of a 
Sey mutant forebrain. (D-F) Black arrows indicate the loss of Jag1 expression at the PSPB 
in Sey mutant embryos and red arrows indicate strong Jag1 expression in the ganglionic 
eminences at E14.5. (A-D) * indicates the cerebral cortex. Wt = Pax6+/+ and Sey = Pax6-/-. 
Scale bars = 200µm. (N=3 embryos). 
 
 
In situ hybridisation analysis of Jag1 in Pax6-/- embryos confirmed a decrease in 
expression at the PSPB of mutant embryos when compared to WT embryos. A less 
dramatic decrease was also visible in the main body of the developing cortex. 
Furthermore, in situ hybridisation analysis allowed us to characterise Jag1 
expression in the developing telencephalon, with strong expression observed at the 
PSPB and in the ganglionic eminences, and lighter expression throughout the cortex 
observed in WT embryos. Analysis of mutant embryos saw a complete loss at the 
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PSPB and a small decrease in the cortex, while staining in the ganglionic eminences 
remained. As was the case with in situ analysis of Dll1 expression (Chapter 3), the 
results for Jag1 in Pax6-/- embryos piqued our interest as to how increased levels of 
Pax6 or timed deletions of Pax6 would affect Jag1 expression. Consequently, in situ 
analysis was carried out using PAX77 and cKO mutant embryos at E12.5 in order to 
compare the effects on Jag1 expression at the embryonic stage where it was most 
affected in Pax6-/- embryos. Due to the results from Pax6-/- in situ analysis of Jag1, it 
is likely that a greater decrease in expression will be observed in the cortex of cKO 
mice, as the likelihood of compensation will be greatly reduced; while Jag1 
expression in PAX77 embryos will increase due to increased levels of Pax6.  
 
 
4.3 Analysis of Jag1 gene expression in PAX77 mutants 
 
At E12.5, Jag1 expression in PAX77 mutant embryos closely mimics the expression 
pattern observed in Pax6-/- mutants at the same developmental stage (Figure 4.4). A 
slight decrease in expression was observed in the developing cortex (asterisk, Figure 
4.4 D-F), along with the abolition of expression at the PSPB (black arrows, Figure 
4.4 D-F), while Jag1 expression in the ganglionic eminences remained unchanged 
(red arrows, Figure 4.4 D-F) when compared to WT control littermates (red arrows, 
Figure 4.4 A-C). As expected, Jag1 expression in WT control littermates for PAX77 
expression analysis was consistent with the expression pattern observed in WT 





Figure 4.4 Jag1 gene expression in the developing forebrain of PAX77 embryos at 
E12.5 
 
(A-C) Jag1 expression in the forebrain of a WT control embryo. (A) Jag1 expression in the 
rostral region of a WT forebrain. (B) Jag1 expression in the medial region of a WT forebrain. 
(C) Jag1 expression in the caudal region of a WT forebrain. (A-C) Black arrows indicate the 
PSPB where there is Jag1 expression and red arrows indicate the ganglionic eminences 
where there is strong Jag1 expression. Jag1 expression is also observed in the developing 
cortex. (D-E) Jag1 expression in the forebrain of a PAX77 mutant embryo. (D) Jag1 
expression in the rostral region of a PAX77 mutant forebrain. (E) Jag1 expression in the 
medial region of a PAX77 mutant forebrain. (F) Jag1 expression in the caudal region of a 
PAX77 mutant forebrain. (D-F) Black arrows indicate the PSPB where there is a loss of Jag1 
expression in PAX77 mutant embryos and red arrows indicate the ganglionic eminences 
where there is strong Jag1 expression at E12.5. Jag1 expression in the developing cortex 
appears reduced in PAX77 mutants. (A-D) * indicates the cortex. Wt = Pax6+/+ and Sey = 
Pax6-/-. Scale bars = 200µm. (N=3 embryos). In Situ hybridisation carried out by project 
student Milena Blaga. 
 
 
Interestingly, analysis of Jag1 expression at E12.5 observed a complete loss of 
expression at the PSPB in PAX77 embryos, and a reduction in expression in the main 
body of the developing cortex. This result is identical to the Pax6-/- data at E12.5, an 
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unexpected result as both a loss and increase of Pax6 expression had the same effect 
on Jag1 expression.   
 
4.4 Analysis of Jag1 expression in cKO mutants 
 
At E12.5, Jag1 expression in control embryos remained similar to the expression 
patterns observed in the aforementioned analysis of control littermates from Pax6-/- 
and PAX77 embryos at E12.5, with strong staining observed at the PSPB and in the 
ganglionic eminences, and a lighter level of expression evident in the cortex (asterisk, 
Figure 4.5 D-F). However, unlike in the case of Pax6-/- and PAX77 mutant embryos, 
the Emx1CreErT2;Pax6loxP/loxP (hereinafter referred to as cKO) embryos did not 





Figure 4.5 Jag1 gene expression in the developing forebrain of cKO embryos at E12.5 
 
(A-C) Jag1 expression in the forebrain of a control embryo. (A) Jag1 expression in the rostral 
region of a control forebrain. (B) Jag1 expression in the medial region of a control forebrain. 
(C) Jag1 expression in the caudal region of a control forebrain. (A-C) Black arrows indicate 
the PSPB where there is Jag1 expression and red arrows indicate the ganglionic eminences 
where there is strong Jag1 expression. Jag1 expression is also observed in the developing 
cortex. (D-E) Jag1 expression in the forebrain of a cKO mutant embryo. (D) Jag1 expression 
in the rostral region of a cKO mutant forebrain. (E) Jag1 expression in the medial region of a 
cKO mutant forebrain. (F) Jag1 expression in the caudal region of a cKO mutant forebrain. 
(D-F) Black arrows indicate the PSPB where there is Jag1 expression in cKO mutant 
embryos and red arrows indicate the ganglionic eminences where there is strong Jag1 
expression at E12.5. Jag1 expression in the developing cortex appears reduced in cKO 
mutants. (A-D) * indicates the cortex. Wt = Pax6+/+ and Sey = Pax6-/-. Scale bars = 200µm. 
(N=3 embryos).  
 
 
4.5 qPCR analysis of Jag1 expression in Pax6-/- mutants  
 
In order to quantify the decrease in Jag1 expression observed in Pax6-/- embryonic 
cortices and to determine whether overall Jag1 mRNA levels were altered, qRT-PCR 
was carried out at E12.5 and E14.5 (Figure 4.6). It was hypothesised that a 
significant decrease in Jag1 would be detected due to the complete loss of the gene 
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at the PSPB. However, no significant decrease in Jag1 expression in the cortex of 
Pax6-/- mutants was observed when compared to Jag1 expression in the cortex of 
WT control embryos at E12.5 (p=0.136) or at E14.5 (p=0.164) when analyzed by 





Figure 4.6 Jag1 gene expression in the developing cortex of Pax6-/- Embryos 
 
Detection of Jag1 gene expression in the developing cortex by qPCR. qPCR was carried out 
on two developmental stages (E12.5 and E14.5) on Sey mutants and WT control littermates. 
Results were normalised to GAPDH. No significant decrease in Jag1 expression was 
detected in Sey mutants at E12.5 (p=0.136) or E14.5 (p=0.164). Wt = Pax6+/+ and Sey = 





As previously discussed, the expression pattern of the Jag1 protein has been 
investigated prior to this research undertaken by our group (Nelson et al., 2013). 
However, the expression pattern for the Jag1 mRNA in the developing murine cortex 












































in WT embryos at E11.5 observed light staining in the developing cortex, with 
stronger staining at the PSPB and strong staining in the ganglionic eminences of the 
ventral telencephalon. Further analysis in WT embryos at E12.5 displayed strong 
staining in the ganglionic eminences of the developing telencephalon and strong 
staining was also observed at the PSPB. Lighter staining was evident in the 
developing cerebral cortex, with a gradient expression pattern observed and Jag1 
expression strongest in the dorsal region of the cortex.  It was observed that Jag1 
expression appeared strongest at E12.5 in WT embryos, suggesting that the gene 
exerts its greatest effect upon telencephalic development at this embryonic stage.  In 
turn, Jag1 expression in WT embryos at E14.5 appeared lighter, with no staining in 
the developing cortex suggesting the possibility that Jag1 may no longer be required 
for cortical development by this stage of embryonic development, despite its 
expression still being required at the PSPB and the ganglionic eminences. However, 
the loss of Jag1 at the cortex does not necessarily mean that its expression is not 
required for cortical development and phenotypic analysis of embryos that do not 
express Jag1 would be required in order to confirm that the gene is required for 
correct cortical development. 
 
In contrast, investigation into Jag1 expression in Pax6-/- embryos found a potential 
reduction in Jag1 expression in the developing cortex at E12.5 and a complete loss 
of expression at the PSPB in all embryonic stages that were investigated. However, 
staining in the ganglionic eminences, where Pax6 is not expressed in the developing 
telencephalon, remained intact. The fact that Jag1 staining is originally evident at the 
PSPB of WT embryos and lost in embryos of Pax6 null embryos is of particular 
interest due to the fact that Pax6 is expressed in a high lateral – low medial gradient 
in the cortex of WT embryos. The observation that Jag1 is expressed strongly where 
Pax6 expression is at its highest and that expression is then lost in Pax6-/- mutants 
indicates that Jag1 may be a direct target of Pax6. This assumption is based on past 
studies of Pax6, where an observed effect in the expression of genes involved in 
developmental processes controlled by the transcription factor has led to the eventual 
identification of these genes of interest as direct targets of Pax6 by bioinformatics 
and binding site validation by technniques such as EMSA, ChiP and luciferase assay, 
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rather than genes downstream of direct interactions that are subsequently indirectly 
regulated by the transcription factor (Scardigli et al., 2003; Holm et al., 2007; Tuoc 
and Stoykova, 2008; Castro and Guillemot, 2011; Castro et al., 2011; Mi et al., 
2013a). 
 
While Jag1 and Pax6 are both expressed at the PSPB and Jag1 staining is also 
present in the cortex where Pax6 expression is also present, it does not display the 
same gradient pattern that Pax6 does in the cortex and Jag1 expression does not 
appear to be strongly affected by a loss of Pax6 in this region. This suggests that 
while Pax6 is likely to directly regulate Jag1 at the PSPB, co-effectors could also be 
involved in regulating Jag1 expression in the main body of the developing cerebral 
cortex. If this is the case, additional co-effectors that regulate Jag1 in the cortex may 
compensate for the loss of Pax6 expression in Pax6-/- embryos. However, evidence 
for transcriptional regulators for Jag1 in the cerebral cortex would be required in 
order to solidify this hypothesis. 
 
The finding that Jag1 is down-regulated in the cortex of PAX77 embryos at E12.5 
was surprising as it was originally hypothesised that an increase in Pax6 expression 
would be likely to result in an increase in Jag1 expression in the cerebral cortex. 
However, analysis of Jag1 expression in the cortex of E12.5 PAX77 mutant embryos 
found staining to closely mirror the expression pattern for Jag1 that was observed in 
Pax6-/- embryos. The strong staining present in the PSPB of WT littermates was 
completely absent in PAX77 mutants, and staining in the developing cortex also 
appeared to be reduced. Staining in the ganglionic eminences where Pax6 is not 
normally expressed remained intact and mirrored staining observed in WT 
littermates. Despite the fact that the opposite of what we originally hypothesised was 
observed in PAX77 mutants, the result is particularly significant for furthering our 
understanding of how Pax6 regulates genes involved in forebrain development. It 
would appear that requirement for Pax6 during brain development and for the 
regulation of gene networks involved in the process, is far more sophisticated than 
the presence of the genes expression simply being required. The fact that an increase 
in Pax6 expression can result in the same eradication of Jag1 expression at the PSPB 
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suggests that a very specific level of Pax6 is required for it to activate or repress the 
expression of genes that it is responsible for regulating during brain development. A 
similar phenomenon has been observed in eye development, where the levels of 
Pax6 expressed dictates how well the eye develops (Dora et al., 2008; Favor et al., 
2008). 
 
Additional research into the effects of Pax6 on Jag1 expression implemented the use 
of our Pax6 cKO line. Control embryos displayed the same expression for Jag1 in 
the developing telencephalon at E12.5 as WT embryos from previous Jag1 
expression analysis, while cKO mutant embryos treated with Tamoxifen at E9.5 also 
displayed no change in Jag1 expression in the ganglionic eminences or the PSPB at 
E12.5. While Pax6 is expression is knocked out in the PSPB of Pax6-/- embryos, the 
timed deletion of Pax6 in cKO mutant embryos is the result of  a tamoxifen inducible 
Cre recombinase under the control of the Emx1 locus (Emx1CreERT2). While Emx1 
and Pax6 are mutually expressed in the developing cerebral cortex, Emx1 expression 
does not reach the PSPB, unlike Pax6. Consequently, Pax6 expression at the PSPB 
of treated cKO embryos remains intact, resulting in no effect upon Jag1 expression. 
Future analysis on the effects of timed deletions of Pax6 on Jag1 expression would 
require the use of a Cre strain whose expression encompasses both the cortex and the 
PSPB, or a CAG Cre which acts to universally dele Pax6 throughout the developing 
embryo. Although this would resolve the issue concerning Pax6 expression at the 
PSPB, the specificity of deleting Pax6 in the cortex would be lost, opening the study 
to the possibility of additional compensation by co-effectors.  
 
Quantification of Jag1 expression in the cortices of Pax6-/- embryos by qPCR was 
undertaken at E12.5 and E14.5. No significant reduction in Jag1 expression was 
observed at either developmental stage, despite the extreme loss of Jag1 at the PSPB 
of mutant embryos. A likely explanation for no significant reduction despite such a 
visible loss of expression in a distinct region of the developing telencephalon would 
be the fact that there is little to no change in expression of Jag1 in the main body of 
the developing cortex. As micro dissections carried out for qPCR analysis 
incorporated the entire developing cerebral cortex (including the PSPB), it stands to 
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reason that an extreme loss of Jag1 at the PSPB would be diluted by the inclusion of 
the rest of the cortex where Jag1 expression is not as radically altered. Additional 
qPCR analysis using dissections exclusive to the PSPB would be required in order to 










WT E11.5 Light Strong Strong
SEY E11.5 Reduced None Strong
WT E12.5 Light Strong Strong
SEY E12.5 Reduced None Strong
WT E14.5 None Light Light 
SEY E14.5 None None Light 
WT (PAX77) E12.5 Light Strong Strong
PAX77 E12.5 Reduced None Strong
C (CKO) E12.5 Light Strong Strong
CKO E12.5 None Strong Strong
 
 
Table 4.1 Chapter 4 results summary  
 
A summary of the in situ hybridisation analysis detailed in chapter 4. Light Jag1 expression 
was observed in the cortex of E11.5 and E12.5 WT embryos, and strong Jag1 expression 
was observed in the PSPB and GEs. In Sey mutant littermates, strong expression remained 
in the GEs, while reduced cortical staining and a complete loss of staining the PSPB was 
observed. At E14.5, No Jag1 expression was observed in the cortex of WT embryos and 
only light expression was observed in the PSPB, while strong staining remained in the GEs. 
In Sey embryos at E14.5, Jag1 expression was once again lost at the PSPB. In PAX77 
mutant embryos at E12.5, Jag1 staining at the PSPB was lost and staining in the cortex was 
reduced when compared to WT littermates. In cKO mutant embryos at E12.5, no Jag1 
expression was detected in the cortex in comparison to the light expression observed in 
control littermates, while strong staining was observed at the PSPB in the GEs for both cKO 
mutants and their control littermates.  
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Previous studies have suggested that the Notch pathway ligands all perform the same 
role during Notch signalling, in that they activate Notch receptors 1-4 in order to 
cleave the NICD that is responsible for the regulation of cellular proliferation and 
differentiation by activation of the proneural inhibitor Hes and Hey gene families 
(Iso et al., 2011; Kageyama et al., 2008a; Kopan and IIagan, 2009; Pierfelice et 
al.,2011). However, despite this, each of the four Notch ligands are expressed in 
different cortical regions and in different progenitor cell subpopulations from one 
another during corticogenesis (Nelson et al., 2013).  
 
While Notch ligands have been identified as genes which are up-regulated in 
progenitor cells that are making the transition to differentiate into neural cells, each 
of the Notch ligands are enriched in a different progenitor cell sub population, 
suggesting that different Notch ligands are responsible for maintaining specific 
progenitor cell populations (Nelson et al., 2013). For example, Jag1 has been 
identified as a gene that is expressed in specific telencephalic regions, specifically 
the PSPB and ganglionic eminences with apparent low expression in the cortex 
during specific regions of development, while fluorescence-activated cells sorting 
(FACS) analysis has identified expression as being restricted to RGCs within the VZ 
of the developing cortex (Nelson et al., 2013; Chapter 4). In contrast, the Delta 
family ligand Dll3 is enriched solely within INPs residing within the SVZ during 
cortical neurogenesis (Campos et al., 2001; Nelson et al., 2013). However, as 
previously discussed, there has been some controversy as to where the Notch 
signalling ligand Dll1 is expressed in terms of progenitor cell populations during 
mammalian embryonic neurogenesis (Chapter 3). Research into the expression of 
Dll1 during forebrain development originally suggested that Dll1 is expressed solely 
within the VZ from E12.5-E14.5 in murine embryos, with staining observed closer to 
the pial surface but still within the VZ rather than the SVZ (Campos et al., 2001), 
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while later studies suggested that Dll1 expression is actually restricted to INPs 
residing within the SVZ (Mizutani et al., 2007; Kawaguchi et al., 2008; Yoon et al., 
2008). Further confusion over the location of Dll1 expression within the developing 
telencephalon was provided by a study conducted by Nelson et al., (2013), in which 
they proposed that Dll1 is expressed in the VZ and the SVZ. This study used FACS 
analysis, which sorted RGC and INP cells dissociated from the forebrains of mouse 
embryos (Nelson et al., 2013).  
 
Due to the fact that Dll1 has been documented as being expressed within the VZ and 
also the SVZ, as well as within specific progenitor cell subpopulations, it would be 
advantageous to establish which progenitor zone and progenitor cell subpopulation 
Dll1 is expressed in in WT embryos during cortical development. While it has been 
established that Pax6 exerts some form of control over Dll1 expression, it is unclear 
what sort of regulatory relationship exists between them or what their relationship 
contributes towards in terms of cortical development during embryonic neurogenesis.  
 
As previously discussed, our working hypothesis developed from published literature 
suggests that Pax6 and Dll1 may mutually regulate one another via the cellular 
mechanism of Cis inhibition that occurs during the process of Notch signalling 
within proliferating neural progenitor cells (Chapter 1). Furthermore, not only does 
our working hypothesis model suggest that Pax6 and Dll1 co-regulate one another, 
we additionally suggest that Pax6 regulates the progressive differentiation of RGCs 
into INPs via a regulatory influence upon Dll1 expression (Chapter 1). Subsequently, 
we are suggesting that Pax6 ultimately controls cellular proliferation and 
differentiation by Notch signalling via regulatory control of genes implicated in the 
pathway. 
 
In order to confirm which progenitor cell subpopulation Dll1 is expressed in, double 
labelling histological analysis, by fluorescent in situ hybridisation and 
immunohistochemistry techniques, was implemented. The aforementioned analytical 
approach provides insight into which progenitor cell subpopulation Dll1 is expressed 
in during the process of corticogenesis by using markers for specific progenitor cell 
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types. Evidence of co-localisation between Dll1 and these cell markers within cells 
ultimately allows the identification of which proliferative zone of the developing 
cortex Dll1 is expressed in, as well as which progenitor cell population(s) it is 
expressed in. Further investigation using Pax6-/- embryos provided insight into how 
Pax6 expression affects Dll1 expression in progenitor cell populations, and if it 
causes any shift in which population Dll1 is expressed by. Additionally, initial 




5.2 Dll1 expression is not co-localised with Tbr2 expression in the 
developing cortex. 
 
In order to determine whether Dll1 is expressed by INPs residing the SVZ, 
fluorescent double labelling analysis for Dll1 and Tbr2 was carried out in WT and 
Pax6-/- mutant embryos at gestational stages E12.5 and E14.5. Tbr2 is well 
documented as a marker for INPs in the SVZ of the developing cerebral cortex and 
its use in double labelling analysis will consequently provide insight into cortical 
progenitor region and progenitor cell type (Englund et al., 2005; Pontious et al., 
2007; Nelson et al., 2013). Due to the fact that Dll1 has previously been reported as a 
gene expressed by INPs, it was hypothesised that Dll1 and Tbr2 would co-express in 
the INP progenitor population (Mizutani et al., 2007; Kawaguchi et al., 2008; Yoon 
et al., 2008). Gestational stage E12.5, documented as the onset of peak neurogenesis 
(Li et al., 2003), was selected for analysis due to evidence from earlier work that 
Dll1 is expressed at this developmental stage, with the gene having been identified as 
actively down-regulated in the cortex of Pax6-/- embryos (Chapter 3). Embryonic 
stage E14.5 was additionally selected due to the fact that previous studies selected 
this stage for Dll1 expression analysis, along with the fact that E14.5 is considered an 
embryonic stage in which neurogenesis reaches its peak and when the SVZ has fully 
developed (Takashi et al., 1995; Li et al., 2003).  
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Dll1/Tbr2 double labelling carried out at E12.5 in the telencephalon of WT embryos 
showed strong Tbr2 expression spanning the length of the cortex (Figure 5.1 A-C, G-
I). As expected, expression was restricted to the developing SVZ, resulting in Tbr2 
expression residing in a relatively small area of the developing cortex when 
compared to Tbr2 expression at later developmental stages. In contrast, Dll1 
expression appeared to be restricted to the VZ of the cortex, with no co-localisation 
observed between Dll1 and Tbr2. Furthermore, analysis of Pax6-/-  mutant embryo 
littermates at E12.5 showed a notable reduction in both Dll1 and Tbr2 expression 
(Figure 5.1 D-F, J-L). Additionally, no evidence of co-expression of Dll1 and Tbr2 
was observed within the cortex, implying that a loss of Pax6 expression does not 






Figure 5.1 In situ hybridisation and Immunohistochemistry showing Dll1 and Tbr2 
expression in the developing cerebral cortex at E12.5 
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Dll1 expression (Magenta) and Tbr2 expression (green) in WT embryos (A-C and G-I) and 
Sey embryos (D-F and J-L). (A) Tbr2 expression in the rostral region of the telencephalon. 
(B) Tbr2 expression in the medial region of the telencephalon. (C) Tbr2 expression in the 
caudal region of the telencephalon. Tbr2 expression appears restricted to the SVZ of the 
developing cortex of WT embryos (A-C). (A) Dll1 expression in the rostral region of the 
telencephalon. (B) Dll1 expression in the medial region of the telencephalon. (C) Dll1 
expression in the caudal region of the telencephalon. Dll1 expression appears restricted to 
the VZ of the developing cortex of WT embryos (A-C). (D) Tbr2 expression in the rostral 
region of the telencephalon. (E) Tbr2 expression in the medial region of the telencephalon. 
(F) Tbr2 expression in the caudal region of the telencephalon. Tbr2 expression appears 
restricted to the SVZ of the developing cortex of Sey embryos (D-F). (D) Dll1 expression in 
the rostral region of the telencephalon. (E) Dll1 expression in the medial region of the 
telencephalon. (F) Dll1 expression in the caudal region of the telencephalon. Dll1 expression 
appears restricted to the VZ of the developing cortex of Sey embryos (D-F). Both Dll1 and 
Tbr2 expression are reduced in Sey embryos (D-F) when compared to WT embryos (A-C). 
(G and M) Tbr2 expression in the rostral region of the developing cortex. (H and N) Tbr2 
expression in the medial region of the developing cortex. (I and O) Tbr2 expression in the 
caudal region of the developing cortex. (J and P) Tbr2 expression in the rostral region of the 
developing cortex. (K and Q) Tbr2 expression in the medial region of the developing cortex. 
(L and R) Tbr2 expression in the caudal region of the developing cortex. No evidence of co-
expression between Dll1 and Tbr2 is evident in the developing cortex of WT embryos (G-I) 
or in the cortex of Sey embryos (J-L). Sey = Pax6-/- and WT = Pax6+/+. Ctx = Cortex. GE = 
Ganglionic Eminences. HP = Hippocampus. (A-F) Scale bars = 80µm. (G-L) = 60µm. (M-R) 
= 40 µm. N = 3 embryos  
 
 
Double labelling analysis for Dll1 and Tbr2 at the later embryonic stage of E14.5 in 
WT embryos showed a notably enlarged area of expression for Tbr2 as a result of the 
now fully formed SVZ accounting for the majority of the progenitor zone of the 
developing cortex, with the prevalence of the VZ decreasing in contrast (Figure 5.2 
A-C, G-I). As was the case at E12.5, Dll1 expression appears to be constrained to the 
VZ, meaning that the level of Dll1 expression appears reduced when compared to 
E12.5, and no co-localisation between Dll1 and Tbr2 was observed (Figure 5.2 G-I; 
Figure 5.1 G-I). Conversely, strong co-localisation was observed within the SVZ of 
the developing hippocampus, suggesting that INP cells in this particular region of the 
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developing telencephalon but not in the cerebral cortex, express Dll1 (Figure 5.3 A 
and C). The fact that Dll1 expression is visible in both the VZ and SVZ of the 
developing hippocampus, suggests that two progenitor cell subtypes (in this case 
RGCs and INPs) express the ligand. This indicates that expression of Notch ligands 
by progenitor cell populations is structure specific rather than uniform for the 
telencephalons proliferative region   as a whole. It also suggests that the molecular 
mechanisms behind neurogenesis differ slightly in different structures of the 
developing forebrain.  
 
 In Pax6-/- mutant littermates at E14.5 (Figure 5.2 D-F, J-I), expression for Dll1 and 
Tbr2 also appeared to be markedly reduced, as was the case for Pax6-/- mutant 
embryos at E12.5 (Figure 5.1 D-F, J-I). Additionally, no co-localisation was 
observed between Dll1 and Tbr2, as was the case in the cortex of WT embryos. 
Moreover, the co-localisation of Dll1 and Tbr2 in the SVZ of the developing 
hippocampus appears severely disrupted in Pax6-/- mutant embryos (Figure 5.3 A 
and C) when compared to WT littermates, with co-expression appearing to be lost 
(Figure 5.3 B and D). This loss of co-localisation in the SVZ of the developing 
hippocampus suggests not only that Dll1 is expressed in multiple progenitor cell 
populations, but also that Pax6 may have a regulatory effect of greater significance 
upon Dll1 in terms of how Dll1 participates during Notch signalling within specific 






Figure 5.2 Dll1 and Tbr2 expression in the developing cerebral cortex at E14.5 
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Dll1 expression (Magenta) and Tbr2 expression (green) in WT embryos (A-C and G-I) and 
Sey embryos (D-F and J-L). (A) Tbr2 expression in the rostral region of the telencephalon. 
(B) Tbr2 expression in the medial region of the telencephalon. (C) Tbr2 expression in the 
caudal region of the telencephalon. Tbr2 expression appears restricted to the SVZ of the 
developing cortex of WT embryos (A-C). (A) Dll1 expression in the rostral region of the 
telencephalon. (B) Dll1 expression in the medial region of the telencephalon. (C) Dll1 
expression in the caudal region of the telencephalon. Dll1 expression appears restricted to 
the VZ of the developing cortex of WT embryos (A-C). (D) Tbr2 expression in the rostral 
region of the telencephalon. (E) Tbr2 expression in the medial region of the telencephalon. 
(F) Tbr2 expression in the caudal region of the telencephalon. Tbr2 expression appears 
restricted to the SVZ of the developing cortex of Sey embryos (D-F). (D) Dll1 expression in 
the rostral region of the telencephalon. (E) Dll1 expression in the medial region of the 
telencephalon. (F) Dll1 expression in the caudal region of the telencephalon. Dll1 expression 
appears restricted to the VZ of the developing cortex of Sey embryos (D-F). Both Dll1 and 
Tbr2 expression are reduced in Sey embryos (D-F) when compared to WT embryos (A-C). 
(G and M) Tbr2 expression in the rostral region of the developing cortex. (H and N) Tbr2 
expression in the medial region of the developing cortex. (I and O) Tbr2 expression in the 
caudal region of the developing cortex. (J and P) Tbr2 expression in the rostral region of the 
developing cortex. (K and Q) Tbr2 expression in the medial region of the developing cortex. 
(L and R) Tbr2 expression in the caudal region of the developing cortex. No evidence of co-
expression between Dll1 and Tbr2 is evident in the developing cortex of WT embryos (G-I) 
or in the cortex of Sey embryos (J-L). Sey = Pax6-/- and WT = Pax6+/+. Ctx = Cortex. GE = 
Ganglionic Eminences. HP = Hippocampus. (A-F) Scale bars = 80µm. (G-L) = 60µm. (M-R) 






Figure 5.3 Dll1 gene expression and Tbr2 expression in the developing hippocampus 
at E14.5 
 
Dll1 expression (magenta) and Tbr2 expression (green) in WT embryos (A and C) and Sey 
embryos (B and D). Tbr2 expression remains restricted to the SVZ in the developing 
hippocampus in both WT (A) and Sey (B) embryos. Dll1 expression is observed in both the 
VZ and the SVZ of the developing hippocampus of WT embryos (A and C). (A and C) white 
arrows show co-expression of Dll1 and Tbr2 in WT embryos. In Sey embryos (B and D), the 
expression of Tbr2 and Dll1 is reduced. Expression within regions observed WT embryos 
are retained in Sey embryos for both Tbr2 and Dll1. (B and D) white arrows depict the 
reduction in co-expression between Dll1 and Tbr2 in the SVZ when compared to WT 
embryos (A and C). Sey = Pax6-/- and WT = Pax6+/+. Ctx = Cortex. GE = Ganglionic 
Eminences. HP = Hippocampus. (A and B) Scale bars = 80µm. (C and D) Scale bars = 
60µm. N = 3 embryos 
 
 
The fact that analysis of Dll1 and Tbr2 double in situ 
hybridisation/immunohistochemistry expression at E12.5 and E14.5 observed little to 
no co-expression between the two in the developing cortex strongly suggests that 
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Dll1 isn’t expressed by INPs residing within the SVZ. Furthermore, Dll1 expression 
was found to be restricted exclusively to the VZ in the cerebral cortex. Interestingly, 
co-expression was identified in the SVZ of the developing hippocampus, with Dll1 
expression apparent in the VZ and the SVZ, suggesting that the regulatory 
mechanisms for Dll1 in the hippocampus differ from the cortex.  
 
5.3 Dll1 expression appears to co-localise with a number of Ngn2 
expressing cells in the developing cortex 
 
While Tbr2 was used to determine which progenitor zone Dll1 is expressed in, Ngn2 
was also used as a marker to learn more about how Pax6 interacts with Dll1 in 
progenitor cell subtypes due to previously documented regulatory relationship 
between Pax6 and Ngn2 (Scardigli et al., 2001; 2003), as well as the regulatory 
relationship between Ngn2 and Dll1 (Castro et al., 2006). Due to the results found 
for Dll1/Tbr2 expression, coupled with what we know about the regulatory 
relationship between Dll1 and Ngn2; it was hypothesised that there would be a high 
level of co-expression between Dll1 and Ngn2 in the VZ of the developing cortex. 
Furthermore, it was hypothesised that Dll1 expression would be dramatically 
reduced in the VZ of Pax6-/- embryonic cortices, due to the fact that Pax6 directly 
regulates Ngn2 and its expression has been shown to reduce dramatically in Pax6-/- 
mutants (Carr, 2009; Sansom et al., 2009). 
 
As was the case with fluorescent double labelling analysis carried out with Dll1 and 
Tbr2, initial double analysis for Dll1 and Ngn2 was carried out on E12.5 WT 
embryos and their Pax6-/- mutant littermates (Figure 5.4). In WT embryos Ngn2 
expression was observed widely throughout the progenitor zone of the developing 
cerebral cortex (Figure 5.4 A-C). Dll1 expression was also observed throughout the 
vast majority of the progenitor zone, suggesting that VZ accounts for the majority of 
the progenitor zone of the developing cortex at this stage of embryonic development. 
Furthermore, an abundance of double labelling between Ngn2 and Dll1 was evident 
within the cortex (Figure 5.4 G-I). In contrast, analysis using Pax6-/- mutant 
littermates observed a reduction in both Dll1 and Ngn2 staining throughout the 
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cortex (Figure 5.4 D-F) and as a result, an apparent reduction in the proportion of 






Figure 5.4 Dll1 and Ngn2 expression in the developing cerebral cortex at E12.5 
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Dll1 expression (Magenta) and Ngn2 expression (green) in WT embryos (A-C and G-I) and 
Sey embryos (D-F and J-L). (A) Dll1 and Ngn2 expression in the rostral region of the 
telencephalon. (B) Dll1 and Ngn2 expression in the medial region of the telencephalon. (C) 
Dll1 and Ngn2 expression in the caudal region of the telencephalon. Dll1 expression appears 
restricted to the VZ of the developing cortex of WT embryos (A-C). Ngn2 expression is 
observed throughout the progenitor zone of the developing cortex. (D) Dll1 and Ngn2 
expression in the rostral region of the telencephalon. (E) Dll1 and Ngn2 expression in the 
medial region of the telencephalon. (F) Dll1 and Ngn2 expression in the caudal region of the 
telencephalon. Dll1 expression appears restricted to the VZ of the developing cortex of Sey 
embryos (D-F). Ngn2 expression is observed throughout the progenitor zone of the 
developing cortex in Sey embryos (D-F). Dll1 and Ngn2 gene expression is reduced in Sey 
embryos (D-F) when compared to WT embryos (A-C). (G and M) Ngn2 expression in the 
rostral region of the developing cortex. (H and N) Ngn2 expression in the medial region of 
the developing cortex. (I and O) Ngn2 expression in the caudal region of the developing 
cortex. (J and P) Ngn2 expression in the rostral region of the developing cortex. (K and Q) 
Ngn2 expression in the medial region of the developing cortex. (L and R) Ngn2 expression in 
the caudal region of the developing cortex.  (G-I and M-O) An abundance of co-expression 
between Dll1 and Ngn2 was observed in the VZ of the cerebral cortex of WT embryos at 
E12.5 (depicted in white). (J-L and P-R) Co-expression of Dll1 and Ngn2 (depicted in white) 
in the cortex of Sey embryos appears reduced when compared to WT controls (G-I). Sey = 
Pax6-/- and WT = Pax6+/+. Ctx = Cortex. GE = Ganglionic Eminences. HP = Hippocampus. 
(A-F) Scale bars = 80µm. (G-L) = 60µm. (M-R) = 40 µm. N = 3 embryos. 
 
 
Further Dll1/Ngn2 analysis was then carried out at the later developmental stage of 
E14.5 (Figure 5.5). Double labelling in WT embryos identified Ngn2 expression 
within the VZ of the developing cerebral cortex and within a proportion of the SVZ 
(Figure 5.5 A-B). Dll1 staining remained confined to the diminishing VZ as 
previously observed in Dll1/Tbr2 double labelling experiments also performed at 
E14.5 (Figure 5.2). Some co-localisation between Dll1 and Ngn2 was observed in the 
VZ where Dll1 expression was identified (Figure 5.5 G-I). Analysis of Dll1/Ngn2 
double labelling in Pax6-/- mutants at E14.5 showed a reduction in both Dll1 and 
Ngn2 staining in the developing cortex (Figure 5.5 D-F). Additionally, co-expression 
that was observed in WT littermates at E14.5 appears vastly reduced in their Pax6-/- 





Figure 5.5 Dll1 and Ngn2 expression in the developing cerebral cortex at E14.5 
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Dll1 expression (Magenta) and Ngn2 expression (green) in WT embryos (A-C and G-I) and 
Sey embryos (D-F and J-L). (A) Dll1 and Ngn2 expression in the rostral region of the 
telencephalon. (B) Dll1 and Ngn2 expression in the medial region of the telencephalon. (C) 
Dll1 and Ngn2 expression in the caudal region of the telencephalon. Dll1 expression appears 
restricted to the VZ of the developing cortex of WT embryos (A-C). Ngn2 expression is 
observed throughout the progenitor zone of the developing cortex. (D) Dll1 and Ngn2 
expression in the rostral region of the telencephalon. (E) Dll1 and Ngn2 expression in the 
medial region of the telencephalon. (F) Dll1 and Ngn2 expression in the caudal region of the 
telencephalon. Dll1 expression appears restricted to the VZ of the developing cortex of Sey 
embryos (D-F). Ngn2 expression is observed throughout the progenitor zone of the 
developing cortex in Sey embryos (D-F). Dll1 and Ngn2 gene expression is reduced in Sey 
embryos (D-F) when compared to WT embryos (A-C). (G and M) Ngn2 expression in the 
rostral region of the developing cortex. (H and N) Ngn2 expression in the caudal region of 
the developing cortex. (I and O) Ngn2 expression in the caudal region of the developing 
cortex. (J and P) Ngn2 expression in the medial region of the developing cortex. (K and Q) 
Ngn2 expression in the medial region of the developing cortex. (L and R) Ngn2 expression in 
the caudal region of the developing cortex. (G-I and M-O) An abundance of co-expression 
between Dll1 and Ngn2 was observed in the VZ of the cerebral cortex of WT embryos at 
E14.5 (depicted in white). (J-L and P-R) Co-expression of Dll1 and Ngn2 (depicted in white) 
in the cortex of Sey embryos appears reduced when compared to WT controls (G-I). Sey = 
Pax6-/- and WT = Pax6+/+. Ctx = Cortex. GE = Ganglionic Eminences. HP = Hippocampus. 
(A-F) Scale bars = 80µm. (G-L) = 60µm. (M-R) = 40 µm. N = 3 embryos. 
 
 
While potential co-expression between Dll1 and Ngn2 was observed when analysis 
of double fluorescent labelling was carried by conventional fluorescence microscopy, 
co-localisation could not be confirmed without additional image analysis of Z 
stacked images produced on a confocal microscope. Z stacked images provide a 
comprehensive, multidimensional view of cells comprising the developing cortex, 
rather than the single level of depth achieved by a traditional fluorescent light 
microscope. Analysis of Z stacked images identified that the proposed co-
localisation of Dll1 and Ngn2 cells was accurate, with co-localisation in whole cell 





Figure 5.6 Z stack analysis of Dll1 and Ngn2 expression in the developing cortex at 
E14.5 
 
(A) A rostral section of the developing cortex at E14.5. (B) A Caudal section of the 
developing cortex at E14.5. (C) Magnification of A. (D) Magnification of B. White arrows 
show examples of co-localisation of the two genes in individual cells within the VZ. Scale 
bars = 60µm. N = 3 embryos.  
 
 
5.4 Dll1 expression in the developing cortex is unaffected by a loss of 
Ngn2 expression at E14.5 
 
Further investigations into the regulatory control of Dll1 by Pax6 was carried out 
using an Ngn2-Cre knockin mutant mouse line previously described by Zirlinger et 
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al., (2002), which produces a homozygous Ngn2-/- genotype (Zirlinger et al., 2002). 
Homozygous Ngn2-/- mutant embryos were selected for the experiment and WT 
littermates were also selected to act as a control. Analysis of Dll1 expression by in 
situ hybridisation was carried out in order to establish whether a similar or greater 
down regulation of Dll1 occurs in the cortex of Ngn2-/- embryos. This approach was 
implemented due to our knowledge of the regulatory effects of Pax6 on Ngn2, as 
well as previous studies which have highlighted that Ngn2 is responsible for the 
activation of Dll1 in the Notch signalling pathway during embryonic neurogenesis 
(Scardigli et al., 2001; 2003; Castro et al., 2006). In situ hybridisation was carried 
out at the developmental stage E14.5, when embryonic neurogenesis is at its peak. 
Quantification of in situ expression data was then carried out by cell count analysis. 
It was hypothesised that a significant decrease in Dll1 expression and density would 
be observed and that this decrease would be greater than the decrease in Dll1 
expression observed in Pax6-/- embryonic cortices.  
 
At E14.5, Dll1 staining was observed as a punctate expression pattern in both Ngn2-/- 
mutants (Figure 5.7 D-F) and their WT control littermates (Figure 5.7 A-C). Dll1 
expression appeared to be predominantly restricted to the VZ of the developing 
telencephalon, with little evidence of expression outwith this proliferative region. 
Analysis of Dll1 expression in the cerebral cortex observed no obvious difference in 
staining between Ngn2-/- mutant embryos (Figure 5.7 G-I) and their WT control 
littermates (Figure 5.7 J-L).  
 
Statistical analysis of the cell density of Dll1 expressing cells by Two-way ANOVA 
of both the dorsal (Figure 5.8 A) and the ventral (Figure 5.8 B) regions of the 
developing cortex at E14.5 reported no interaction, region or genotype effect. Further 
analysis by Tukey’s multiple comparison testing yielded no significant differences. 
Analysis of total cell number in the developing cortex of Ngn2-/- and WT control 
embryos by two-way ANOVA also produced no interaction, region or genotype 
effects, and Tukey’s multiple comparison tests also yielded no significant differences 





Figure 5.7 Dll1 expression in the developing forebrain of Ngn2-/- embryos at E14.5 
 
(A-C) Dll1 gene expression in a WT control embryo. (A) Dll1 expression in the rostral region 
of the WT forebrain. (B) Dll1 expression in the medial region of the WT forebrain. (C) Dll1 
expression in the caudal region of the WT forebrain. (D-F) Dll1 expression in an Ngn2-/- 
mutant embryo. (D) Dll1 expression in the rostral region of the Ngn2-/- forebrain. (E) Dll1 
expression in the medial region of the Ngn2-/- forebrain. (F) Dll1 expression in the caudal 
region of the Ngn2-/- forebrain. (G-I) Dll1s punctate expression pattern in the developing 
cerebral cortex of WT control embryos at E14.5. (J-L) Dll1 expression in the developing 
cerebral cortex of Ngn2-/- mutant embryos. No discernable difference in Dll1 expression is 
apparent between WT control (G-I) and Sey mutant (J-L) embryos. (A-F) Scale bars = 
200µm. (A-F) * indicates the cortex. (G-L) Ctx = Cortex (G-L) Scale bars = 20µm. (N=3 




Figure 5.8 Dll1 expression in the dorsal and ventral regions of the developing cortex of 
Ngn2-/- embryos at E14.5 
 
(A) Dll1 cell density in the dorsal region of the cortex in WT controls and Ngn2-/- mutants. (B) 
Dll1 cell density in the ventral region of the cortex in WT controls and Ngn2-/- mutants. (A-B) 
No significant difference in Dll1 density was detected when comparing Ngn2-/- mutants to WT 
controls. (C) Total cell density in the dorsal region of the cortex in WT controls and Ngn2-/- 
mutants. (D) Total cell density in the ventral region of the cortex in WT controls and Ngn2-/- 
mutants. (C-D) No significant difference in total cell density was detected when comparing 
Ngn2-/- mutants to WT controls. Ngn2-Cre = Ngn2-/- embryos. Analysis carried out by project 
student Elena Purlyte.  
 
 
Analysis of Dll1 expression and density by in situ hybridisation and cell count 
quantification respectively, identified no significant decrease in Ngn2-/- embryos 
when compared to their WT littermates. This was surprising as activation of Dll1 is 
directly regulated by Ngn2. As a result, the fact that a more noteworthy decrease was 
observed in Pax6-/- embryos, it begs the question as to whether Pax6 plays a greater 
role in the regulation of Dll1 than originally hypothesised.  
 
5.5 Dll1 is enriched in RGCs and INPs in the developing cortex at E14.5  
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In situ hybridisation analysis of Dll1 has observed expression of the gene to be 
restricted to the VZ of the developing cerebral cortex (Campos et al., 2001; Chapter 
3; Chapter 5). Furthermore, double labelling analysis of Dll1 expression and Tbr2 
expression indicated that Dll1 is not expressed by INPs (Chapter 5). It can therefore 
be proposed that Dll1 is likely to be expressed by RGCs residing within the VZ.  
However, as previously discussed, past studies have claimed that Dll1 expression is 
restricted to INPs predominately within the VZ. The fact that conflicting data on Dll1 
analysed protein rather than mRNA expression is of particular interest and relevance 
in determining why there are discrepancies between studies of Dll1. One such 
conflicting study is the 2013 research article by Nelson et al., which included FACS 
analysis, carried out using a Tbr2 green fluorescent protein (GFP) reporter mouse 
line. This study identified that Tbr2 positive GFP labelled cells also expressed Dll1. 
However, some anomalies exist in their data set, such as the apparent expression of 
Pax6 by INPs rather than RGCs. Pax6 has been well documented as a marker of 
RGCs during cortical development for both its mRNA and protein expression. This 
not only highlights the possibility that Dll1 protein may be present in INPs even 
though Dll1 mRNA is not, but equally brings into question the reliability of the 
FACS data presented by Nelson et al., (2013).  
 
In order to resolve this, Dll1 protein expression was analysed by flow cytometry, a 
similar experiment to the FACS analysis conducted by Nelson et al., (2013). Double 
staining of Dll1 and the INP marker Tbr2 was carried out on dissociated embryonic 
cortical cells of WT embryos at E14.5 prior to conducting flow cytometry analysis. 
This gave the ability to distinguish whether Dll1 protein is expressed in INPs in the 
developing cerebral cortex. It was found that a proportion of Dll1 expressing cells 
expressed Tbr2 but not all Dll1 expressing cells were Tbr2 positive. Additionally, not 







Figure 5.9 Dll1 and Tbr2 flow cytometry analysis  
 
(A) An example of the channel gating used to select cells for analysis. (B) Gating set for Dll1 
and Tbr2 expression. Expression to the left of the gate is considered as background and 
discounted from analysis. (C) Example scatter plots depicting Dll1 expressing cells. 






Investigations into the location of Dll1 expression within the progenitor cell 
population were carried out in order to solidify which sub population the Notch 
ligand is expressed in. As previously described, past studies have produced 
conflicting results concerning which progenitor cell population Dll1 is expressed in. 
While it could initially be concluded from the literature that Dll1 may simply be 
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expressed within multiple progenitor zones, the fact that each individual study did 
not reflect this makes this unlikely. 
 
In order to establish which progenitor cell population Dll1 is expressed in, double 
labelling was carried out using the INP marker Tbr2. Co-expression of Dll1 and Tbr2 
would signify that INP cells express Dll1, while any expression of Dll1 within the 
progenitor zone, outwith the expression of Tbr2, would indicate expression of Dll1 
within RGCs residing in the VZ of the developing cortex. Analysis of WT embryos 
at E12.5 and E14.5 identified no co-expression of Tbr2 and Dll1 in the developing 
cerebral cortex, with Dll1 expression residing distinctly within the VZ. This suggests 
that Dll1 is expressed in RGCs rather than in INPs. However, it is possible that Dll1 
could be expressed by INPs residing within the VZ. It has been suggested that 
INPVZs could potentially be newly generated INPs in the processes of migrating to 
the SVZ following the asymmetric division of a RGC within the VZ. If this is the 
case, Dll1 could potentially be a link between the differentiation of RGCs into INPs, 
with Dll1 expression signifying a RGC fated to divide to produce an INP and its 
expression within INPVZs acting as a remnant of the progenitor cell subtype that it 
was generated from (Englund et al., 2005; Corbin et al., 2009; Nelson et al., 2013). 
 
The 2013 study by Nelson et al., further solidified the previous claim that INPs are a 
major source of Dll1 expression, while also suggesting that the ligand is also 
expressed by INPVZs and potentially a small, subpopulation of RGCs in the VZ 
(Nelson et al., 2013). Their initial investigations implemented a FACs-based gene 
expression profiling approach, in order to identify genes expressed in proliferating 
INPs vs. proliferating RGCs. In order to achieve this, the cortices of E14.5 
Tbr2GFP+ embryos were used in order to sort replicating progenitors (>2N DNA) 
and then further sort INPs (GFP+ ) from RGCs (GFP-) by FACs. Sorted cells were 
then used as RNA sources for comparative transcriptomic profiling of the progenitor 
subtypes by microarray analysis. It was concluded that Dll1 is expressed exclusively 
by INPs, along with Notch components Dll3 and Hey1; while RGCs expressed N1-3, 
Hes5 and Jag1. While this aligned with previous claims that Dll1 is solely expressed 
by INPs (Mizutani et al., 2007; Kawaguchi et al., 2008; Yoon et al., 2008), this 
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result not only conflicts with the findings detailed in this chapter (5.2), but also with 
previous research (Campos et al., 2001) and with subsequent findings detailed in 
Nelson et al., (2013). It was noted that Pax6 expression was documented as being 
exclusive to INPs, a claim that can automatically be identified as incorrect due to the 
fact that Pax6 is well known as a marker of RGCs in the developing cortex (Manuel 
et al., 2015). As a result, this throws into question the validity of the entire 
FACs/microarray analysis carried out by Nelson et al., (2013). It is plausible that the 
Tbr2GFP reporter used could be leaky, labelling some RGCs as well as INPs, 
although this wouldn’t account for Pax6 being expressed exclusively by INPs; 
leaving the possibility of manual/mechanical error during the experimental process 
or during analysis of the subsequent data. Regardless, the claim that Dll1 is 
expressed solely by INPs cannot be relied upon solely based upon these results. 
Immunohistochemical analysis of Dll1 expression by Nelson et al., (2013) suggested 
that Dll1 is expressed in the cell bodies of INPs, while expression found surrounding 
RGCs was located on cell process extending from INPs. However, the expression 
data provided was somewhat unconvincing, with few panels of low expression 
shown. Furthermore, investigations for this thesis using the same Dll1 antibody and 
immunohistochemistry methods as Nelson et al., (2013) were in fact abandoned due 
to the irreproducibility of the results and overall, faint and unconvincing expression 
for Dll1; even when imaged using a confocal microscope. Further evidence was 
provided to determine which progenitor cells express Dll1 by analysis of slice 
cultures and live cell imaging, which utilised embryonic cortices electroporated 
Dll1Lacz and Dll1YFP reporters respectively, observed Dll1 expression originating 
from both INPs and a subset of RGCs, suggesting that Dll1 is expressed by both 
progenitor cell populations (Nelson et al., 2013). However, how the SVZ, VZ, INPs 
and RGCs were distinguished is not thoroughly detailed in the paper and appears to 
be based on the identification of apical/apical and basal attachments in order to 
determine progenitor cell subtype. This method of identification relies heavily upon 
the quality of the images produced and leaves considerable room for human error. 
Additionally, the proportions of INPs and RGCs expressing Dll1 were not quantified, 
so the number of each cell type expressing Dll1 and whether this number is 
significant, is unknown. Interestingly, recent investigations by Shimojo et al., (2016) 
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into the effects of Dll1 on Notch oscillations and neurogenesis, identified an increase 
in expression of the INP marker Tbr2 in Dll1 mutant embryos, and a reduction in the 
size of the VZ and number of mitotic cells residing there. This suggests that Dll1 is 
likely to be expressed by RGCs in the VZ, as proliferation is disrupted within this 
proliferative zone of the cortex (Shimojo et al., 2016). 
 
While no co-expression between Dll1 and Tbr2 was identified in the developing 
cerebral cortex, apparent co-localisation between Tbr2 and Dll1 was observed within 
the SVZ of the developing hippocampus at E14.5. This was of particular interest due 
to the fact that Notch signalling is a key player during hippocampal development, 
with Notch ligands and receptors being broadly expressed during all stages of the 
development of the hippocampus, while also orchestrating the maintenance of neural 
stem cells postnatally (Urban and Guillemot, 2014; Pleasure et al., 2000). In terms of 
Dll1 specifically, the ligand has previously been identified in the subgranular zone of 
the adult murine hippocampus, where it has been found to play a critical role in the 
maintenance of the quiescence of adult neural stem cells that reside there 
(Kawaguchi et al., 2013; Kirby et al., 2015).  The fact that Dll1 and Tbr2 were found 
to co-express in the SVZ of the developing hippocampus at E14.5, suggests that the 
molecular mechanisms that drive cell proliferation in different progenitor cells 
populations differ in specific telencephalic structures rather than being uniform for 
the proliferative region of the telencephalon as a whole. Specifically, it highlights 
that the mechanisms of Notch signalling vary in the progenitor cell populations in 
different telencephalic structures. This difference is most likely due to different co-
effectors acting within the hippocampus at E14.5, resulting in the progenitor cells 
within its progenitor zone being maintained differently. In addition to the role of Dll1 
expression in development and maintenance of both the embryonic and postnatal 
hippocampus, the fact that Pax6 is also required for the production and maintenance 
of neural progenitor cells in the hippocampus (Maekawa et al., 2005; Duan et al., 
2013) is noteworthy as this evidence suggests that a regulatory relationship between 
Pax6 and Dll1 could exist in the hippocampus, both directly or indirectly via Pax6’s 
control of Tbr2. Interestingly, there is no evidence of co-expression of Dll1 and Tbr2 
in the developing hippocampus at E12.5. This suggests that genetic factors 
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responsible for the shift in Dll1s expression to multiple progenitor populations do not 
occur until E14.5. It would subsequently be of significance to analyse later 
developmental stages in order to determine if this shift continues and whether or not 
it applies to other telencephalic regions such as the cerebral cortex.  
 
Analysis of Pax6-/- mutant embryos observed both Dll1 and Tbr2 to be down 
regulated in the telencephalon at E12.5 and E14.5. This observation was expected 
due to our work highlighting Pax6’s regulatory effect on Dll1, and previous studies 
which have identified Tbr2 as a positive target of Pax6 (Warren et al., 1999; 
Englund et al., 2005; Carr, 2009; Sansom et al., 2009; Diaz-Alonso et al., 2014). 
Interestingly, the level of co-expression between Dll1 and Tbr2 in the SVZ of the 
developing hippocampus is markedly reduced. This could be due to the fact that 
Pax6 drives the expression of Tbr2 and Dll1 within the same progenitor cell type, 
accounting for the observed reduction. However, the decrease could also purely be 
due to a decrease in the number of Tbr2/Dll1 expressing cells as observed in the 
cortex of Pax6-/- mutant embryos, and that there is no shift in gene expression caused 
by a lack of Pax6 in the hippocampus at E14.5. 
 
In order to gain further understanding of Pax6’s regulatory control, Dll1 double 
labelling analysis with Dll1 and Ngn2 was carried out at embryonic stage E12.5 and 
E14.5. This approach allowed us to examine the relationship between Dll1 and a 
gene directly regulated by Pax6 (Scardigli et al., 2003; Sansom et al., 2009), as well 
as a direct activator of Dll1. According to literature, if Dll1 is an indirect target of 
Pax6, it is most likely that any regulatory control that the transcription factor exerts 
over Dll1 would be via Pax6’s up regulation of Ngn2. As previously mentioned, our 
working hypothesis states that Pax6 and Dll1 may exhibit a mutual regulatory effect 
upon one another via the mechanism termed ‘cis-inhibition’ actively involved in 
progenitor cell maintenance by Notch signalling (Chapter 1). Consequently, it is 
anticipated that there should be a high level of co-localisation between Dll1 and 
Ngn2, and that in Pax6-/- embryos, the reduction in Dll1 and Ngn2 expression should 
be relatively similar due to the fact that Ngn2 activates Dll1 and that Ngn2-/- is vastly 
down-regulated in Pax6-/- embryos (Carr, 2009; Sansom et al., 2009). 
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Double labelling analysis at E12.5 showed Ngn2 expression throughout the VZ and 
the newly developing SVZ, while Dll1 expression remained constrained to the VZ as 
previously shown. At E12.5 in WT embryos, an abundance of Dll1/Ngn2 co-
expression was apparent throughout the VZ of the developing cerebral cortex. 
However, not every Dll1 expressing cell co-expresses Ngn2. At E14.5, Ngn2 
expression remained prevalent in the fully formed SVZ and the now diminished VZ 
of the cerebral cortex, with co-expression between Dll1 and Ngn2 remaining 
predominant within the boundaries of the VZ. The fact that a reduction in Ngn2 and 
Dll1 expression was identified in the cortex of Pax6-/- mutant embryos at E12.5 and 
E14.5 was unsurprising due to the conclusions drawn from previous investigations 
from our lab and the published research of other groups (Chapter 3; Chapter 5; Carr 
2009; Scardigli et al., 2001; 2003). However, the fact that Dll1 expression does not 
appear to be as reduced as Ngn2 expression at both stages of embryonic development 
is of particular interest as it signifies that Ngn2 is not solely responsible for the 
activation of Dll1. 
 
Further research into the literature surrounding Dll1 uncovered that the proneural 
gene Mash1 is also responsible for the activation of Dll1 (Casarosa et al., 1999; 
Castro et al., 2006). This link is of key significance to our observation that Dll1 does 
not appear to be as reduced as Ngn2 in the developing cortex of Pax6-/- mutant 
embryos, due to the fact that Mash1 and Ngn2 have opposing levels of expression in 
the developing cortex (Carr et al., 2009; Sansom et al., 2009). Mash1 has been 
identified as a target of Pax6 and is up-regulated in Pax6-/- mutant embryos (Kroll et 
al., 2005; Carr, 2009; Sansom et al., 2009), meaning that Pax6 acts to repress Mash1 
expression in the developing cortex of WT embryos. It stands to reason that an up-
regulation of Mash1 would account for the fact that Dll1 does not display as striking 
a reduction in expression as Ngn2, due to the up-regulation in Mash1 accounting for 
any decrease in Dll1 as a result of a decrease in Ngn2 expression. However, the up-
regulation of Mash1 does not completely restore Dll1 expression in WT embryos 
(Chapter 3) suggesting that the activation of Dll1 by Mash1 does not fully 
compensate for the loss of Dll1 activation by Ngn2. This implies that Ngn2 is 
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responsible for a higher proportion of Dll1 expression than Mash1, most likely 
resulting in the reduction in Dll1 expression observed in the cortex of Pax6-/- mutant 
embryos due to the up-regulation of Mash1 expression being unable to fully 
compensate for the down-regulation in Ngn2 in relation to activating Dll1. 
 
In order to further investigate the hypothesis that Pax6 is likely to be regulating Dll1 
via Ngn2, further analysis using an Ngn2 mutant mouse line was implemented. It was 
observed that Ngn2 mutant embryos did not appear to display any difference in Dll1 
gene expression at E14.5 when compared to WT control littermates. Furthermore, 
cell count analysis yielded no significant difference in Dll1 expression between WT 
control and Ngn2 mutant embryos. This result was of key interest to our study of 
Pax6’s regulatory effects upon Dll1, as it did not match our hypothesis based upon 
previous studies of the regulatory relationship between Ngn2 and Dll1. Our initial 
expectation was that we would observe a dramatic reduction in Dll1 expression due 
to the fact that Ngn2 has been documented as one of the proneural genes responsible 
for the activation of Dll1. However, no significant difference was observed, 
suggesting that the loss of Dll1 activation by Ngn2 is compensated for in the cortex 
of Ngn2 mutant embryos. This observation could be the result of an increase in 
Mash1 expression, as previous studies of Ngn2 mutant embryos have identified that 
Mash1 is up regulated in the developing cerebral cortex and that Mash1 is habitually 
repressed by Ngn2 in the cortex of WT embryos (Fode et al., 2000). Conversely, 
while a similar phenomenon occurs in Pax6-/- mutant embryos, a significant decrease 
in Dll1 expression is observed. This indicates that Mash1 could potentially be up 
regulated to a higher degree in Ngn2 mutants when compared to Pax6 mutants, or 
that another co-effector is responsible for the regulation of Dll1 and is compensating 
for the loss of Dll1 activation by Ngn2. The fact that Dll1 expression is reduced in 
Pax6 mutants suggests that any compensation observed in Ngn2 mutants could be 
due to Pax6 expression directly regulating the gene, or indirectly via another gene 
other than Ngn2 and Mash1. In order to identify whether the steady expression of 
Dll1 in Ngn2-/- mutants and their WT counterparts is due to a higher level of Mash1 
expression in Ngn2-/- mutants than the up regulation of Mash1 observed in Pax6-/- 
mutants, qPCR could be utilised. This would allow Mash1 expression levels to be 
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efficiently compared in the developing cortex of Ngn2-/-, Pax6-/- and WT control 
embryos at a variety of different embryonic stages. If no discernable difference in 
Mash1 expression levels were detected by qPCR, the hypothesis that Pax6 could be 
regulating Dll1 levels via a different proneural gene such as Math1 (Gazit et al., 
2004; Duprac et al., 2006), or directly, could be investigated further. It is also worth 
acknowledging that previous research has identified that most neural progenitor cells 
express only Pax6 or only Tbr2, suggesting that Pax6 is expressed by the vast 
majority of RGCs in the cerebral cortex, while Tbr2 is expressed by the INPs; as 
when 1989 cells that were immunoreactive for Pax6 and Tbr2 were analysed at 
E14.5, 55.7 ± 9.9% were Pax6 positive, 32.8 ± 10.2% were Tbr2 positive, and 11.5 ± 
1.0% were Pax6 and Tbr2 positive (Englund et al., 2005). This suggests that it would 
be highly likely that the majority (if not all) Dll1 positive cells in the VZ would also 
co-express Pax6, although future cell counts for Dll1/Pax6 in situ hybridisation 
would have to be carried out in order to ascertain this.  
 
Flow cytometry analysis confirmed that Dll1 protein is expressed in INPs, with a 
proportion of Dll1 expressing cells found to be positive for the INP marker Tbr2. 
However, the fact that some Dll1 stained cells did not co-express Tbr2 suggests that 
Dll1 is also expressed by RGCs. The fact that Dll1 mRNA expression is restricted to 
the VZ while Dll1 protein expression is not is initially puzzling. However, it is 
possible that Dll1 protein expression remains ‘switched on’ in a cell longer than its 
mRNA counterpart does due to the fact that the expression of a protein is not 
instantaneous but rather a gradual increase and decrease as its expression is 
instigated and then stopped (Englund et al., 2005). Therefore, Dll1 protein 
expression could originate in RGCs residing in the VZ, where Dll1 mRNA is 
expressed, and could remain present while RGCs go on to produce INPs and migrate 
to the SVZ where Dll1 protein expression slowly diminishes. This would explain 
why we see Dll1 mRNA expression in the VZ and no expression in INPs residing 
within the SVZ, as well as detecting Dll1 protein expression within a proportion of 
INPs. However, further investigations would need to be undertaken to confirm 
whether this hypothesis is correct, such as lineage tracing of progenitor cells and 
looking at protein levels of Dll1 in RGCs and INPs during corticogenesis. 
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STAGE/GENOTYPE DLL1/TBR2 DLL1/NGN2 
E12.5 WT Dll1: Restricted to VZ 
 
Tbr2: Restricted to SVZ 
 
Co-expression: None 








in the VZ of the cortex 
E12.5 SEY Dll1: Reduced staining 
compared to WT 
Restricted to VZ 
 
Tbr2: Reduced staining 
compared to WT 
Restricted to SVZ 
 
Co-expression: None 
Dll1: Reduced staining 
compared to WT 
Restricted to the VZ 
 
Ngn2: Reduced staining 
compared to WT 
Expressed throughout 




in the VZ of the cortex 
compared to WT 
E14.5 WT Dll1: Restricted to VZ in 
the cortex 
Expression in the VZ and 
SVZ of the hippocampus 
 
Tbr2: Restricted to SVZ 
 
Co-expression: None in 
the cortex 
Dll1/Ngn2 co-expression 
in the SVZ of the 
hippocampus 








in the VZ of the cortex 
E14.5 SEY Dll1: Reduced staining 
compared to WT 
Restricted to VZ in cortex 
Expression in the VZ and 
SVZ of the hippocampus 
 
Tbr2: Reduced staining 
compared to WT 
Restricted to SVZ 
 
Co-expression: None in 
the cortex 
Reduced Dll1/Ngn2 co-
Dll1: Reduced staining 
compared to WT 
Restricted to the VZ 
 
Ngn2: Reduced staining 
compared to WT 
Expressed throughout 




in the VZ of the cortex 
compared to WT 
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expression in the SVZ of 
the hippocampus 
compared to WT 
 
 
Table 5.1 Chapter 5 results summary (1/2) 
 
A summary of the double in situ hybridisation/immunohistochemistry (Dll1/Tbr2) results, and 
the double in situ hybridisation (Dll1/Ngn2) results detailed in chapter 5. At E12.5 and E14.5, 
Dll1 was found to be restricted to the VZ of the cortex and Tbr2 to the SVZ. The expression 
of both Dll1 and Tbr2 were reduced in Sey embryos compared to WT littermates and both 
developmental stages. At E14.5, Dll1 expression was observed in the VZ and the SVZ of the 
developing hippocampus, and co-expression of Dll1 and Tbr2 was observed in the SVZ. At 
E12.5 and E14.5, Ngn2 expression was observed in the VZ and the SVZ of the developing 
cortex, and co-expression of Dll1 and Ngn2 was evident in the VZ. Dll1 and Ngn2 expression 























Table 5.2 Chapter 5 results summary (2/2) 
 
Summaries of the cell count analysis and flow cytometry results detailed in chapter 5. 
Analysis of the density of Dll1 expressing cells and total cell density in WT/Ngn2-Cre 
embryos at E14.5 observed no significant differences in the dorsal and ventral regions of the 
cerebral cortex. Flow cytometry analysis of WT E14.5 dissociated cortical cells observed cell 

















E14.5 WT Yes Yes Yes 
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As previously discussed in chapter 4, in situ hybridisation analysis of Jag1 
expression in Pax6-/- mutant embryos and their WT littermates provides convincing 
evidence to support Jag1 as a prime candidate of direct regulation by Pax6 in the 
developing cerebral cortex (Chapter 4). The complete loss of Jag1 expression at the 
PSPB of Pax6-/- and Pax77 mutants suggests that not only is Jag1 likely to be directly 
activated by Pax6, but that Jag1 is also highly sensitive to levels of Pax6 expression. 
Furthermore, the observation that Jag1 is a target of Pax6 at the PSPB by microarray 
analysis, also provides support to the hypothesis that Jag1 could potentially be a 
direct target of Pax6 as there is evidence that Pax6 does regulate the gene, although it 
is unknown whether it is direct or indirect target (Carr, 2009).   
 
Previous studies that have identified direct targets often began with the assumption 
that a substantial increase or decrease in gene expression when Pax6 expression is 
lost would lead to the discovery that the gene in question is a direct target of Pax6 
(Holm et al., 2007; Wen et al., 2008; Sansom et al., 2009; Mi et al., 2013a). The 
2003 study by Scardigli et al., is one such example, where the vast effect upon Ngn2 
gene expression in Pax6-/- mice was noted and subsequent research identified 
putative binding sites for Pax6 (Scardigli et al., 2001; 2003). Furthermore, work in 
our own lab identified the cell cycle gene Cdk6 as a direct target of Pax6, with the 
discovery that Pax6 represses Cdk6 expression in the developing cerebral cortex 
during embryogenesis (Mi et al., 2013b). Due to the fact that such a dramatic 
decrease in Jag1 expression is shown at the PSPB of Pax6-/- mutant embryos, it is 
plausible that Pax6 could be directly regulating Jag1 gene expression in this region 
of the developing telencephalon. 
 
In order to ascertain whether Pax6 directly regulates potential gene targets, past 
studies have implemented bioinformatics to reveal potential binding sites (Coutinho 
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et al., 2011; Bhatia et al., 2013; Mi et al., 2013a; Ravi et al., 2013). Work by 
Coutinho et al., (2011) implemented a bioinformatics approach and identified over 
600 putative Pax6 binding sites and over 200 predicted direct target genes by 
utilising hidden Markov models (HMMs) generated from experimentally validated 
Pax6 binding sites (Countinho et al., 2011). This led to the identification of several 
novel target genes, such as Foxp2, implicated in development and disease 
(Countinho et al., 2011). Further studies implementing a bioinformatics approach 
identified numerous targets of eyeless (the Drosophila Melanogaster Pax6 gene) 
including the early retinal development genes eya, so, Optix and ato (Ostrin et al., 
2006), while studies in Medaka fish identified and validated Atoh7, Pax2, Pax5 and 
Pax8 as direct targets of Pax6 (Del Bene et al., 2007; Ramialison et al., 2008). As 
previously discussed, work by Scardigli et al., (2001; 2003) and Mi et al., (2013) 
identified and validated Ngn2 and Cdk6 respectively as direct targets of Pax6, and 
implemented bioinformatics in order to identify putative binding sites. 
Bioinformatics screening provides a useful complementary resource alongside 
conventional “wet lab” approaches such as ChIP screening and expression analysis 
experiments (Countinho et al., 2011). Ultimately, bioinformatics allows a relatively 
quick and cost effective resource to screen candidate genes and identify potential 
putative binding sites for transcriptional regulators such as Pax6, which can be 
analysed and explored further in order to validate them (Stormo, 2000; Countinho et 
al., 2011). 
 
It can therefore be assumed that screening by bioinformatics is an ideal strategy to 
further explore the possibility that Pax6 may directly regulate Jag1. Consequently, it 
was determined that a bioinformatics approach would be implemented in order to 
determine if there were any likely binding sites for Pax6. Past studies have 
determined that many enhancer and binding sites for the activation or repression of a 
gene tend to be relatively close to the promoter region of the gene in question, 
usually within a few Kb upstream of the 5’UTR (Bulger and Groudine, 2010). With 
this in mind, it was decided that Jag1 gene would be screened and 10Kb upstream 
and downstream of the gene would also be included.  
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If screening of Jag1 by bioinformatics is found to be successful, binding sites will be 
analysed by their position and conservation score to determine which are the most 
likely candidates to be true binding sites of Pax6. Selected binding sites will be 
tested further to establish whether they are genuine putative Pax6 binding sites and to 
conclude whether Pax6 directly regulates Jag1. Our bioinformatics approach will 
utilise previously designed position weight matrixes (PWMs) for a validated 
consensus Pax6 binding site and the use of the UCSC genome browser to identify 
areas of high sequence alignment across 30 vertebrate species. This will allow us to 
identify potential conserved regulatory elements for Jag1. We will then be able to 
screen for and identify sequences of high conservation between regulatory elements 
for Jag1 and the consensus Pax6 binding site, providing us with a comprehensive list 
of potential putative binding sites for Pax6. 
 
In order to assess whether Pax6 directly binds to our selected candidate binding sites, 
a cloning approach will be implemented to clone our site of interest into a luciferase 
construct. This approach will involve designing primers to clone our region of 
interest from genomic DNA and then using an in-fusion PCR approach to clone our 
region of interest into a luciferase construct. Following production of our construct, 
the candidate sites will be tested by luciferase assay in order to ascertain whether 
Pax6 directly activates them.  
 
Luciferase assay analysis will be implemented using HEK cells transfected with 
luciferase constructs containing our candidate sites of interest cloned upstream of the 
firefly reporter and a renilla construct to act as an internal control. HEK cells will 
also be transfected with increasing amounts of a Pax6 expressing construct. If Pax6 
binds to Jag1UE and activates firefly expression as a result, we should observe an 
increase in firefly expression for each expression as Pax6 dosage increased, as well 
as an increase in comparison to any of our control experiments (Chapter 2.14). This 
would not only validate our candidate sites, but also provide evidence to support our 




6.2 Bioinformatic screening of Jag1 
 
Bioinformatics was implemented using a custom made PaxPWM-CEs track built by 
Dr Ian Simpson. The track utilised four different Pax6 consensus site PWMs: 
M00808 (Hufnagel et al., 2007); M00097 (Epstein et al., 1994); M00979 (Roth 
et al., 1991; Duncan et al., 1996; Sander et al., 1997; Duncan et al., 1998; 
Zhou et al., 2000) and C0000010 (Countinho et al., 2011) (Figure 6.1). The 
designed track screened the aforementioned PWMs for Pax6 against highly 
conserved regions on or flanking Jag1 across 30 vertebrate species. This allowed for 
screening for high conservation between regulatory elements and the consensus Pax6 
binding site. Position specific estimates of evolutionary constraint (GERP scores) 
were then used to discover multiple positions that combine to give a signal that is 
indicative of a putative functional element (constrained elements). Constrained 
elements were determined and scored using a sum of log-likelihoods to provide a 
‘score’ for the likelihood of a particular base pair residing in a specific position 
within the sequence. An algorithm was then implemented to compare highly 
conserved areas surrounding the Jag1 gene to the Pax6 motifs. This produced a set of 
probable Pax6 targets which could be visualised on the custom made track on the 
UCSC genome browser (Figure 6.2). Dr Ian Simpson (Informatics Forum) carried 
out all bioinformatics screening and the resulting scores were then analysed by our 






Figure 6.1 Pax6 consensus binding site motifs  
 
Images taken from Countinho et al., 2011 and www.snnper.chip.org. The four validated Pax6 
consensus binding site motifs utilised in our bioinformatic screening for Jag1 putative Pax6 
bindings sites. (A) M00097 (Epstein et al., 1994) (B) M00979 (Roth et al., 1991; Duncan et 
al., 1996; Sander et al., 1997; Duncan et al., 1998; Zhou et al., 2000) (C) M00808 (Hufnagel 
et al., 2007) (D) C0000010 (Countinho et al., 2011). Position = bp position in sequence. 







Figure 6.2  Customised Jag1 Pax6PWM_CEs track  
 
Developed by Dr Ian Simpson. Pax6PWM_CEs track applied to the UCSC genome browser 
to screen for and visualise sequences of high conservation between Jag1 regulatory 
elements and the consensus Pax6 binding site. Using the UCSC genome browser to find 
areas of high sequence alignment across 60 vertebrate species including rat, rabbit, human, 
dog and elephant screened for potential regulatory elements for Jag1. Potential binding sites 
are marked by black lines and labelled with the Pax6 consensus motif they align with.  
 
 
Analysis of the scores for each conserved site found that six of the constrained 
elements with the highest scores were all located within a 3Kb radius of one another 
(Figure 6.3A). Further analysis of the custom track also determined that the 
constrained elements were located around 1.5Kb upstream of the 5’UTR of Jag1. 
The number and positioning of the constrained elements made them a particularly 
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attractive candidate as an enhancer element for Jag1, as enhancers are typically 





Figure 6.3 Visualisation of candidate binding sites on the Pax6PWM_CEs track and 
binding site chromosome positions and sequences 
 
(A) The six constrained elements selected as a potential enhancer element (Jag1UE) 
visualised on the Jag1/Pax6PWM_CEs track. Jag1UE is located 1.5Kb upstream of the 
5’UTR for Jag1. All of the six constrained elements are within 3.5Kb of one another. (B) The 
chromosome positions and sequences for each of the six constrained elements that 
constitute Jag1UE. The sequences for the constrained elements are highlighted in blue. 
Three of the constrained elements are highly conserved amongst the screened vertebrate 
species and are highlighted in red.  
 
 
As a result, it was determined that the six constrained elements should be treated as a 
potential enhancer element and dubbed ‘Jagged1 upstream enhancer’ (Jag1UE). 
Jag1UE was selected as the most likely predicted putative Pax6 binding site with the 
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hypothesis that Pax6 was likely to directly bind to one, several or all of the 
constrained elements that make up Jag1UE.  
 
 
6.3 Cloning Jag1UE 
 
Once Jag1UE was identified, the region was cloned into a luciferase vector in order 
to carry out analysis of the enhancer by luciferase assay. Due to the fact that Jag1UE 
is situated 1.5Kb upstream of the 5’UTR, within the ‘gene desert’ of the genome 
(large tracts of the genome devoid of protein coding genes), BLAT was used to 
obtain the entire sequence encompassing Jag1UE. This was achieved by using the 
5’UTR sequence of Jag1 and the sequences of the six individual constrained 
elements obtained from the Jag1 specific PaxPWM-CEs track (Figure 6.3B). Once 
the sequence was obtained, primers were designed that encompassed the six 
constrained elements (Figure 6.4A) and In-fusion PCR software was used to convert 
them to in-fusion PCR primers which were specific to our region of interest and our 
selected luciferase vector (Figure 6.4B). Jag1UE was cloned from genomic DNA and 
sequenced. In-fusion PCR was then carried out to clone Jag1UE into our selected 
luciferase vector, pGL4.23, in order to produce pGL4.23+Jag1UE: a luciferase 
vector with Jag1UE inserted upstream of a minimal promoter which will drive 






Figure 6.4 A map of the pGL4.23 luciferase vector with a minimal promoter and the 
developed In-Fusion PCR primer sequences for cloning Jag1UE. 
 
(A) pGL4.23 was selected as the luciferase vector to clone Jag1UE into due to the fact that it 
contains a minimal promoter and we were unable to identify the exact location of the 
promoter for Jag1UE. Due to the fact that our region of interest is located 1.5Kb upstream of 
the 5’UTR for Jag1, we presumed that the region does not contain the promoter region for 
Jag1 and chose to treat our region of interest as a potential enhancer for Jag1. (B) The 
primer sequences designed for cloning Jag1UE. Standard 16bp primers (highlighted in blue) 
were initially designed and then run through Clontech In-Fusion PCR software to produce 
primers specific to Jag1UE and pGL4.23. The developed primers will only produce and 






Figure 6.5  pGL4.23+Jag1UE construct map 
 
A map of Jag1UE (purple) inserted into the Xho1 site within the multiple cloning site (blue) of 
pGL4.23. Jag1UE will work to activate the minimal promoter (red) of pGL4.23 when 
regulated by the presence of Pax6 expression. pGL4.23+Jag1UE = 7596bp.  
 
 
6.4 The effect of Pax6 on Jag1UE Expression 
 
Analysis of Jag1UE as a putative Pax6 binding site was carried out by luciferase 
assay, utilising the pGL4.23+Jag1UE construct described in 6.5. Pax6 non-
expressing HEK293 cells were transfected with pGL4.23+Jag1UE and increasing 
amounts of Pax6 in order to demonstrate that Pax6 binds and activates Jag1UE 
(Figure 6.6). This allowed us to fully investigate the effects of Pax6 upon Jag1UE 
without having to compensate for background Pax6 expression. HEK293 cells were 
also transfected with a Renilla luciferase control and with different levels of Pax6 
(0ng, 50ng, 100ng, 200ng, 400ng, 500ng) per transfection. Three additional controls 
were used as standard for each luciferase assay experiment: an empty pGL4.23 
vector control to demonstrate that firefly is being activated by Pax6’s effect on 
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Jag1UE, an empty pCMV vector in order to demonstrate that Pax6 is responsible for 
the increase in firefly activity, and a no transfection control to account for 
background levels of Firefly and Renilla. Analysis by linear regression yielded no 
significant difference in Jag1UE expression (P=0.1494) as Pax6 levels increased 
(0ng-500ng) and an R2 value = 0.1254  (Figure 6.6A). Additionally, no significant 
difference was found for the expression of the pGL4.23 control (P=0.3048) as pax6 
levels increased (0ng-500ng) and an R2 value = 0.06564 (Figure 6.6B). In order to 
demonstrate that Pax6 levels increased as Pax6 transfection dosage increased, 
western blot analysis of the transfected HEK 293 cells was carried out. Western blot 
analysis showed that Pax6 levels increased as the dose of Pax6 plasmid that the cells 
were transfected with increased (Figure 6.7). The increase in Pax6 expression as dose 
of Pax6 increases (Figure 6.7C) correlates with the slight increase in Jag1UE 
expression (Figure 6.6A). However, the slight increase in Jag1UE expression was not 





Figure 6.6 Luciferase assay analysis of Jag1UE expression   
 
(A) Measure of firefly luciferase activity (relative to Renilla control) in HEK293 cells 
transfected with a range of Pax6 levels (0-500ng). Statistical analysis by linear regression 
detected no significant difference in Jag1UE expression (P=0.1494). R2=0.1254. (B) 
Measure of firefly luciferase activity (relative to Renilla control) in HEK293 cells transfected 
with a range of Pax6 levels (0-500ng). Statistical analysis by linear regression detected no 




Figure 6.7 Western blot carried out on transfected HEK293 cells  
 
(A) Western blot for GAPDH and Pax6. Lane 1 = ladder shown in red. Lanes 2-7 = 0ng-
500ng Pax6 transfected HEK293 cells, red = GAPDH and green = Pax6. GAPDH used as a 
positive control to normalise to. (B) GAPDH and Pax6 western blot results separated for 
analysis. GAPDH expression indicated by red arrow and Pax6 expression indicated by green 
arrow. Little to no Pax6 expression is apparent in HEK293 cells that were transfected with 
0ng of Pax6. (C) Quantitative analysis of western blot for Pax6 expression. Pax6 pixel 
intensity for 0ng-500ng HEK293 cells was calculated and results were normalised to the 





Bioinformatic screening for putative Pax6 binding sites yielded a potential enhancer 
element for Jag1 (6.2). The potential enhancer site, dubbed Jag1UE, was successfully 
cloned into the pGL4.23 construct with a minimal promoter and analysis by 
luciferase assay was carried out in order to validate Jag1UE as an enhancer element 
activated by direct Pax6 binding.  However, while a small increase in firefly 
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expression was observed as Pax6 expression increased, it was not deemed 
statistically significant when tested by linear regression analysis. While it could 
automatically be assumed that this result suggests that Jag1UE is not an enhancer 
element activated by Pax6, this conclusion is likely to be too hasty and a non-
significant result could be due to multiple reasons that will be outlined below. 
 
While the use of HEK293 cells for transfection gave us a distinct advantage due to 
the fact that they do not express Pax6, they are vastly removed from mouse 
embryonic cortical cells. It is impossible to confirm whether the same relationship 
between Jag1 and Pax6 applies in kidney cells or in human embryos without further 
investigation. As a result, future attempts to analyse the effects of Pax6 on Jag1UE 
by luciferase assay would be best to utilise dissociated cortical cells from Pax6-/- 
mutant embryos. Not only would this provide experimental conditions as close as 
possible to the conditions implemented for our expression data analysis for Jag1, but 
it would also provide cells that do not normally express Pax6 but with all of the 
components required for Pax6 regulation. Additionally, a further analysis could be 
carried out using WT cortical cells and PAX77 cortical cells in order to further 
examine the effects of Pax6 levels upon Jag1UE. 
 
In order to further validate the luciferase assay experiment in the future, additional 
positive controls could be included. This would most effectively be achieved by 
including a previously tested construct that has been validated as a direct target of 
Pax6. Furthermore, while the Pax6 construct used for this experiment has 
successfully identified a Pax6 target previously (Mi et al., 2013b), re-confirming that 
the Pax6 protein used is functional would be advantageous in order to validate the 
luciferase assay experiment carried out for this thesis. The best way to achieve the 
aforementioned points would be to carry out an additional control run using the 
validated Cdk6 constructs detailed in Mi et al., (2013b). As this study used the same 
experimental design for their luciferase assay, the Cdk6 construct would provide the 
best positive control in order to validate this experimental set-up, and would also 
provide evidence that the Pax6 protein used is functional (Mi et al., 2013b).  
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Another explanation for our luciferase assay results could be that Pax6 may only 
bind to one or a few of the binding sites that make up Jag1UE. Similar instances 
have been documented previously, where a region that included multiple binding 
sites was initially tested as a whole before each individual site was re-tested and it 
was discovered that only one or two of the binding sites were actually directly 
activated by Pax6 (Scardigli et al., 2003; Mi et al., 2013a). If this is the case it could 
be that inclusion of the additional binding sites having a repressive effect upon the 
activity of Jag1UE as a whole (Whitfield et al., 2012). In order to determine whether 
this is in fact the case with Jag1UE, testing each individual binding site by designing 
constructs for each individual binding site and different combinations of the binding 
sites would confirm whether this was the case, or mutating combinations of the 
binding sites within Jag1UE to render them non-functional would help to prove or 
disprove this hypothesis.  
 
It is also plausible that Pax6 may only be partially responsible for the activation of 
Jag1UE and that another transcription factor is also responsible for its activation 
(Brindle et al., 1990). This would account for such a small increase in firefly 
expression as Pax6 expression increases. However, taking our Jag1 expression data 
into consideration (Chapter 4) would suggest that Pax6 expression should evoke a 
much larger effect upon an enhancer element for Jag1. This would suggest that if 
there is an additional transcription factor responsible for binding and activating 
Jag1UE, HEK293 cells might not express it. Furthermore, it could also be possible 
that Pax6 exerts its direct regulatory effects on Jag1 by binding to additional putative 
Pax6 binding sites located at a different region of the genome. This is highly likely as 
our bioinformatic screening of Jag1 against Pax6 yielded over 60 potential binding 
sites. In order to test this, further analysis of these additional binding sites would 
need to be undertaken and selected candidates would have to be tested by luciferase 
assay.  
 
While analysis by luciferase assay is a suitable approach to identify whether Pax6 
directly binds Jag1UE, it is also far removed from what occurs in the developing 
cerebral cortex during murine embryogenesis. As a result, an in vitro approach may 
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be too removed from the biological process occurring between Pax6 and Jag1 in an 
embryo and as a result, it may cease to function correctly. As a result, an in vivo 
approach would be more suitable to test Pax6’s effects upon Jag1UE. A 
microinjection approach as described in Scardigli et al., (2003) would be ideal as a 
Jag1UE construct with a LacZ reporter could be integrated into the DNA of 
developing WT embryos and then they could be analysed at specific developmental 
stages. If Pax6 activates Jag1UE, the reporter would visualise Jag1’s expression 
pattern at the PSPB (Scardigli et al., 2013). Mutation of the binding sites that 
comprise Jag1UE would further validate Jag1UE as expression should be lost if 
some/all of the binding sites are disrupted. 
 
Although the luciferase assay results were not significant, a small increase in firefly 
expression was evident as Pax6 levels increased. Due to the fact that WB validated 
increasing Pax6 levels, technical issues may have resulted in no statistically 
significant increase in firefly expression as Pax6 levels increase. While carrying out 
luciferase assay experiments, extreme difficulties with transfection rates were 
initially experienced. While transfection efficiency was optimised as much as 
possible within the time constraints of the project, it is possible that transfection 
efficiency was still was still relatively poor for one if not all of the experimental 
constructs used. If this were the case, poor transfection efficiency would account for 
no significant increase in firefly expression as Pax6 levels increase. In order to 
combat this, future luciferase experiments would need to optimise transfection 
efficiency further and confirm that each repeat had similar transfection efficiencies 
for all constructs. 
 
While the results from our analysis of Jag1UE by luciferase assay remain 
inconclusive, it is still likely that Jag1UE could be an enhancer element or  contains 
at least one putative Pax6 binding site. Further research into Jag1UE in order to 
validate it as an enhancer element would be required, and analysis of the other 
potential putative Pax6 binding sites may also be required in order to ascertain 




ACTIVITY OF CELLS 
TRANSFECTED WITH A RANGE 
OF PAX6 LEVELS (0-500NG) 
LINEAR REGRESSION ANALYSIS 
JAG1UE No significant difference 
PGL4.23 No significant difference 
 
AMOUNT PAX6 TRANSFECTED 
(NG) 
INCREASE IN PAX6 EXPRESSION 











Table 6.1  Chapter 6 results summary  
 
A summary of the luciferase assay results and western blot results detailed in chapter 6. 
Linear regression analysis of luciferase expression for Jag1UE and the control pGL4.23 
construct observed no significant difference. Western blot analysis of Pax6 expression levels 
by cells transfected with increasing amounts of Pax6 (0ng-500ng) observed an increase in 
Pax6 levels up to 200ng and then a decrease for 400ng and 500ng. 
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7.0 General discussion 
 
 
7.1 Pax6 regulates Dll1 and Jag1 during cortical development 
 
The initial aim of this project was to discover new target genes of Pax6 implicated in 
the development of the embryonic cerebral cortex (Chapter 1). Notch pathway genes 
were highlighted from past microarray (Carr et al., 2009) and ChIP (Sansom et al., 
2009) studies and some were confirmed as Pax6 targets including N1 and Hes5 
(Dorà, 2011). Both Dll1 and Jag1 were identified as potential targets of Pax6 (Carr et 
al., 2009; Sansom et al., 2009). 
 
Expression analysis of Dll1 by in situ hybridisation and subsequent quantification by 
cell count analysis found that Dll1 expression is significantly reduced in areas of the 
cerebral cortex from E11.5-E12.5 in Pax6-/- and from E12.5-E13.5 in cKO embryos 
(Chapter 3). This allowed us to conclude that Dll1 is a Pax6 target. However, it is 
unclear whether Dll1 is directly or indirectly regulated by the transcription factor. 
Analysis carried out in chapter 3 suggests that Dll1 is more likely to be an indirect 
target due to the fact that it is not as severely affected as some validated Pax6 targets 
such as Ngn2 where expression is severely reduced in the cortex of Pax6-/- mutant 
embryos (Stoykova et al., 2000; Toresson et al., 2000; Yun et al., 2001; Scardigli et 
al., 2003; Holm et al., 2007; Quinn et al., 2007; Sansom and Livesey, 2009 and Cdk6 
(Mi et al., 2013a; 2013b). Although Dll1 appears to be most likely only indirectly 
regulated by Pax6, their relationship could potentially be particularly interesting to 
study further due to the role of both Pax6 and Dll1 in cell proliferation (Pierfelice et 
al., 2007; Manuel et al., 2013). As a result, their relationship could be integral to the 
process of cortical neurogenesis during embryonic development. 
 
While the relationship between Dll1 and Pax6 appears to be quite complex, the 
relationship between Pax6 and Jag1 is likely to be much more straightforward. 
Expression analysis of Jag1 in Pax6-/- embryos from E11.5-E14.5 saw a complete 
loss of Jag1 expression at the PSPB and diminished expression in the main body of 
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the developing cortex (Chapter 4). Taking the dramatic change in expression levels 
of validated Pax6 targets like Ngn2 into consideration, Jag1 is a likely direct target of 
Pax6 due to the complete loss of Jag1 expression at the PSPB of Pax6-/- mutant 
embryos. Interestingly, Jag1 expression was also lost at the PSPB of PAX77 mutant 
embryos (Chapter 4), suggesting that specific levels of Pax6 are required to activate 
Jag1 expression in this telencephalic region. Dll1, on the other hand, saw no 
significant increase or decrease in expression when analysed in PAX77 embryos 
(Chapter 3). This suggests that Pax6 interacts with the two Notch ligands in very 
different ways, despite Dll1 and Jag1 fundamentally carrying out the same role 
during embryonic neurogenesis.  
 
 
7.2  Dll1 mRNA is expressed in the VZ and Dll1 protein is co-expressed 
with Tbr2 in a subset of progenitor cells 
 
Following the identification of two notch ligands as Pax6 targets, we endeavoured to 
learn as much as possible about the relationships between them. While we concluded 
that the regulatory relationship between Pax6 and Jag1 was likely to be relatively 
straightforward, it was determined that the relationship between Pax6 and Dll1 was 
likely to be far more complex. In order to form a hypothesis centred on how Pax6 
and Jag1 may interact with one another during cortical development, an extensive 
research of the literature on Dll1 during forebrain development was carried out. As 
previously discussed, many discrepancies in the literature were discovered for the 
location of Dll1 expression in the developing cerebral cortex during embryogenesis 
(Chapter 5). 
 
To briefly summarise what has already been covered in chapter 5, some studies 
determined that Dll1 is expressed in the VZ of the developing cortex (Campos et al., 
2001), while others reported that Dll1 is expressed within the SVZ (Mizutani et al., 
2007; Kawaguchi et al., 2008; Yoon et al., 2008). A further study conducted by 
Nelson et al., (2013) suggested that Dll1 is predominately expressed in INPs residing 
within the SVZ, but also expressed in the VZ in a subpopulation of INPs that reside 
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there (INPVZ) (Nelson et al., 2013). These inconsistencies in the published literature 
proved detrimental to our analysis of the relationship between Pax6 and Dll1, as it 
was unclear whether the fundamental basics the model developed from our 
hypothesis were correct (Chapter 1). As a result, we carried out analysis of Dll1 
expression in order to determine where the ligand is expressed in the embryonic 
cerebral cortex (Chapter 3, Chapter 5).  
 
Single and double labelling expression data concluded that Dll1 is expressed within 
the VZ of the developing cerebral cortex (Chapter 3 and Chapter 5) and that INP 
cells do not express Dll1 (Chapter 5). However, studies describing Dll1 expression in 
the SVZ and in INPs analysed Dll1 protein expression rather than Dll1 mRNA 
expression (Nelson et al., 2013). In order to disprove or validate these findings; we 
carried out flow cytometry analysis of Dll1 and Tbr2 expression in dissociated E14.5 
WT cortical cells (Chapter 5). A proportion of cells were found to co-express Tbr2 
and Dll1 (Chapter 5), but not all cells expressing Dll1 also expressed Tbr2 and vice 
versa. In chapter 5, the notion that Dll1 mRNA expression diminishes before Dll1 
protein expression was considered (Chapter 5). This would account for Dll1 protein 
expression in INP cells and possibly RGCs, as well as Dll1 mRNA expression in 
RGCs only. However, it is also plausible that the co-expression of Dll1 and Tbr2 
observed in our flow cytometry analysis could be in INPVZ s that are still expressing 
Dll1 and are beginning to express Tbr2 as they migrate to the SVZ where they settle 
as fully matured INPs that no longer express Dll1.  
 
 
7.3 Dll1 and Jag1 as direct targets of Pax6  
 
As previously discussed, Jag1 was identified as a candidate gene for direct regulation 
by Pax6 (Chapter 4; Chapter 7.1). Subsequent screening by bioinformatics yielded a 
comprehensive list of around 30 constrained elements on or around Jag1 that were 
likely putative Pax6 binding sites (Chapter 6.2). We determined that a cluster of 6 
constrained elements around 1.5Kb upstream of the 5”UTR of Jag1 was likely to be 
an enhancer element for the gene (Chapter 6.2). However, analysis of the proposed 
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enhancer element (Jag1UE) by luciferase analysis did not yield a significant result to 
validate Jag1UE as an enhancer. Despite this, as discussed in detail in chapter 6, it is 
still possible that Jag1UE may be an enhancer element that binds Pax6 (Chapter 6.5). 
Additionally, there is the distinct possibility that some of the untested binding sites 
from our bioinformatics screen could be putative Pax6 sites (Chapter 6.5). 
Consequently, although Jag1 was not confirmed as a direct target of Pax6 by our 
investigations, it remains a prime candidate and further research is required to 
confirm or disprove it. 
 
While we approached Dll1 as a likely indirect target of Pax6 regulation due to our 
initial investigations in chapter 3, it cannot be disproved as a potential direct target 
without further research. Our investigations into Dll1 expression in the developing 
cortex of Ngn2-/- mutant embryos showed that expression levels are not significantly 
reduced like they are in Pax6-/- embryos (Chapter 5). As discussed in chapter 5, Dll1 
is a direct target of Ngn2 (Castro et al., 2006) so it was initially surprising that Dll1 
expression was not reduced. While compensation by Mash1 is the likely resolution, it 
does not explain the significant reduction in Dll1 expression in Pax6 mutant embryos 
(Chapter 3), as Mash1 is up-regulated in the cortex of Pax6-/- embryos (Kroll et al., 
2005; Carr, 2009). This ultimately begs the question of whether Mash1 is simply up-
regulated to a greater degree in the cortex of Ngn2-/- embryos when compared to 
Pax6-/- embryos or whether Pax6 may have a different regulatory relationship with 
Dll1 than originally presumed. However, if this were found not to be the case, it 
would provide circumstantial evidence that Pax6 could potentially directly regulate 
Dll1 rather than indirectly regulate it. Subsequently, it would be advantageous to 
investigate Dll1 as potential direct target of Pax6 in the future.   
 
 
7.4 The Pax6/Notch ligand model revisited  
 
In light of the findings of this project highlighted in sections 7.1-7.3, the 
experimental model (Figure 1.8) produced from our initial hypothesis (Chapter 1.11) 
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may require revising. Three potential revisions of the model are described in the 
following paragraphs. 
 
In light of our findings, a new model depicting that Dll1 mRNA and protein are first 
expressed in RGCs residing within the VZ could be applied. In this revision of our 
model, both Dll1 mRNA and protein would continue to be expressed by newly 
generated INPVZs, with Dll1 mRNA levels starting to slowly diminish as INPVZs 
(Figure 7.1a) migrate towards the SVZ. In order to account for the fact that Dll1 
mRNA is not expressed in the SVZ but that Dll1 protein has been visualised in the 
SVZ (Nelson et al., 2013), the model would depict that mature INPs residing in the 
SVZ do not express Dll1 mRNA (Figure 7.1a) but do continue to express Dll1 
protein (Figure 7.1b). This phenomenon would be explained by the notion that once 
Dll1 mRNA is no longer expressed, the protein levels persist for some time. This 
would suggest that Dll1 expression in the SVZ is the result of Dll1 protein produced 
by RGCs and that its protein expression lingers long after Dll1 mRNA is no longer 
expressed. As a result, it is likely that Dll1 protein levels in INPs slowly diminish 






Figure 7.1 Adapted hypothesis model 
 
(A) Dll1 mRNA expression in progenitor cell subpopulations during corticogenesis. Dll1 is 
expressed in RGCs. Newly generated INPs (INPVZs) still express Dll1 but mRNA levels 
decrease as INPVZs migrate to the SVZ where they settle as mature INPs. INPs do not 
express Dll1. (B) Dll1 protein is expressed by RGCs and expression of Dll1 is retained in 
INPVZs and INPs. It is likely that Dll1 expression slowly diminishes in INPs until the protein is 
no longer expressed. Green cell = RGC. Blue cell = INPVZ. Purple cell = INP.  = sustained 
expression.  = diminishing expression.  = No longer expressed. 
 
 
An additional possible revision of the existing model would depict that Dll1 is only 
expressed by RGCs and INPVZs in the VZ, and not in INP cells in the SVZ. This 
would account for our Dll1 mRNA expression data (Chapter 3, Chapter 5) and the 
results of our flow cytometry analysis (Chapter 5), as well as some of the data from 
previous Dll1 forebrain studies (Campos et al., 2001; Nelson et al., 2013). However, 
the fact that data from Nelson et al., 2013 suggested that cells expressing Dll1 also 
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co-express Tbr2 and that Dll1 was also visualised in cells within the SVZ using a 
GFP reporter makes this scenario far less likely (Nelson et al., 2013).  
 
The final potential revision of our existing model explores the idea that Dll1 could be 
expressed in INPVZs only. This would account for cells that co-express Dll1 and 
Tbr2, as well as Dll1 expression in the VZ. However, in situ hybridisation analysis 
suggested that Dll1 is expressed in the majority of cells residing in the VZ and INPVZ 
cells comprise a relatively small percentage of the VZ in comparison to RGCs 
(Englund et al., 2005; Götz and Huttner, 2005; Corbin et al., 2009; Nelson et al., 
2013), making this revision of the model redundant. 
 
Taking all of the experimental evidence from this project as well as previous studies 
into account, the first revision of our original model seems to be the most likely 
scenario. Furthermore, this model would still incorporate the proposed co-regulatory 
relationship between Dll1 and Pax6 from the original (Chapter 1.11), although the 
possibility that Dll1 and Pax6 may both be co-expressed in RGCs provides the 
possibility for an alternative regulatory relationship between the two genes, whether 
this is a revision of the original version (Chapter 1.1) that compensates for the 
molecular signalling mechanism of RGCs, or an additional regulatory model unique 
to RGCs.  
 
 
7.5 Pax6 controls cortical cell proliferation/differentiation via is regulation of 
Dll1 and Jag1 
 
As previously stated, it is largely accepted that Pax6 is critical during cortical 
development and is a key regulator of cell proliferation and differentiation during 
corticogenesis (Stoykova et al., 2000; England et al., 2005; Georgala et al., 2011a; 
2011b). Although the molecular mechanisms that Pax6 controls to exert its effects 
upon cell proliferation are still poorly understood (Carr, 2009; Sansom et al., 2009). 
Interestingly, the discovery that components of the Notch signalling pathway 
(namely Dll1 and Jag1) appeared to be targets of Pax6, provided potential 
	 187
explanation as to how Pax6 could be exerting its effects upon cell proliferation 
during corticogenesis (Carr, 2009; Sansom et al., 2009; Dorà 2011; Chapter 1.11). 
The Notch signalling pathway is known to play a critical role in orchestrating the 
balance between cell proliferation and differentiation – maintaining the progenitor 
cell pool and dictating when cells differentiate into neurons that form the multiple 
layers of the murine cerebral cortex (Pierfelice et al., 2011). When Notch signalling 
is disrupted, there is a depletion of the neural progenitor cell pool and as a result, a 
decrease in the production of neurons, resulting in the layers of the cortex failing to 
form correctly and as a result an overall decrease in cortical size and optimal 
function (Kageyama et al., 2008; Pierfelice et al., 2011; Shimojo et al., 2016).  
 
Our discovery that a loss of Pax6 reduces the expression of Notch ligands Dll1 and 
Jag1 (Chapter 3; Chapter 4) has given rise to the hypothesis that Pax6 controls 
corticogenesis via is regulation of key components of the Notch signalling pathway. 
Furthermore, our conclusions that support previous findings that Jag1 and Dll1 are 
expressed in the VZ and most likely by RGCs/predominately by RGCs, gives our 
hypothesis traction; as Pax6 could be directly regulating Dll1 and Jag1 within the 
RGC population, subsequently instructing RGCs to remain in a proliferative state 
within the neural progenitor pool (Chapter 5).  
 
The original model of the hypothesis presented in this thesis depicts the direct 
regulation of Jag1 by Pax6 in RGCs, consequently instructing a proliferative cell fate 
in neighbouring RGCs (Figure 1.8) (Chapter 1.11). Previous research presented Jag1 
as a gene expressed by RGCs within the VZ (Nelson et al., 2013). This part of the 
model was predominately supported by our findings as Jag1 expression decreased in 
the cortex of Pax6-/- embryos and was completely lost at the PSPB, where Pax6 
expression is highest (Chapter 3). Furthermore, while our findings from Chapter 6 
were inconclusive, it is still feasible that Jag1 could be a direct target of Pax6.  
 
While the original hypothesis model (Figure 1.8) described in Chapter 1.11 relied 
heavily upon evidence described by Nelson et al., (2013), our findings largely 
contradicted the data presented in the aforementioned article and as a result, our own 
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original hypothesis. While the hypothesis model (Figure 1.1) suggested that Pax6 
and Dll1 indirectly regulate one another in INPs residing within the VZ (Chapter 
1.11), the findings detailed in this thesis do not support this and instead suggest that 
Dll1 is in fact expressed solely within the VZ and by RGCs, as there is no co-
expression between Dll1 and Tbr2; a known marker of the INP cell population, that 
is also expressed by INPVZs (Pontious et al., 2007; Nelson et al., 2013). While our 
findings detailed in Chapter 5.2 contradict Nelson et al., (2013), they compliment the 
findings of Shimojo et al., (2016), where a disruption in correct Dll1 expression 
resulted in the quenching of Notch pathway oscillations and a decrease in the 
proliferation of RGCs within the VZ. 
 
The observations by Shimojo et al., 2016 surrounding Dll1 are of particular interest 
in regards to the work undertaken in this thesis. The fact that a disruption in Dll1 
expression resulted in the quenching of Notch oscillations and consequently, a 
disturbance in normal levels of cell proliferation vs differentiation in the VZ, 
demonstrated that Dll1 is a key player in maintaining Notch signalling and 
subsequently, correct cortical development. This was demonstrated by the 
observation that not only was there a reduction in the size of the VZ in Dll1 mutant 
mice as a result of a reduction in Notch signalling, but also by the fact that there was 
an overall reduction in the size of the cerebral cortex; suggesting that as proliferative 
cell pool within the VZ reduced, it resulted in an insufficient neuron yield to allow 
for correct structural development (Shimojo et al., 2016). The fact that Dll1 has been 
highlighted as playing a critical role in Notch signalling, with no apparent 
compensation provided by other Notch pathway components; aids our hypothesis 
that Pax6 controls cell proliferation by regulating genes involved in Notch signalling. 
As it is generally accepted that Notch signalling is a critical for the mediation 
between cell proliferation and differentiation during neurogenesis, the fact that a loss 
of normal Dll1 expression disrupts this so severely gives traction to our hypothesis 
that Pax6 controls cell proliferation during corticogenesis due to the fact that Pax6 
has been proven to regulate the expression of a gene that is vital to the process 




7.6 Future work  
 
In order to ascertain which version of our model is correct, further experiments need 
to be conducted outwith the time constraints of this project. This would allow us to 
answer the remaining questions from this project and would allow us to prove or 
disprove further aspects of the model for Pax6s regulation of Dll1 and Jag1 during 
cortical neurogenesis.  
 
In order to validate Jag1 as a direct target of Pax6, follow up experiments for Jag1UE 
would need to be conducted, as well as further testing of other putative bindings sites 
that were highlighted in our bioinformatics screen (Chapter 6.2). As previously 
discussed in depth in chapter 6, further optimisation of our original luciferase assay 
experiment, coupled with an in in vivo approach would be ideal (Chapter 6.5). While 
additional testing of other candidate binding sites by our luciferase method would be 
beneficial if the sites that comprise Jag1UE are disproved entirely.  
 
Results from this project raised the question of whether Dll1 is truly an indirect 
target of Pax6 or if it may actually be a direct target. In order to examine the 
developing hypothesis that it could be a direct target, a bioinformatics approach like 
the one carried out for Jag1 (Chapter 6.2) could be implemented. This would provide 
a comprehensive list of any potential putative Pax6 binding sites for Dll1 that could 
be analysed further and then tested by the same luciferase assay approach 
implemented for Jag1 (Chapter 6.6). 
 
In light of our original model, which suggests that Pax6 and Dll1 may be capable of 
indirectly co-regulating one another within INPvzs, it would be beneficial to examine 
whether Dll1 and Pax6 are capable of mutually co-regulating one another. This 
would further solidify our model and provide insight into the relationship between 
Pax6 and Dll1 during cell proliferation. Examining the effects of a loss of Dll1 on 
Pax6 expression in the embryonic cerebral cortex would be a straightforward 
approach to beginning to answer this complex question. This could be conducted 
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using Dll1 mutant line like the one described by Hrabe de Angelis et al., (1997) and 
Machka et al., (2005) and would allow examination of Pax6 expression at different 
stages of development (Hrabe de Angelis et al., 1997; Machka et al., 2005). 
Complimentary gain-of-function studies for both Pax6 and Dll1 by electroporation in 
order to assess the affect on the other would also be a favourable approach (Marin et 
al., 2013).  
 
Due to time constraints, whether Dll1 is expressed in RGCs was never tested. The 
fact that a great deal of our model hinges on the precise location of Dll1 expression 
in progenitor cells subpopulations makes this an increasingly crucial question that 
requires a definitive answer. Double in situ hybridisation and flow cytometry for 
Dll1 and a RGC marker would provide the evidence required to prove or disprove 
whether RGCs express Dll1. Use of Pax6 to undertake these experiments would not 
only provide evidence that Dll1 is expressed in RGCs, but would also confirm 
whether Pax6 and Dll1 are co-expressed by progenitor cells. This would not only, 
prove areas of our existing model, but also provide evidence to prove and disprove 
some of the revised versions of the model outlined in section 7.4. 
 
To further solidify our model and allow us to revise aspects of it, providing evidence 
that INPVZs simultaneously express Dll1, Tbr2 and Pax6 would be of the utmost 
importance. A triple label flow cytometry approach would confirm whether there are 
cortical cells that express all three simultaneously but would not confirm that these 
cells are INPVZ cells. INPVZs are typically characterised by their position within the 
cortex and their expression of Tbr2. A an adaptation of the live-cell imaging 
approach of slice cultures transfected with a Dll1 reporter construct as described by 
Nelson et al., (2013) and subsequent immunohistochemical labelling would allow the 
identification of INPVZs and confirm whether they simultaneously express Dll1,Tbr2 






This study has identified that the Notch ligands Dll1 and Jag1 are Pax6 targets. Steps 
have also been taken in identifying the specifics surrounding regulatory relationships 
that Pax6 has with Dll1 and Jag1. Potential putative Pax6 binding sites for Jag1 have 
been identified but further testing is required to validate them. The precise location 
of Dll1 in the proliferative zone of the cortex was previously inconclusive, with 
multiple studies stating that it was expressed by different progenitor cells. This study 
has identified that Dll1 mRNA expression is restricted to the VZ, while Dll1 protein 
expression is co-expressed by a proportion of Tbr2 positive cells. However, it cannot 
be concluded if these are INP cells or INPVZ cells. A model for how Pax6 may 
control cell proliferation during neurogenesis has been designed but revisions of the 
original and further testing is required in order to validate it. As a result, this study 
has identified a potential mechanism by which Pax6 exerts control over cell 
proliferation during cortical neurogenesis by controlling the Notch signalling 
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Passive lysis buffer preparation: 
 
Prepare 1X passive lysis buffer solution (1ml 5X passive lysis buffer solution (supplied with 




Resuspend the lyophilized Luciferase Assay Substrate in Luciferase Assay Buffer II. Store at 
-20°C for 1 month or at -70°C for 1 year. 
 
Stop and Glo Reagent: 
 
Add 2.1ml of 50X Stop and Glo Substrate to 105ml of Stop and Glo Buffer in the stop and 
Glo bottle provided. Vortex for 10 seconds. Store at -20°C for up to 15 days. 
 
 
Cell Preparation  
 
Wash cells in 500μl of 1X PBS. 
Remove 1X PBS and add 100μl of 1X passive lysis buffer (PLB) to each well of transfected 
cells. 
Place on a rocking platform for 15 minutes at RT. 
Use a plastic cell scraper (Fisher Scientific) to collect all cell lysate into a 2ml eppendorf 
tube.  
Centrifuge at 13000rpm for 5 minutes at 4°C. 
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Collect supernatant. Aliquot 25μl into 0.25ml PCR tubes and retain for luciferase assay 
analysis. Aliquot the remaining supernatant into an additional 0.25ml PCR tube and retain 





Aliquot 20ul of cell lysis into each well of the 96 well plate.  
 
Transfer LAR II and Stop and Glo Reagent into 30ml universal tubes for use with the 





2.1 Operation of Promega Glomax Luminometer  
 
 
Follow the Dual Luciferase Reporter Assay System Technical Manual for the Preparation of 
samples and reagents. 
 
1. Turn on computer and then turn on luminometer. 
2. Computer User name is Glomax and Password is blank. 
3. Double-click on the Glomax X icon. 
4. Select ‘Run Promega Protocol’ 
5. Double-click on DLR folder 
6. Select ‘DLR with 2 injections column format’ option 
7. Prepare the injectors for use as follows: 
 
Flush both injectors: 
 
i) Remove the injector tips from the injector tip holders and place them into Waste 
beaker. 







Prime both injectors: 
 
i) Insert inlet tubing into reagent bottles as follows: 
 




ii) Remove the injection tips from the injection tips holder and place them in waste 
container 
iii) Prime (into waste container). 
iv) Return injection tips to the injection tip holder. 
 
8. Place Multiwell plate containing lysates (20ul each) in luminometer and select wells 
for measurement via ‘Options’ 
 
A whole row can be selected by clicking on letter to left of row 
 
9. Press START to start the assays  
 
10. At the end of the run save a copy of the excel file containing the renilla and firefly 
measurements. 
 
11. Calculate the averages for each set of triplicate measurements and then calculate the 






3.1 Protein transfer 
 
 
1L 1X transfer buffer recipe: 
 
NuPAGE Transfer Buffer (20X) – 50ml 
Methanol – 100ml 
ddH2O – 850ml 
 
 
Cut nitrocellulose to the correct size and soak in 1x transfer buffer for 10 minutes. 
Additionally, soak scotch-brite pads and filter papers in transfer buffer for 10 minutes. 
 
Remove the gel from the western blot tank and soak in transfer buffer for 10 minutes so that 














Cover the whole module with transfer buffer. After transfer take apart and treat 
nitrocellulose with care.  
